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INTRODUCTION 
Pediatric acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children 
as it accounts for more than a quarter of all pediatric malignancies.1 The peak 
incidence occurs at 3 to 5 years of age.2 Over the past decades, advances in the 
treatment of ALL have resulted in current 5-year overall survival rates of 
approximately 90% in many developed countries.3-10 In the Netherlands, patients 
are currently treated according to the Dutch Childhood Oncology Group (DCOG) 
ALL-11 treatment protocol, which contains several treatment phases: the 
induction, consolidation, intensification and maintenance phase. These treatment 
phases consist of a combination of chemotherapeutic agents including vincristine, 
corticosteroids, methotrexate, cytarabine, cyclophosphamide, mercaptopurine, 
anthracyclines and asparaginase.  
According to DCOG ALL-11, patients are stratified after induction to a standard, 
medium and high risk group based on treatment response and cytogenetic 
aberrations of the leukemia. As approximately 70% of the patients is stratified in 
the medium risk group and these patients are most intensively treated with 
asparaginase, this thesis mainly focusses on the medium risk treatment protocol.   
 
Asparaginase 
Since the 1970’s, asparaginase is one of the key components of pediatric ALL 
therapy. The enzymatic drug catalyzes the hydrolysis of asparagine to aspartic acid 
and ammonia. Normal cells are able to restore their intracellular asparagine 
storage from aspartic acid with the enzyme asparagine synthetase. In contrast, 
leukemic cells depend on extracellular asparagine pools. Hence, extracellular 
asparagine depletion, accomplished by asparaginase therapy, selectively kills the 
leukemic cells.11 This is not necessarily caused by a lack of asparagine synthetase in 
the leukemic cells: although asparaginase resistance has been associated with 
asparagine synthetase expression12, 13, several other studies have failed to 
reproduce this correlation.14-16 Thus, other mechanisms may also play a role.17  
For many years, the general consensus of opinion is that a minimal asparaginase 
activity level of 100 IU/L is required for complete asparagine depletion in both 
serum and cerebrospinal fluid (CSF).18-27 In vivo, asparagine measurement is 
challenging, though, due to ex vivo asparaginase activity in blood samples. Due to 
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this, the asparaginase activity levels currently reported at which asparagine is 
supposed to be completely depleted vary between 20 – 400 IU/L. In only one out of 
11 studies (the study of Angiolillo et al.), asparagine levels rebounded when 
asparaginase activity levels became <400 IU/L.28. All other ten  studies, however, 
report thresholds around 100 IU/L or lower.19, 20, 29, 30, 22, 24, 25  Table 1 shows the 
different studies with adequate sample handling (directly put on ice, centrifuged, 
deproteinized and stored at -20 to -80°C). Thus, an asparaginase activity level of 
100 IU/L is currently considered as the minimal asparaginase activity level required.  
 
Table 1. Minimal asparaginase activity level for complete asparagine depletion 
Study Number of patients Limit of quantification  Minimal asparaginase level 
Ahlke et al. 199719 11 0.1 μM 100 IU/L 
Riccardi et al. 1982 7 (+ rhesus monkeys) 0.2 μM 100 IU/L 
Rizzari et al. 200020 62  0.2 μM  50 IU/L 
Albertsen et al. 200131 15 0.2 μM 100 IU/L 
Rizzari et al. 200622 20 0.2 μM 30 IU/L 
Avramis et al. 200723 5 0.01 μM 100 IU/L 
Pieters et al. 200825 32 0.5 μM 20 IU/L 
Appel et al. 200824 57 0.2 μM 100 IU/L 
Strullu et al. 201026 33 0.1 μM  100 IU/L 
Tong et al. 201332 23  0.2 μM 40 IU/L 
Angiolillo et al. 201428 165 0.05 μM 400 IU/L 
 
Several formulations of asparaginase, which are derived from bacteria, are 
available for clinical practice. Asparaginase gained from the Escherichia coli 
bacteria is used in its native form (native E. coli asparaginase) but also in a poly-
ethylene glycol (PEG) conjugated form, PEGasparaginase. By PEGylating a drug, 
polyethylene glycol groups are linked to the drug in order to decrease 
immunogenicity and prolong a drug’s half-life.33, 34 Hence, PEGasparaginase is less 
immunogenic than native E. coli asparaginase and has to be administered less 
frequently (biweekly versus every three days).35 Native E. coli asparaginase is also 
available in a recombinant version, produced in E. coli cells by recombinant DNA 
technology, which has equal pharmacokinetic properties as the natural 
formulation.  
A third type of asparaginase is derived from Erwinia Chrysanthemi bacteria (Erwinia 
asparaginase) and is, therefore, immunologically distinct from the E. coli 
asparaginase formulations. Unfortunately, Erwinia asparaginase therapy has 
several disadvantages: the drug has a relative short half-life, which results in an 
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inconvenient dosing schedule as it requires an administration frequency of at least 
three times a week. Consequently, Erwinia asparaginase therapy is relatively 
expensive when compared to the other formulations. Furthermore, if patients 
develop an immunological reaction to this formulation, there are no alternatives.  
Several studies have shown that intensive and adequate asparaginase treatment 
improves the event-free survival (EFS) of ALL with approximately 10% (Table 2).36-39, 
3, 4, 10 This conclusion was not only based on studies in which patients were treated 
either with or without intensified asparaginase therapy, but also on studies that 
compared identical dose schedules of native E. coli asparaginase and Erwinia 
asparaginase, the latter administrated in a less effective dosing schedule due to a 
lack of pharmacokinetic knowledge in those days.   
 
Table 2. Efficacy of intensified asparaginase treatment 




Mondelaers et al. 201740 1552 24 vs. 12 doses of native E. coli asparaginase 87% vs. 84%  
Vilmer et al. 201041 653 Native E. coli asparaginase vs Erwinia 
asparaginase, both 25,000 IU/m2 
74% vs. 61% * 
Moghrabi et al. 20074 286 Native E. coli asparaginase vs. Erwinia 
asparaginase, both 25,000 IU/m2, weekly 
89% vs. 78% * 
Pession et al. 20053 355 >20 weeks vs. ≤ 20 weeks of asparaginase 88% vs. 83% * 
Silverman et al. 200138 377 >25 weeks vs. ≤ 25 weeks of asparaginase 90% vs. 73% * 
Duval et al. 200239 700 Native E. coli asparaginase vs. Erwinia 
asparaginase, both 10,000 IU/m2, weekly 
73% vs. 60% * 
Rizzari et al. 200137 610 >20 weeks vs. ≤ 20 weeks of asparaginase 75% vs. 72%  
Amylon et al. 199936 317 >20 weeks vs. ≤ 20 weeks of asparaginase in 
patients with T-cell ALL 
68% vs. 55% * 
EFS: event-free survival; ALL: acute lymphoblastic leukemia; vs.: versus; *: statistically significant difference  
 
Asparaginase toxicity 
Although asparaginase is very effective, patients may develop severe adverse 
events, possibly limiting the efficacy of the therapy. These events include the 
development of hypersensitivity reactions, pancreatitis, thromboembolic events, 
central neurotoxicity, hepatotoxicity, hypertriglyceridemia, and bone marrow 
suppression, which are elaborated below.  
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Hypersensitivity reactions 
Patients may develop a hypersensitivity reaction to asparaginase, neutralizing the 
drug completely.42-44 The neutralizing reactions vary from mild allergic reactions to 
an anaphylactic shock, all accompanied by asparaginase activity levels of zero. In 
addition, asparaginase may even be neutralized in absence of clinical symptoms, 
which is called silent inactivation.45, 19, 26 The rates of these reactions vary in the 
literature, partly due to the type of asparaginase used. Hypersensitivity reactions 
have been reported up to 75% in patients treated with native E. coli asparaginase 
and in 3-30% of the patients treated with PEGasparaginase. 38, 46-50 Hypersensitivity 
reactions to Erwinia asparaginase are reported in 3-37%.51, 52, 4, 48, 53, 54, 49  
Beside the formulation, the dosing schedule plays an important role: if 
asparaginase treatment is interrupted for several weeks or months, patients may 
develop anti-asparaginase antibodies during this period of interruption, causing 
hypersensitivity reactions to asparaginase directly after this period.21, 49 Also the 
route of administration was thought to be a risk factor but a recent review of 
Beaupin et al. has shown that hypersensitivity reactions occur just as often when 
asparaginase is administered intravenously as intramuscularly.55 In the 
Netherlands, asparaginase is administered intravenously. 
Several studies have shown that, although by PEGylation the immunogenicity has 
been decreased, patients can develop antibodies to the PEG moiety itself, possibly 
resulting in allergic reactions and/or rapid clearance of the PEGylated drug.56-60 
PEGasparaginase consists of E. coli asparaginase, PEG and a succinimidyl succinate 
linker (SS-linker). Currently, the role of antibodies to the PEG and linker moieties, 
so other than to the asparaginase itself, in the development of hypersensitivity to 
PEGasparaginase is unclear.  
 
Pancreatitis 
Pancreatitis has been reported in 2-18% of the patients treated with 
asparaginase.61-65 These percentages include Common Terminology Criteria for 
Adverse Events (CTCAE) grade 2 pancreatitis, which, according to version 4.03, is 
described as enzyme elevation or radiologic findings only. Thus, it can be 
questioned whether these patients had an actual pancreatitis. Grade 3 and 4 
asparaginase-associated pancreatitis occurs in 5-10% of the patients .61, 63, 65 The 
pathophysiology of asparaginase-associated pancreatitis is unknown but the 
systemic asparagine depletion is believed to affect especially organs with a high 
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protein turnover, as is the pancreas.66 In addition, genetic predispositions seem to 
play a role, for example variants in the CPAP2 gene which encodes for the 
pancreatic zymogen carboxypeptidase.67 Currently, it has been recommended by 
the Ponte de Legno Toxicity Working Group to use the following modified Atlanta 
criteria of which at least two out of the three criteria are required to diagnose 
asparaginase-associated pancreatitis: 1) abdominal symptoms suggestive of 
pancreatitis; 2) serum lipase, amylase or both being three times or more than the 
upper limit of normal; and 3) imaging findings characteristic of acute pancreatitis.68 
As such, a CTCAE grade 2 pancreatitis does not fulfill these criteria. In general, 
asparaginase will be discontinued in case of pancreatitis although Hijiya et al. 
recommend to consider continuation if symptoms resolve within 48 hours with no 
signs of pseudocysts or necrosis on imaging.69 An international study reported that 
23% of the patients who were re-exposed to asparaginase after having experienced 
pancreatitis developed a second pancreatitis. However, risk factors predicting a 
second pancreatitis were not found.68       
 
Thromboembolic events 
Asparaginase treatment is associated with reduced coagulation and fibrinolysis 
proteins. Mainly the decline in anticoagulant proteins C and S, and antithrombin III 
levels may lead to thrombotic events, especially in combination with 
corticosteroids.70, 71 Previous studies have shown that not necessarily the dosage of 
asparaginase but the length of exposure is associated with the development of 
these events.72, 73 The incidence of thromboembolic events during ALL treatment 
vary from 1 to 36%, depending upon the patient groups studied (children versus 
adults), treatment protocols, and study design (symptomatic events only versus 
screening, and in- and exclusion of thrombotic events related to central venous 
catheters (CVC)).71 In children with ALL, the incidence is in the lower range. The 
meta-analysis of Caruso et al. reports an overall incidence of 5% thrombotic events 
during pediatric ALL treatment. Almost one third of these events was related to 
CVC’s and more than half of the events occurred in the central nervous system.  
Furthermore, most events were during the induction phase, probably due to the 
intensive treatment and still active disease in this treatment phase.72 Grace et al. 
have studied thrombotic events in a treatment protocol similar to the DCOG 
treatment protocols, with asparaginase during induction followed by 30 weeks of 
asparaginase during intensification. This study reports an incidence of 5%, 
General introduction |   15 
1
increasing with the patient’s age. This incidence, however, also include CVC related 
thrombotic events (35%).74 Hijaya et al. recommend to discontinue asparaginase 
temporarily in case of clinically significant bleeding or thrombosis.69  However, re-
exposure of asparaginase is recommended with low-molecular-weight heparin 
once clinical symptoms have been resolved, enabling around 75% of the patients to 
finish their treatment safely. 75, 74, 69    
 
Central neurotoxicity 
Asparaginase-associated central neurotoxicity has been described less extensively 
in the literature and is often caused by thrombotic events such as sagittal sinus 
thrombosis or, less frequently, cerebral hemorrhages.76 Focusing on neurotoxicity 
not caused by coagulation alterations, the exact relationship between asparaginase 
treatment and the development of neurotoxicity is unclear.69 Central neurotoxicity 
includes symptoms of ataxia, somnolence, depressed level of consciousness, 
agitation, seizures and posterior reversible encephalopathy syndrome (PRES). 
Asparaginase-associated central neurotoxicity usually has a good prognosis and 
symptoms resolve without complications in most cases.77, 69 
 
Hepatotoxicity 
Hepatotoxicity (hepatic transaminase and bilirubin elevation) caused by asparagine 
depletion as a result of asparaginase treatment is rarely fatal but may cause a delay 
in treatment, negatively affecting treatment outcomes.69 As many drugs 
concomitantly used with asparaginase can cause hepatotoxicity, it is difficult to 
study the exact contribution of asparaginase to the occurrence of hepatotoxicity.46, 
35 The incidence of grade 3-4 hepatotoxicity is the highest in adult patients treated 
with asparaginase (35 to 60% of the patients), and occurs less often in children (4 
to 8% of the patients).78, 69 It has been recommended to postpone  an asparaginase 
dose in case of increased transaminases (>10 times the upper limit of normal) or 
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Hypertriglyceridemia 
Hypertriglyceridemia is common in pediatric ALL patients treated with 
asparaginase, especially in combination with corticosteroids, and is described in up 
to 67% of the patients.79, 69 Although increased triglyceride concentrations have 
been associated with the occurrence of pancreatitis and thrombosis, asparaginase 
induced hypertriglyceridemia is not and has no clinical consequences.80-82  
 
Myelosuppression 
The precise myelosuppressive effect of asparaginase is unclear: asparaginase either 
could cause myelosuppression directly or by inducing the myelosuppressive effects 
of other drugs as methotrexate and 6-mercaptopurine.69  Merryman et al. have 
shown that patients have more myelosuppression and require more 6-
mercaptopurine and methotrexate dose reductions during concomitant 
asparaginase therapy than during continuation therapy without asparaginase, 
showing the myelosuppressive effect of asparaginase. 83  
 
Previous results  
Until April 2012, patients were treated according to the DCOG ALL-10 treatment 
protocol. According to this protocol, patients were treated with 5,000 IU/m2 native 
E. coli asparaginase during induction and 2,500 IU/m2 PEGasparaginase during 
intensification after an asparaginase-free interval of approximately 12 weeks. 
Studies of the asparaginase treatment in this protocol have led to several insights 
on which the aims for this thesis were based.  
It was shown that 22% of the patients treated according to ALL-10 developed an 
allergy to and 8% silent inactivation of PEGasparaginase during intensification, 
almost exclusively on the second PEGasparaginase dose. These reactions were 
caused by antibodies to native E. coli asparaginase, developed during the 
asparaginase-free interval after induction, and cross-reacting with PEGasparaginase 
during intensification. However, these antibody titers also increased in part of the 
patients without a hypersensitivity reaction.49 The incidence of hypersensitivity 
reactions was much lower during the native E.coli asparaginase doses administered 
in induction: 5% had either an allergic reaction to or silent inactivation of the drug. 
Of the patients without a reaction or silent inactivation, the mean trough 
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PEGasparaginase activity level was 899 IU/L, which is relatively high compared to 
the recommended level of 100 IU/L.49 The asparaginase activity levels measured 
were positively correlated with triglyceride concentrations and 47% of the patients 
developed grade 3-4 hypertriglyceridemia during PEGasparaginase treatment. 
During intensification, grade 3-4 pancreatitis occurred in 5% of the patients; 
thrombotic events (excluding CVC-related events) in 3%; and central neurotoxicity 
in 10%.65  
During induction, the native E. coli asparaginase levels ranged between 143 – 182 
IU/L , being lower than the PEGasparaginase levels during intensification. 
Pancreatitis occurred in 1%, and both thrombosis and central neurotoxicity in 2%.84 
Hypertriglyceridemia during induction was not reported. 
 
The DCOG ALL-11 treatment protocol 
Based on these results, certain adjustments were made in the subsequent DCOG 
ALL-11 treatment protocol. First, native E. coli asparaginase in induction was 
replaced by PEGasparaginase so PEGasparaginase was used in both the induction 
and intensification phase. Thus, medium risk patients are treated with three 
PEGasparaginase doses during induction and another 14 doses during 
intensification.  
Second, a unique therapeutic drug monitoring (TDM) program was implemented to 
1) adjust the PEGasparaginase dosage based on asparaginase activity levels in order 
to prevent too high trough levels and 2) identify patients with silent inactivation of 
PEGasparaginase. The first three doses during induction had a fixed dose of 1,500 
IU/m2 PEGasparaginase but after the third dose, the dose was adjusted based on 
trough PEGasparaginase serum levels. If patients developed a hypersensitivity 
reaction to PEGasparaginase, the formulation was switched to Erwinia 
asparaginase. Also the Erwinia asparaginase treatment was individualized to ensure 
optimal asparaginase activity levels.  
Third, patients were either randomized to a standard discontinuous asparaginase 
dosing schedule, similar to the previous ALL-10 dosing schedule, or an experimental 
continuous asparaginase dosing schedule, to study whether this will decrease the 
occurrence of hypersensitivity reactions.  
By continuous administration of the PEGasparaginase doses, patients are treated 
concomitantly with asparaginase and 6-mercaptopurine, cytarabine and 
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cyclophosphamide in the first consolidation course, and with asparaginase and high 
dose methotrexate and 6-mercaptopurine during the second consolidation course. 
Previous studies have shown a possible effect of asparaginase on methotrexate 
efficacy and toxicity in vitro, depending on the sequence of administration.85-88 
However, the exact effect in vivo is unclear. The asparaginase randomization study, 
thus, allows us to compare the methotrexate efficacy and toxicity with and without 
concomitant asparaginase treatment. 
 
Aims 
The aim of this thesis was to study the feasibility, efficacy and toxicity of 
individualized asparaginase treatment and optimize the asparaginase treatment of 
children with ALL.  
The specific aims were: 
 To study the feasibility, efficacy and toxicity of individualized asparaginase 
treatment in children with ALL. 
 To develop a model to describe the population pharmacokinetics of 
PEGasparaginase and identify factors explaining variability in order to 
improve asparaginase therapeutic drug monitoring. 
 To study the different types of hypersensitivity reactions to asparaginase. 
 To develop a sensitive assay to measure antibodies to the different 
components of PEGasparaginase (PEG, the SS-linker and asparaginase) and 
study the different types of antibodies formed. 
 To study the influence of asparaginase on methotrexate efficacy and 
toxicity. 
 To compare the costs of an individualized dosing schedule with a fixed 
dosing schedule. 
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Outline of the thesis 
In chapter 2, the feasibility, efficacy and toxicity of individualized asparaginase 
treatment in children treated according to the DCOG ALL-11 protocol have been 
studied. In chapter 3, the population pharmacokinetics of PEGasparaginase are 
studied using non-linear mixed effects modelling (NONMEM), identifying factors 
explaining the variability in asparaginase activity that was observed. With this 
model, dosing guidelines were provided.  
 
In chapter 4, a new, atypical type of hypersensitivity reaction to asparaginase was 
described. These allergic-like reactions mimic real allergic reactions but are not 
accompanied by inactivation of the drug. In chapter 5, an assay to measure 
antibodies against the asparaginase, PEG and the linker was developed. Next, it 
was studied which types of antibodies were formed in patients with a 
hypersensitivity reaction to PEGasparaginase.  
 
In chapter 6, the influence of asparaginase on high dose methotrexate efficacy and 
toxicity was studied. 
 
In chapter 7, the costs of individualized asparaginase treatment were compared 
with the costs of a fixed dosing schedule. Chapter 8 is a cost-effectiveness analysis 
of Erwinia asparaginase treatment.  
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ABSTRACT 
Background In the DCOG ALL-11 protocol, PEGasparaginase and Erwinia 
asparaginase treatment of pediatric acute lymphoblastic leukemia is individualized 
with therapeutic drug monitoring (TDM). The efficacy of TDM and its effect on 
asparaginase-associated toxicity is reported.   
Methods After induction with 3 fixed intravenous doses of 1,500 IU/m2 
PEGasparaginase, 382 medium risk patients received fourteen individualized doses 
targeting trough levels of 100–250 IU/L; standard risk patients one individualized 
dose; high risk patients 2–5 fixed administrations (1,500 IU/m2). After a neutralizing 
hypersensitivity reaction, patients started with 20,000 IU/m2 3x/week Erwinia 
asparaginase. (L-)asparagine was measured monitoring asparaginase efficacy. 
Several asparaginase-associated toxicities were studied.  
Results The final median PEGasparaginase dose could be lowered to a medium of 
450 IU/m2. Overall, 97% of all trough levels of non-allergic patients was >100 IU/L. 
Asparagine was <0.5 μM in 96% and 67% of the PEGasparaginase and Erwinia 
asparaginase levels >100 IU/L, respectively. Ten percent developed a neutralizing 
hypersensitivity reaction to PEGasparaginase, of which 40% was silent inactivation. 
The cumulative incidences of grade 3-4 pancreatitis, central neurotoxicity and 
thromboses were 12%, 4% and 6%, respectively, and were not associated with 
asparaginase activity levels. During medium risk intensification, 50% had increased 
alanine transaminase; 3% hyperbilirubinemia (both correlated with asparaginase 
activity levels) and 37% hypertriglyceridemia (all grade 3-4). Hypertriglyceridemia 
occurred less in intensification compared to ALL-10 (37% versus 47%), which is 
similar to ALL-11 but with higher asparaginase levels during intensification.  
Conclusion In conclusion, TDM of asparaginase results in a significant reduction of 
the PEGasparaginase dose with adequate asparaginase activity levels and sufficient 
asparagine depletion. Also, with TDM, silent inactivation and allergic-like reactions 
are identified. However, there is limited effect of reduced asparaginase activity 
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INTRODUCTION 
Asparaginase is essential for pediatric acute lymphoblastic leukemia (ALL) 
treatment. 1-7 The drug starves leukemic cells by converting extracellular 
asparagine, an essential amino acid for these cells.8 Asparaginase activity >100 IU/L 
is considered to be sufficient for complete asparagine depletion. 9-16 
Hypersensitivity reactions to asparaginase occur with or without clinical symptoms 
of an allergy. The latter is called silent inactivation (SI), neutralizing the drug 
completely and requiring a switch from E.coli asparaginase to Erwinia 
asparaginase.17 Patients may also develop atypical allergies without inactivation, 
allergic-like reactions, which do not require a switch in formulation to ensure 
adequate treatment.18 Currently, in most countries, polyethylene glycol conjugated 
E.coli asparaginase (PEGasparaginase) is used as a first line formulation and Erwinia 
asparaginase (Erwinase®) as second line.  
Also other asparaginase-associated toxicity hampers asparaginase treatment, 
possibly resulting in worse outcomes.19 We showed that a fixed PEGasparaginase 
dose of 2,500 IU/m2 results in high trough asparaginase activity levels, possibly 
causing unnecessary toxicity.20 Furthermore, asparaginase activity levels show large 
inter- and intra-patient variability.21, 22 Therefore, therapeutic drug monitoring 
(TDM) was implemented in the Dutch Childhood Oncology Group (DCOG) ALL-11 
treatment protocol. This way, also SI is detected and allergic-like reactions are 
identified.  
Here, the efficacy of the ALL-11 TDM program and the effect on asparaginase-




Patients and therapy 
Patients treated according to the ALL-11 protocol in the Netherlands between April 
2012 and December 2016 were included. Asparaginase related side effects 
(hypersensitivity reactions, pancreatitis, central neurotoxicity, thrombosis and 
infections) were nationally registered by the DCOG. In 50 patients treated in the 
Erasmus MC Rotterdam or Amsterdam UMC hepatotoxicity, hypertriglyceridemia, 
the number of transfusions and hyperglycemia were also assessed. Informed 
consent was signed by patients and parents according to Dutch law. The study 
(CCMO register: NL50250.078.14) was approved by the institutional review boards 
according to the declaration of Helsinki.  
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The ALL-11 protocol is described in Supplemental table 1. The TDM is described in 
Supplemental figure 1. In induction, patients were treated with three intravenous 
PEGasparaginase doses (1,500 IU/m2, biweekly). Thereafter, patients were 
stratified as standard risk (SR), medium risk (MR) or high risk (HR). After an interval 
of approximately 12 weeks, SR patients were treated with one individualized dose 
during protocol IV; MR patients were treated with 14 individualized doses biweekly 
during intensification. The algorithm of dose reductions is described in 
Supplemental table 2. HR patients were treated with 2–5 doses of 1,500 IU/m2 with 
intervals of approximately 7 weeks.  
For the nation-wide TDM program, trough serum asparaginase activity levels were 
measured for dose adjustments, targeting 100–250 IU/L. Week levels were 
measured after the first PEGasparaginase dose or the first dose following an 
asparaginase-free interval for early detection of SI. When asparaginase activity 
levels were stable within the target range, trough levels were measured every four 
weeks. In HR patients, week levels were measured after each dose to detect SI. The 
asparaginase activity level measurements and formulation of dosing advices were 
performed centrally.   
In case of a neutralizing hypersensitivity reaction, patients were switched to 
intravenous Erwinase®, starting with 20,000 IU/m2 three times a week for two 
weeks. After two weeks, the dose and/or dosing schedule was adjusted to ensure 
Erwinase® activity levels >100 IU/L.  
 
Efficacy  
PEGasparaginase doses and trough asparaginase activity levels were analyzed with 
a target range of 100-250 IU/L. For TDM of Erwinase®, also the adjusted dosing 
intervals were analyzed. Asparagine and glutamine concentrations were measured 
in serum samples collected in the Erasmus MC. Beside total asparagine levels, L-
asparagine was measured as this type of asparagine is incorporated in proteins and 
hydrolyzed by L-asparaginase (Supplemental methods).23 
 
Toxicity 
Asparaginase-associated toxicity (<2 weeks after an asparaginase dose) was graded 
according to the Common Terminology Criteria for Adverse Events (CTCAE) version 
4.03. Hypersensitivity reactions (neutralizing allergies, allergic-like reactions or SI), 
≥grade 3 central neurotoxicity (ataxia, somnolence, a depressed level of 
consciousness, agitation, seizures and posterior reversible encephalopathy 
syndrome (PRES)), ≥grade 3 pancreatitis, fulfilling the criteria described by 
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Schmiegelow et al.24, the number of patients with at least one infection (≥grade 2), 
and ≥grade 3 thrombosis without central line thromboses, were registered by the 
DCOG. Hepatotoxicity, hypertriglyceridemia, the number of transfusions, and 
hyperglycemia were analyzed in a subset of 50 patients.  
Toxicity was correlated with the asparaginase activity levels and compared to 
patients treated according to the ALL-10 protocol, which is similar to ALL-11 but 
with native E.coli asparaginase treatment during induction (8x5,000 IU/m2, trough 
levels 143-182 IU/L), and PEGasparaginase during intensification (2,500 IU/m2, 
mean trough level 899 IU/L) (Table 2).20, 25  
 
Measurements and statistical analysis  
The measurements of asparaginase activity levels, asparagine and glutamine 
concentrations, and antibodies, as well as the statistical analysis are described in 





Three hundred eighty-two patients were included with a median age of 5.3 years 
(IQR 3.3–10.3); the median age of the patients in whom the extra laboratory 
measurements were performed was 4.7, IQR 3.4–7.7 years. After induction, 108 
patients were treated as SR, 243 patients as MR, and 18 as patients HR. 
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Figure 1 shows the PEGasparaginase dose (median and interquartile range), the trough asparaginase 
activity levels (median and interquartile range), and corresponding asparagine levels during the 
different PEGasparaginase doses. The first three doses had a fixed dose of 1500 IU/m2, after which the 
doses were individualized.  
The asparagine comprised both L- and D-asparagine as L-asparagine was measured in only 50 patients. 
This figure only includes patients without a neutralizing hypersensitivity reaction. 
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Efficacy  
Figure 1 shows the PEGasparaginase doses and corresponding trough 
PEGasparaginase activity levels of non-allergic patients. The first three doses were 
fixed at 1,500 IU/m2. Thereafter, doses were reduced in all patients targeting 
trough levels of 100-250 IU/L. Overall, 97% of the trough levels was ≥100 IU/L. 
After the 10th administration, stable median asparaginase activity levels within 
range were reached, with a median dose of 450 IU/m2 (IQR 450 – 500 IU/m2). There 
were no PEGasparaginase levels <50 IU/L at that point; 68-87% of the trough levels 
was within the target range of 100-250 IU/L (Table 1).  
Thirty-seven patients started with 20,000 IU/m2 Erwinase®, three times a week, for 
two weeks. In 26 patients, the dose and/or dosing frequency was adjusted. During 
the first two weeks, 89 out of 117 48h levels (76%) and 16 out of 67 72h levels 
(24%) were >100 IU/L. Thereafter, the Erwinase® dose varied between 15,000–
40,000 IU/m2. Thirteen patients (57%) were treated every-other-day (72% of the 
48h levels (120/166 levels) >100 IU/L), and three patients (13%) were treated two 
times a week (63% 72h levels (10/19) and 44% 96h levels (7/16) >100 IU/L). Of the 
ten patients who continued treatment 3x/week after the first two weeks, 76% of 
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Table 1. Asparaginase activity levels of patients without a hypersensitivity reaction 
   Trough asparaginase activity level 
 
  n <50 IU/L 
n (%) 
50 - 99 IU/L 
n (%) 




All patients After dose 1  319 1 (<0.5%) 7 (2%) 61 (19%) 250 (79%) 
After dose 2 287 4 (1%) 10 (4%) 26 (9%) 247 (86%) 
After dose 3*  - - - - 
SR + MR 
patients 




After dose 5 184 2 (1%) 2 (1%) 17 (9%) 163 (89%) 
After dose 6 177 1 (1%) 2 (1%) 37 (21%) 137 (77%) 
After dose 7 187 1 (1%) 1 (1%) 84 (45%) 101 (54%) 
After dose 8 169 0 3 (2%) 77 (46%) 89 (53%) 
After dose 9 165 0 2 (1%) 96 (58%) 67 (41%) 
After dose 10 144 0 5 (4%) 95 (66%) 44 (30%) 
After dose 11 149 0 3 (2%) 101 (68%) 45 (30%) 
After dose 12 122 0 4 (3%) 84 (69%) 34 (28%) 
After dose 13 129 0 7 (5%) 105 (82%) 17 (13%) 
After dose 14 120 1 (1%) 7 (6%) 96 (80%) 16 (13%) 
After dose 15 108 0 6 (6%) 83 (77%) 19 (17%) 
After dose 16 148 0 5 (3%) 129 (87%) 14 (10%) 
After dose 17 77 0 4 (5%) 60 (78%) 13 (17%) 
* There was no asparaginase activity level measured after the third PEGasparaginase dose. Just prior to 
that dose, a trough level was measured on which the first dose adjustment of the first dose in 
intensification was based. 
 
 
Asparagine and glutamine were measured in 754 samples (637 samples 
PEGasparaginase (asparagine concentrations in Figure 1); 117 samples Erwinase®) 
in 110 patients. Median baseline asparagine and glutamine levels were 68.52 μM 
and 557 μM (n=12), respectively. During asparaginase treatment, asparagine varied 
between 0.03–1.26 μM. Of the samples >100 IU/L, asparagine was <0.2 μM in 45%, 
and <0.5 μM (<1% of baseline asparagine concentration) in 96% for 
PEGasparaginase, but in 11% and 67%, respectively, for Erwinase®. 
Beside total asparagine levels, L-asparagine was measured. The median L-
asparagine concentration in PEGasparaginase samples (n=50, asparaginase activity 
level 11–752 IU/L) was 0.15 μM (IQR 0.08–0.24 μM), and 0.10 μM (IQR 0.05–0.15 
μM) in Erwinase® samples (n=20, asparaginase activity level 13–530 IU/L) 
(Supplemental figure 3). Overall, 76% of the samples with an asparaginase activity 
level >100 IU/L had an L-asparagine level <0.2 μM. 
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The mean glutamine level was 571 µM (SD 159 µM) during PEGasparaginase and 
600 µM (SD 192 µM) during Erwinase® treatment, which was not lower than the 




Ten percent (n=40) had a neutralizing hypersensitivity reaction to PEGasparaginase 
(Table 2): 6% (n=22) had an allergy; 4% (n=18) SI. The incidence was 3% (n=13) 
during induction and 7% (n=27) during MR intensification. SI and allergies during 
induction occurred after all doses; during intensification, SI only occurred after the 
first dose. Of the eight patients with an allergy during MR intensification, five (62%) 
were during the first and three (38%) during the second dose.  
None of the patients with a reaction during induction had PEGasparaginase or 
native E.coli asparaginase antibodies. Of the reactions during the first dose of 
intensification, 33% were accompanied with PEGasparaginase antibodies and 11% 
with anti-native E.coli asparaginase antibodies. The three patients with an allergy 
during the second dose of intensification were positive for both antibodies.  
Five patients (1%) had an allergic-like reaction (Table 2). PEGasparaginase was 
completed in 4 patients. One patient was switched to Erwinase® because the 
reaction was not recognized as an allergic-like reaction.  
Of the 37 patients switched to Erwinase®, four patients (10%) developed an allergy 
(n=2) to or SI (n=2) of Erwinase® (Table 1). Four patients (10%) had an allergic-like 
reaction; Erwinase® was completed in two of these four.  
Pancreatitis 
The cumulative incidence of pancreatitis was 12% (n=34, Figure 2).The median age 
at diagnosis was 8.3 years (IQR 5.0–13.5 years) versus 5.2 years (IQR 3.2–9.8 years) 
in patients without pancreatitis (p=0.001). The cumulative incidence during 
induction was 4% (n=14). After induction, this was 0% for SR patients, 8% for MR 
patients, and 6% for HR patients (one patient). There was no statistically significant 
correlation between pancreatitis and asparaginase activity levels. PEGasparaginase 
was successfully reintroduced in three patients.  
In ALL-10, pancreatitis occurred in 1% of the patients during induction and in 5% of 
the patients during intensification (Table 3).26, 25 
 










































































































































































































































































































































































































































































































































































































































































































































































































Table 3. Asparaginase-associated toxicity during DCOG ALL-10 and DCOG ALL-11 
 DCOG ALL-1026, 25 DCOG ALL-11 
 Native E. coli asparaginase 
Trough levels: 143 – 182 
IU/L 
PEGasparaginase 
Median trough level: 403 IU/L 
Induction   
   Pancreatitis (≥grade 3) Incidence 1% Cumulative incidence 4% 
   Thrombosis (≥grade 3) Incidence 2% Cumulative incidence 4% 
   Central neurotoxicity (≥grade 3) Incidence 2% Cumulative incidence 1% 
   Infections (number of    
patients  
   with at least one ≥grade 2  
   infection) 
Protocol 1A: 37% 
Protocol 1B: 41% 
Protocol 1A: 35% 
Protocol 1B: 42% 
   Hepatotoxicity Alanine transaminase 
increased in 36% of the 
patients 
Grade 3/4 
hyperbilirubinemia in 11% 
of the patients 
Alanine transaminase increased 
in 26% of the patients 
Grade 3/4 hyperbilirubinemia in 
10% of the patients 
   Dyslipidemia Not reported Grade 3/4 hypertriglyceridemia 
in 12% of the patients   
Intensification PEGasparaginase 
Mean trough level 899 IU/L 
PEGasparaginase 
Median trough level: 272 IU/L 
   Pancreatitis (≥grade 3) Incidence 5% Cumulative incidence 8% 
   Thrombosis (≥grade 3) Incidence 3% Cumulative incidence 2% 
   Central neurotoxicity (≥grade 3) Incidence 10% Cumulative incidence 3% 
   Infections (number of patients  
   with at least one ≥grade 2  
   infection) 
Week 1-19: 46% 
Week 20-35: 53% 
Week 1-19: 35% 
Week 20-35: 38% 
   Hepatotoxicity Not reported Alanine transaminase increased 
in 50% of the patients 
Grade 3/4 hyperbilirubinemia in 
3% of the patients 
   Dyslipidemia Grade 3/4 
hypertriglyceridemia in 47% 
of the patients   
Grade 3/4 hypertriglyceridemia 
in 37% of the patients   
* The ALL-10 intensification phase included 6 doses of doxorubicin. The ALL-11 intensification phase 









The cumulative incidence of central neurotoxicity was 4% (n=12, Figure 2), the 
majority having PRES (8/12 patients). Age at diagnosis of the patients with and 
without neurotoxicity did not differ. During induction, four patients (cumulative 
incidence 1%) had central neurotoxicity. After induction, this was 0% for SR 
patients, 3% for MR patients and 6% for HR patients (one patient). There was no 
statistically significant correlation between central neurotoxicity and asparaginase 
levels. In all but one patient, asparaginase was completed.  
In ALL-10, central neurotoxicity occurred in 2% of the patients during induction and 
10% during intensification (Table 3).26, 25  
 
Thrombosis 
The cumulative incidence of thrombosis was 6% (n=19, Figure 2), of which 84% was 
a sagittal sinus thrombosis and 16% deep venous thrombosis of an extremity. The 
median age was 9.2 years (IQR 6.8–11.3 years) versus 5.2 years (IQR 3.2–9.9 years) 
of patients without thrombosis(p=0.003). The cumulative incidence was 4% (n=14) 
during induction. After induction, this was 0% in SR and HR patients, and 2% in MR 
intensification. There was no statistically significant correlation between 
thrombosis and asparaginase activity levels. Asparaginase, with concomitant 
LMWH administration, was completed in 18 out of the 19 patients.  
In ALL-10, thrombosis occurred in 2% of patients during induction and 3% during 
intensification (Table 3).26, 25  
 
Infections 
The number of patients with at least one infection during induction was 
comparable between ALL-11 and ALL-10: 35% versus 37% in protocol 1A, and 42% 
versus 41% in protocol 1B. However, less patients had an infection during MR 
intensification in ALL-11: 35% versus 46% in the first 19 weeks, and 38% versus 53% 
in week 20-35 (Table 3).27 ALL-10 intensification, however, included 6 doses of 
doxorubicin instead of 4 doses (or none in case of EVT6/RUNX1 positive leukemia’s 













Figure 2 shows the cumulative incidences of asparaginase-associated pancreatitis, central neurotoxicity and 
thrombosis for all patients (left) and after risk stratification (right) for standard risk (SR), medium risk (MR) and high 
risk (HR) patients. Of note, only 18 patients were stratified as HR and the cumulative incidence of 6% for 
pancreatitis and central neurotoxicity reflect only one patient.  
The end of induction is indicated with a vertical dotted line. The cumulative incidences after risk stratification did 
not comprise the toxicity which occurred during induction.  
 




The hepatotoxicity was reflected by alanine transaminase (ALT) and bilirubin 
concentrations (Supplemental table 3 and Figure 3). Grade 3/4 increased ALT 
occurred in 26% of the patients during induction and 50% during intensification; 
grade 3/4 hyperbilirubinemia occurred in 10% of the patients during induction and 
3% during intensification. Longitudinal analysis showed that ALT and bilirubin were 
higher with higher asparaginase activity levels (p=0.004 and p<0.001, respectively) 
(Supplemental figure 2). In ALL-10, ALT was increased in 36% of the patients and 
grade 3/4 hyperbilirubinemia occurred in 11% of the patients during induction 
(Table 3).26, 25  
 
Hypertriglyceridemia 
Grade 3/4 hypertriglyceridemia occurred in 12% of the patients during induction 
and 37% during intensification (Supplemental table 3), without clinical 
consequences. Triglycerides were mainly increased prior to the 6th 
PEGasparaginase dose (Figure 3), directly after administration of dexamethasone. 
In ALL-10, 47% of the patients had grade 3/4 hypertriglyceridemia during 
intensification. We found  no correlation between triglyceride concentrations and 
asparaginase activity levels.  
 
Other toxicity 
During induction, the median number of erythrocyte and thrombocyte transfusions 
administrated since the start of asparaginase to two weeks after the third dose was 
1 (IQR 1–2 and 0–2, respectively), and 0 (IQR 0–1 and 0–0, respectively) during 
intensification (Supplemental table 3). Glucose levels were rarely increased 
throughout the asparaginase treatment (Figure 3), and only one patient had grade 




































































































































































































































































































































































































The efficacy and toxicity of individualized asparaginase therapy was analyzed. With 
our nation-wide TDM program, the PEGasparaginase dose was reduced to a 
median of 450 IU/m2 with asparaginase activity levels >100 IU/L in 97% of the non-
allergic patients. This dose reduction leads to a substantial reduction of the 
asparaginase-associated costs.28 The starting dose of 1,500 IU/m2 proved to be 
adequate as trough asparaginase activity levels were >100 IU/L in 98% of the 
patients after the first dose, and in 95% after the second.  
 
Efficacy of the TDM program was evaluated by measurement of asparagine and 
glutamine. Accurate sample handling is essential to avoid ex vivo asparaginase 
activity.29, 30 In our samples, asparagine was measurable and glutamine was not 
decreased, confirming that the samples were adequately processed. Asparagine 
was <0.5 μM in 96% of the PEGasparaginase samples >100 IU/L but only in 67% of 
the Erwinase® samples. However, L-asparagine concentrations measured in these 
samples were very low (73% of the samples <0.2 μM), showing a considerable 
influence of the irrelevant D-asparagine on total asparagine concentrations. This is 
the first study reporting L-asparagine concentrations during asparaginase 
treatment.  
 
Compared to ALL-10, the pattern of occurrence of a hypersensitivity reaction and 
the formation of antibodies have changed fundamentally in ALL-11. Patients were 
treated during induction with native E.coli asparaginase in ALL-10 and 
PEGasparaginase in ALL-11, whereas both protocols used PEGasparaginase during 
intensification. In ALL-10, during induction, 5% had a hypersensitivity reaction to 
native E.coli asparaginase.25 In ALL-11, this percentage was 3% to PEGasparaginase. 
During ALL-10 intensification, 30% had a neutralizing hypersensitivity reaction, 
which is much more than the 7% in ALL-11. In ALL-10, these reactions almost 
exclusively occurred during the second PEGasparaginase dose, and they were all 
accompanied with antibodies to E.coli asparaginase.26 In contrast, in ALL-11, the 
reactions occurred during both the first and second PEGasparaginase dose in 
intensification, and native E.coli asparaginase antibodies were absent in the 
majority of the patients, as was also the case with the reactions during induction. 
Only the three patients with a reaction during the second PEGasparaginase dose 
during intensification had, like ALL-10, antibodies to native E.coli asparaginase and 
PEGasparaginase. Thus, by using PEGasparaginase, patients do not necessarily 




seem to develop reactions to the asparaginase moiety, except for the few patients 
with a reaction during the second dose during intensification.   
In ALL-11, PEGasparaginase antibodies were also absent in the far majority of the 
patients with a neutralizing reaction. More detailed measurements have shown 
that by coating the plates with PEGasparaginase in a basic carbonate coating buffer 
(pH 9.5), PEG hydrolyses from PEGasparaginase.31 Thus, possible anti-PEG 
antibodies were not measured with the assay used. As anti-PEG antibodies have 
been described earlier32, the majority of the hypersensitivity reactions in ALL-11 
were probably against the PEG moiety or even against the linker connecting the 
PEG to asparaginase.31  
 
In order to assess whether lowering asparaginase levels by TDM leads to less 
toxicity, toxicity was correlated with asparaginase activity levels and compared to 
ALL-10 (Table 2). In ALL-10, the asparaginase activity levels were significantly lower 
during induction but much higher during intensification compared to ALL-11. 
During induction, the occurrence of thrombosis and central neurotoxicity was 
similar between the two protocols and there was no correlation with asparaginase 
activity levels. Pancreatitis, however, seems to occur more frequently in ALL-11 (4% 
versus 1% in ALL-10). This might be due to the longer asparaginase exposure during 
ALL-11 induction (42 days in ALL-11 versus 24 in ALL-10) as there was no correlation 
between the PEGasparaginase level itself and pancreatitis. The percentage of 
patients who developed grade 3/4 hyperbilirubinemia did not differ, despite the 
correlation between asparaginase activity levels and bilirubin levels, which is, 
though statistically significant, clinically irrelevant.  
The toxicity during the intensification phase was comparable as well. Only central 
neurotoxicity occurred more often (10% versus 3%) and infection occurred more 
often in ALL-10 versus ALL-11.27 However, the anthracycline therapy was less 
intensive in ALL-11, resulting in less myelosuppression, but only during the first 13 
weeks of the intensification. Grade 3/4 hypertriglyceridemia occurred less often in 
ALL-11 (37% versus 47% in ALL-10), although a correlation with asparaginase 
activity levels was not found. This is in contrast to the correlation found in our 
earlier studies, which could be explained by less variation in the ALL-11 
asparaginase levels as a result of the TDM. Comparing the rough data of ALL-10 
triglycerides26 with ALL-11, the median triglycerides are higher during ALL-10 (4.6 
mmol/L) than ALL-11 (2.6 mmol/L), with more outliers in ALL10 (Supplemental 
figure 4). Thus, the correlation between asparaginase activity levels and 
triglycerides only holds for higher asparaginase levels. 
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We conclude that TDM of asparaginase is feasible in a nation-wide program and 
results in a substantial dose reduction without loss of efficacy of treatment – 
reflected by asparagine depletion –  though survival analyses should be awaited. In 
addition, TDM leads to detection of SI in 4% and identification of  allergic-like 
reactions in 1% of the patients. However, the effect of the PEGasparaginase dose 
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Asparaginase activity levels were measured using the L-aspartic β-hydroxamate 
(AHA) assay as described earlier.1, 2 Asparaginase inactivation was defined as 
PEGasparaginase activity <100 IU/L after 7±1 days (week level) and/or <10 IU/L 
after 14±1 days (trough level).  
For asparagine and glutamine measurement, whole blood was directly put on ice 
and 10% sulfosalicylic acid was added. The samples were stored in -80°C until 
analysis using liquid chromatography tandem-mass spectrometry (limit of 
quantification: 0.05 μM). Human asparagine measured comprises both L-
asparagine and D-asparagine. The latter is also present in humans but not 
incorporated in proteins, and ranges between 0.017–0.18 µM.3 Therefore, beside 
the total asparagine concentration, L-asparagine was measured in 50 patients with 
varying asparaginase activity levels.  
PEGasparaginase and native E. coli asparaginase antibodies were measured with 
Enzyme-Linked Immuno Sorbent Assay (ELISA) as described earlier.5 The threshold 
for a positive antibody measurement was calculated using the F-measure.6  
 
Statistical analysis 
The data was analyzed with the software package SPSS Statistics version 21.0 (IBM 
Corp, Armonk, New York, USA) and R Sigmaplot Version 3.3.3 (Systat Software Inc, 
London, UK). Continuous data was presented as mean and standard deviation (SD) 
or median and interquartile range (IQR). Student t-tests, Mann-Whitney U tests, χ2-
(trend)tests, and Fisher exact tests were used to compare baseline characteristics. 
To account for the repeated measurement design to estimate the effect of 
asparaginase activity levels on laboratory measurements, marginal models were 
estimated. The cumulative incidence of pancreatitis, central neurotoxicity and 
thrombosis starting from asparaginase treatment were estimated by using Kaplan-
Meier’s methodology. Due to the presence of repeated measurements, a mixed 
effect model was estimated to study the association between pancreatitis, central 
neurotoxicity and thrombosis and asparaginase activity levels. 
 
 
Chapter 250   |
46 
 
Supplemental Table 1: DCOG ALL-11 treatment protocol 
Treatment phase Therapy 
Protocol 1A  
   Prednisone 60 mg/m2/day for 29 days followed by 3x3 days tapering 
   Vincristine 1.5 mg/m2/dose at day 8, 15, 22 and 29 
   Daunorubicin 30 mg/m2/dose at day 8, 15, 22 and 29 (not in case of 
Down syndrome) 
   PEGasparaginase 1,500 IU/m2 at day 12, 26 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 15 and 33. Only intrathecal 
methotrexate at day 1. 
Protocol 1B  
   PEGasparaginase 1,500 IU/m2 at day 40 
   Cyclophosphamide 1,000 mg/m2/dose at day 36 and 64 
   Cytarabine 75 mg/m2/day at days 38 – 41, 45 – 48, 52 – 55, 59 – 62 
   6-Mercaptopurine 60 mg/m2/day at days 36 – 63 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 45 and 59 
Protocol M for SR and MR patients  
   6-Mercaptopurine 25 mg/m2/day for 56 days 
   Methotrexate 5,000 mg/m2/dose at day 8, 22, 36 and 50 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 8, 22, 36 and 50 
Protocol IV for SR patients  
   Dexamethasone 10 mg/m2/day for 15 days followed by 3x3 days tapering 
   Vincristine 1.5 mg/m2/dose at day 1 and 8 
   PEGasparaginase   Individualized dose at day 1 
Maintenance for SR patients  
   6-Mercaptopurine* 50 mg/m2/day for 81 weeks 
   Methotrexate*  20 mg/m2/week for 81 weeks 
Intensification and maintenance for MR 
patients 
 
   Dexamethasone 6 mg/m2/day for 5 days every 3 weeks until week 82 
   Vincristine 2 mg/m2/dose every three weeks until week 82 
   Doxorubicin 30 mg/m2/dose at week 1, 4, 7 and 10 (not in case of Down 
syndrome or TEL/AML1) 
   PEGasparaginase Individualized doses biweekly from week 1 – 27** 
   Methotrexate* 30 mg/m2/week from week 13 – 84 (or week 2 – 84 in case 
of Down syndrome or TEL/AML1), not during intrathecal 
therapy 
In case of an IKZF1 deletion, 200 mg/m2/dose every three 
weeks from week 85 - 136 
   6-Mercaptopurine* 50 mg/m2/day from week 1 – 12 in courses of 2 weeks with 
1 week interruption (without interruption in case of Down 
syndrome or TEL/AML1) and from week 13 – 84 daily, 
without interruption 
In case of an IKZF1 deletion, 100 mg/m2/day for 10 days 
after each methotrexate dose from week 85 - 136 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 










High risk blocks for HR patients 
HR block 1  
   6-Mercaptopurine 25mg/m2/day from days 1 - 14 
   Methotrexate 5,000 mg/m2 at day 1 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 1 
   Cyclophosphamide 1,200 mg/m2/dose at day 15, 16 and 17 
   Etoposide 350 mg/m2/dose at day 15, 16 and 17 
   PEGasparaginase 1,500 IU/m2 at day 22 
   Vincristine 1.5 mg/m2/dose at day 22 and 29 
HR block 2  
   Methotrexate 5,000 mg/m2 at day 1 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 1 
   Cytarabine 1,500 mg/m2/dose at day 15, 16, 17, 18 and 19 
   Mitoxantrone 5.25 mg/m2/dose at day 15, 16, 17, 18 and 19 
   PEGasparaginase 1,500 IU/m2 at day 22 
   Vincristine 1.5 mg/m2/dose at day 22 and 29 
HR block 3  
   Methotrexate 5,000 mg/m2 at day 1 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 1 
   Idarubicin 6 mg/m2/dose at day 15, 16 and 17 
   Fludarabine 22.5 mg/m2/dose at day 15, 16, 17, 18 and 19 
   Cytarabine 1,500 mg/m2/dose at day 15, 16, 17, 18 and 19 
HR block 4   Equal to HR block 1, but without 6-Mercaptopurine 
HR block 5  Equal to HR block 2 
HR block 6  Equal to HR block 3, but without Idarubicin 
HR Protocol II   
   Dexamethasone 10 mg/m2/day at days 1 – 21 followed by 3x3 days tapering 
   Vincristine 1.5 mg/m2/dose at day 8, 15, 22 and 29 
   Doxorubicin 30 mg/m2/dose at day 8, 15, 22 and 29 
   PEGasparaginase 1,500 IU/m2 at day 8 
   Cyclophosphamide 1,000 mg/m2 at day 36 
   6-Thioguanine 60 mg/m2/day at days 36 – 49 
   Cytarabine 75 mg/m2/day at days 36 – 39 and 43 – 46 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 36 and 43  
HR maintenance   
   6-Mercaptopurine 50 mg/m2/day from week 1 – 37 
   Methotrexate 20 mg/m2/week from week 1 – 37 
* Not if patients are eligible for a stem cell transplantation 
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>600 IU/L 50% 
500 – 599 IU/L 60% 
400 – 499 IU/L 70% 
300 – 399 IU/L 80% 
200 – 299 IU/L 100% 
100 – 199 IU/L  100% 
50 – 99 IU/L 100% 
30 – 49 IU/L 150% 






Supplemental table 3. Transfusions and laboratory measurements during 
induction and intensification 
Maximal toxicity Induction 
N=50 
Medium risk intensification 
N=30 
Number of erythrocyte transfusions 
(median, IQR) 
1 (1 – 2) 0 (0 – 1) 
Number of thrombocyte transfusions 
(median, IQR) 
1 (0 – 2) 0 (0 – 0) 
 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 
Increased ALT 36 (72%) 13 (26%) 11 (36%) 15 (50%) 
Increased bilirubin 34 (68%) 5 (10%) 15 (50%) 1 (3%) 
Increased glucose 21 (42%) 1 (2%) 17 (57%) 0 
Hypertriglyceridemia 26 (52%) 6 (12%) 13 (43%) 11 (37%) 
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Supplemental figure 2 shows the alanine transaminase (ALT) and bilirubin levels for different asparaginase 
activity levels. Longitudinal analysis showed that ALT and bilirubin levels were significantly higher with 
higher asparaginase activity levels (p=0.004 and p<0.001, respectively). 
The triglyceride, amylase and glucose levels were not included in this figure as longitudinal analyses did 
not show a correlation between these parameters and asparaginase activity levels. 
The boxplot includes the 25th, 50th and 75th percentile in the boxes, the outliers (○), extreme outliers (*),  
and the ranges (indicated by the whiskers). 

















Supplemental figure 3 shows the L-asparagine levels of 50 PEGasparaginase and 20 Erwinase® 
samples in the box plots. The boxplot includes the 25th, 50th and 75th percentile in the boxes and the 
ranges (indicated by the whiskers). 
 
For both the PEGasparaginase and Erwinase® samples, there was no association between L-
asparagine and asparaginase activity levels (p=0.587 and p=0.267, respectively).  
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Supplemental figure 4 shows the triglyceride levels, plotted against the asparaginase activity levels, for 
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Background Considerable inter- and intra-patient variability exist in serum activity 
levels of PEGasparaginase, an essential component of pediatric acute 
lymphoblastic leukemia treatment. Here, a population pharmacokinetic (popPK) 
model was developed, identifying patient characteristics explaining these 
variabilities. 
Methods Patients (n=92) were treated according to the Dutch Childhood Oncology 
Group ALL-11 protocol, using therapeutic drug monitoring to individualize the 
PEGasparaginase doses. Non-linear mixed effects modeling (NONMEM) was used 
to analyze the popPK evaluating several covariates. The final model was validated 
using an independent database (n=28) and guidelines for starting doses and dose 
adjustments were developed. 
Results A 1-compartment model with time-dependent clearance (CL) adequately 
described the popPK. The inter-individual variability in CL and volume of 
distribution was reduced by normalization of these parameters by body surface 
area (BSA). CL was 0.084 L/day/m2 for 12.7 days, increasing with 0.082 
L/day/m2/day thereafter. CL was 38% higher during an infection (p<0.001), and 11-
19% higher during induction treatment than during intensification and 
maintenance. Targeting an asparaginase activity level of 100 IU/L, a loading dose 
of 800 IU/m2 (induction) and 600 IU/m2 (intensification) is advised. 
Conclusion In conclusion, variability of PEGasparaginase activity levels can be 
explained by BSA, treatment phase and the occurrence of an infection. With the 
popPK model developed in this study, PEGasparaginase treatment can be 
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Asparaginase plays an important role in the treatment of pediatric acute 
lymphoblastic leukemia (ALL). The drug converts asparagine in aspartic acid and 
ammonia, resulting in apoptosis of the leukemic cells, as these cells highly depend 
on extracellular asparagine pools for protein synthesis.1-3 An asparaginase activity 
level of >100 IU/L is considered to be sufficient for complete asparagine 
depletion.4-10 Currently, different formulations of asparaginase derived from 
Erwinia chrysanthemi or E. coli are available in clinical practice, all with different 
pharmacokinetic properties.11, 12 One of these formulations is the polyethylene 
glycol (PEG) conjugated form of E. coli asparaginase, also known as 
PEGasparaginase, which has several advantages compared to the native E.coli 
asparaginase. First, the risk of developing a neutralizing hypersensitivity reaction 
to asparaginase is reduced when using PEGasparaginase.13-15 Second, 
PEGasparaginase can be administered less frequently than other asparaginase 
formulations because of its relatively long half-life.16, 17 Therefore, 
PEGasparaginase is currently used as a first-line formulation in most developed 
countries. However, considerable inter- and intra-patient variability of 
PEGasparaginase levels has been observed and it is, therefore, difficult to 
determine the right dose for the individual patient.17, 18 Currently, asparaginase 
therapy in Dutch pediatric patients with ALL is individualized with therapeutic drug 
monitoring (TDM). However, more insight in PEGasparaginase population 
pharmacokinetics (PK) – and especially in characteristics explaining the variability – 
is needed to optimize individualized dosing. Recently, Hempel et al. have described 
body surface area (BSA) as an important factor explaining variability in clearance 
(CL). However, the influence of other patient factors is still unknown.17 Therefore, 
the aim of this study was to describe the PK of PEGasparaginase in our cohort, to 
gain more insight in factors influencing the CL, and to develop a dosing guideline 




Patients and treatment protocol 
Patients (1-18 years old) with newly diagnosed ALL between November 2014 and 
May 2017, treated according to the Dutch Childhood Oncology Group (DCOG) ALL-
Chapter 362   |
58 
 
11 treatment protocol in the Sophia Children’s Hospital – Erasmus MC, Rotterdam, 
The Netherlands, were included. In these patients, trough-, top-, week- and other 
levels were prospectively measured. Data from asparaginase activity levels 
measured after the last dose as part of our nationwide TDM program from several 
patients from other Dutch pediatric oncology centers were included as well, 
providing asparaginase activity levels measured after the last dose. The study was 
approved by the Institutional Review Board (CCMO register: NL50250.078.14). 
Informed consent was obtained from  patients 12 years or older, the parents or 
guardians in accordance with the Declaration of Helsinki.   
According to the DCOG ALL-11 protocol, patients were stratified in a standard- 
(SR), medium- (MR) and high risk group (HR) after induction. Supplemental Table 1 
describes the complete treatment for each risk group. Figure 1 schematically 
shows the concomitant chemotherapy per treatment phase.  
Figure 1. Concomitant chemotherapy 
 
Regarding the PEGasparaginase therapy, all patients were treated with three doses 
of PEGasparaginase (1,500 IU/m2, biweekly) during the induction phase (protocol 
1A and 1B). For the SR and MR patients, the subsequent dose(s) were 
individualized based on trough asparaginase activity levels. SR patients received 
one individualized dose after an interval of approximately 12 weeks during 
protocol IV; MR patients received another 14 individualized doses, either directly 
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after the first three doses or after an interval of approximately 12 weeks during 
the intensification and maintenance phase as part of a randomized study. HR 
patients received another 2-5 doses with a fixed dose of 1,500 IU/m2. When a 
neutralizing allergy or silent inactivation occurred, patients were switched to 




Asparaginase activity levels were measured using the L-aspartic β-hydroxamate 
(AHA) assay as described previously.19 Briefly, AHA is added to patient serum 
containing PEGasparaginase and consequently hydrolyzed to L-aspartic acid and 
hydroxylamine. Hydroxylamine condenses with 8-hydroxyquinoline and oxidizes to 
indooxine, which is quantified by photometric detection at 690 nm. The lower limit 
of quantification (LLQ) was 10 IU/L.  
Trough asparaginase activity levels and occasional week levels were standardly 
measured as part of the TDM program. Additional asparaginase activity levels were 
determined in residual blood, which was left over after other laboratory 
measurements. Furthermore, at several time points, top levels were measured in 
blood drawn within 1h after the administration of PEGasparaginase. 
Anti-asparaginase antibodies were measured using enzyme-linked immunosorbent 
assay (ELISA) and expressed as optical density (OD) readings as described earlier.18  
 
Population pharmacokinetic analysis 
The population pharmacokinetic analysis was performed using NONMEM® Version 
7.2 (Icon Development Solutions, Ellicott City, Maryland, USA). Other statistical 
analyses were performed using IBM SPSS Statistics (IBM Corp, Armonk, New York, 
USA) version 21.0 for Windows. The graphs to evaluate the models were prepared 
in R and Sigmaplot Version 3.4.1 (Systat Software Inc, London, UK).  
The complete modeling process is described in the Supplemental methods. Briefly, 
after log transformation of the data, several structural models were evaluated 
using one- and two compartment models with linear, nonlinear, and time-
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dependent elimination. Since body surface area (BSA) is known to highly influence 
the pharmacokinetics of PEGasparaginase, BSA (calculated with the Mosteller 
formula20) was included in the structural model to scale volume of distribution (Vd) 
and CL.  
 
Covariate analysis 
Several demographic, clinical and therapy-related covariates were evaluated and 
listed in Supplemental table 2.  Beside differences between treatment phase and 
concomitant chemotherapy, administration of ciprofloxacin, antihistaminic drugs, 
hydrocortisone, itraconazole,  fluconazole, valaciclovir and gabapentin were 
evaluated. In case of missing data of continuous covariates, the last known value 
or the median was implemented. Missing discontinuous data was excluded from 
the analysis.  
First, the covariates were explored with univariate analyses after which the 
significant covariates (p<0.05) were evaluated using a stepwise forward inclusion, 
followed by backward elimination (p<0.001) in a multivariate analysis.  
 
Model validation and development of dosing guidelines 
The final model was validated using goodness of fit plots and visual predictive 
checks (VPC) which are described in the Supplemental methods. An independent 
database, which was obtained by randomly selecting 25% of the total population, 
was used for external validation of the model.  
To develop dosing guidelines for dose adjustments, Monte Carlo simulations were 
performed. A starting dose for PEGasparaginase was calculated taking into account 
the significant covariates influencing the PEGasparaginase CL. Doses were 
calculated targeting trough asparaginase activity levels higher than 100 IU/L, 250 
IU/L and 350 IU/L. By stepwise increasing the PEGasparaginase dose in simulations, 
it was evaluated which loading and maintenance dose provides adequate trough 
levels in 95% of the simulated patients.   
Next, a guideline was developed to adjust the PEGasparaginase dose based on 
week- or trough levels targeting at a trough asparaginase activity level of 100-250 
IU/L or 250-400 IU/L. For adjustment of the PEGasparaginase dose based on levels 
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measured after one week, trough levels were predicted on the basis of the 




Patients and samples 
In total, 120 patients were included in the study. Ninety-two patients were 
included in the index dataset and 28 patients in the validation dataset. 
Supplemental table 2 describes the patient characteristics of the two datasets. The 
patients in the validation database were older (median 8.0 years, interquartile 
range (IQR) 3.3 – 12.5 years) than in the main database (median 4.8 years, IQR  3.3 
– 8.2 years), and had a higher weight (median 28.0, IQR 16.6 – 47.9 versus 19.2, 
14.9 – 29.3).  
Table 1 shows the characteristics and distribution of the samples. In the index 
database, 816 samples were measured in 92 patients. The majority of the levels 
were top-, week- or trough levels, and were measured during the intensification 
and maintenance phase of the MR group. Supplemental figure 1 shows all 
asparaginase activity levels plotted against the time after dose. 
Table 1. Sample characteristics 
 Index dataset  
n = 92 
Validation dataset 
n = 28 
Total number of samples 816 405 
Number of levels per patient, median (IQR) (range) 3 (2 – 12) (1 – 38) 6 (2 – 33) (1 – 39) 
Sample time (%) 
   0-7 days 
   8-14 days 









Number of levels per treatment phase 
   1A 
   1B 
   M 
   MR intensification 
   MR maintenance 
   SR protocol IV 























The development of the structural pharmacokinetic model is described in the 
Supplemental results. The estimated population PK parameters are given in Table 
2. Concentration-time profiles were best described by a one-compartment model. 
Adding a second compartment did not improve the model. Normalization of the CL 
by BSA reduced the (unexplained) inter-individual variability (IIV) of this parameter 
from 29.6% to 24.1%. Intra-patient variability (IOV) was 25.7%. As demonstrated in  






Bootstrap of the final model 
Estimate 95% CI 
OFV -1140.4 -1203.77   
CL (L/day/m2) 0.075 (5.2%) 0.084 (4.4%) 0.084 0.078 – 0.090 
Vd (L/m2) 0.92 (4.7%) 0.94 (4.5%) 0.94 0.87 – 1.01 
Slope CLind (L/day/m2/day) 0.079 (31.5%) 0.082 (20.5%) 0.080 0.052 – 0.115 
Split point (days) 12.9 (1.1%) 12.7 (0.2%) 12.7 11.8 – 13.1 
Correlation CL and Vd 1.11 (13.4%) 1.26 (10.2%) 1.28 0.98 – 1.51  
Covariates 
     Treatment phase 1A 
                                     1B 
                                     M 
                                     MRG intens. 
                                     MRG maint. 
                                     SRG protocol IV 




























0.80 – 0.95 
0.82 – 0.98 
0.75 – 0.86 
0.73 – 0.90 
1.15 – 1.67 
IIV 
   CL (%) 











14.6 – 24.0 
NA 
IOV 








18.5 – 27.5 
Residual variability 
   Additional (IU/L) 











12.7 – 298 
14.2 – 19.5 
Shrinkage 
   IIV CL 













Final model:   
 TAD <12.7 days:  
CL = 0.075 * BSA * 1.38INFECTION * 0.87M * 0.89MRG INTENS. * 0.81MRG MAINT. * 0.81SRG PROTOCOL IV * eηIIV + ηIOV 
 TAD >12.7 days: 
CL = 0.075 * BSA * (1+0.079 * (TAD – 12.7)) * 1.38INFECTION * 0.87M * 0.89MRG INTENS. * 0.81MRG MAINT. * 0.81SRG 
PROTOCOL IV * eηIIV + ηIOV 
Vd = 0.92 * e1.11 * ηIIV) 
Values for INFECTION, M, MG INTENS., MRG MAINT. And SRG PROTOCOL IV: 0 (no) or 1 (yes). 
RSE: relative standard error; CI: confidence interval; OFV: objective function value; CL: clearance, Vd: 
volume of distribution, Cind: induced clearance; MRG intens.: medium risk group intensification; MRG 
maint.: medium risk group maintenance; IIV: inter-individual variability; IOV: interoccasion variability; NA: 
not applicable; TAD: time after dose. 
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Supplemental figure 1, the elimination of PEGasparaginase was not linear. Several 
models with time dependent CL were evaluated.21 The structural model – so 
without the effect of covariates – best described the data with a CL of 0.075 
L/day/m2 for the first 12.9 days after a dose, increasing with 0.079 L/day/m2 per 
day thereafter. Thus, during the first 12.9 days, the half-life of PEGasparaginase 
was 8.5 days and, thereafter, decreased to 4.1 days after one day, and 2.7 days 
after two days. 
 
Covariate analysis 
The univariate analysis resulted in 16 covariates significantly correlated with 
PEGasparaginase CL (Table 3). In the stepwise forward inclusion procedure, the 
presence of an infection was first added to the structural model, followed by 
treatment phase. The CL increased with 38% when a patient had an infection. In 
comparison with treatment phase 1A, which was used as a reference, CL was lower 
during protocol M, MR intensification and maintenance, and SR protocol IV. This 
association was independent of the presence of an infection. The CL in phase 1B 
was equal to 1A. Only two patients were treated as high risk, so the association 
between the HR blocks and PEGasparaginase CL could not be estimated reliably 
and was fixed to one. Adding ICU admission to the model (beside infection and 
treatment phase),  did not improve the fit of the model to the data, nor did the 
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Table 3. Univariate covariate analysis 
Covariate Effect: Θ (95% CI) Δ OFV Included after backward 
elimination? 
Anti-native E. coli asparaginase  
   antibodies (extinction values) 
0.05 (-0.01 – 0.11) -12.9 No 
Anti-PEGasparaginase  
   antibodies (extinction values) 
0.04 (-0.01 – 0.10) -7.3 No 
Creatinine -0.21 (-0.36 – -0.07) -17.0 No 
Leukocytes -0.09 (-0.13 – 0.05) -22.9 No 
ICU admission 1.61 (1.55 – 1.67) -31.0 No 
Infection 1.45 (1.11 – 1.79) -52.5 Yes 
Treatment phase 
   1A 
   1B 
   M 
   MRG intens. 
   MRG maint. 




0.86 (0.78 – 0.94) 
0.86 (0.77 – 0.95) 
0.78 (0.71 – 0.85) 
0.78 (0.67 – 0.88) 
-42.3 Yes 
Other chemotherapy 
   Prednisone    
   Vincristine 
   Daunorubicine 
   6-Mercaptopurine 
   Cyclophosphamide 
   Cytarabine 
   Methotrexate 
   Dexamethasone 
   Doxorubicin 
 
1.11 (0.97 – 1.25) 
0.89 (0.82 – 0.96) 
1.11 (0.97 – 1.25) 
0.91 (0.84 – 0.99) 
1.13 (0.98 – 1.22) 
1.13 (0.93 – 1.33) 
0.85 (0.80 – 0.91) 
0.85 (0.78 – 0.91) 





















* To evaluate any chemotherapy-related effects on clearance on top of the treatment phase, all 
chemotherapy were first included in the multivariate analysis. Only inclusion of doxorubicin and 
methotrexate resulted in a significant improvement of the model (OFV -6.0, mean effect (RSE): 
1.24 (6%) and OFV -10.3, mean effect (RSE): 0.88 (5%), respectively). 
CI: confidence interval; OFV: objective function value; ICU: intensive care unit,  
MRG intens.: medium risk intensification; MRG maint.: medium risk maintenance phase. 
Covariates significantly influenced the clearance in the univariate analysis when the OFV decreased 
with >3.84 (p<0.05). 
 
Evaluation of the effect of a specific chemotherapeutic agent on CL was difficult 
because blood concentrations of those agents were not measured and many 
chemotherapeutics are administrated concomitantly. Therefore, it was assumed 
that a possible effect of the agent on CL was present during the entire treatment 
phase. As a result, the treatment phase and the administration of a 
chemotherapeutic agent was highly correlated. 
However, as shown in Figure 1, the intensification phase of MR patients with a 
TEL/AML1 translocation did not contain doxorubicin but these patients were 
treated with methotrexate beside dexamethasone, vincristine, 6-mercaptopurine 
and PEGasparaginase. The other MR patients first received 4x doxorubicin in 12 
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weeks, followed by methotrexate. Although not significant in the univariate 
analysis, based on clinical grounds, both doxorubicin and methotrexate were 
evaluated in the multivariate analysis as the effect of these drugs could be 
analyzed  independently of treatment phase. In the univariate analysis, CL 
appeared 11% lower during MR intensification and 19% lower during MR 
maintenance compared to protocol 1A.  
Separate addition of the agents to the model both improved the fit of the model 
(doxorubicin higher CL, methotrexate lower CL).  However, in the backward 
elimination, both drugs turned out not to influence the PEGasparaginase CL 
significantly and were, therefore, excluded from the final model.   
Thus, the final population PK model included, besides BSA, the presence of an 
infection and treatment phase as covariates significantly associated with the CL of 
PEGasparaginase. Inclusion of these parameters reduced the IIV of CL from 24.1% 
to 19.7% (18% reduction), and IOV from 25.7% to 23.6% (8% reduction) (Table 2). 
In this final model, CL was 0.084 L/day/m2 for 12.7 days, increasing with 0.082 
L/day/m2/day thereafter. 
 
Goodness of fit and model validation 
The parameter estimates of the final model were precise regarding the relative 
standard errors, and the shrinkage values were acceptable (Table 2). The goodness 
of fit plots showed an even distribution of the population predictions and 
individual predictions around the line of unity (Supplemental figure 2). The 
conditional weighted residuals plotted against the time after dose were also 
evenly distributed with a mean of zero, and no trend was found. The bootstrap 
analysis showed that the bootstrap estimates were consistent with the parameter 
estimates of the final model and the 95% confidence intervals were accurate 
(Table 2). The visual predictive check of the index dataset is shown in 
Supplemental figure 3. Both the median estimates and the 95% confidence 
intervals are within the simulated predicted values.  Thus, the final model is 
accurate in predicting the PEGasparaginase population pharmacokinetics.  
As an external validation, the final model derived from the index dataset was used 
to predict the asparaginase activity levels of the independent validation dataset. 
The goodness of fit plots and VPC of the validation dataset also show that the final 
model is adequate to describe the PEGasparaginase pharmacokinetics 
(Supplemental figure 2 and 3). 




Table 4 shows several dosing regimens for PEGasparaginase (loading dose and 
maintenance dose) during induction and MRG intensification. Targeting at a trough 
PEGasparaginase activity level of 100 IU/L, the loading dose recommended during 
induction is 800 IU/m2 followed by a biweekly maintenance dose of 600 IU/m2. For 
PEGasparaginase treatment during intensification, lower doses should be 
administered due to decreased CL, being 600 IU/m2 and 400 IU/m2, respectively, to 
target 100 IU/L.  
Table 4. Dosing guideline, starting dose 
 Target trough 
asparaginase level  
Loading dose Maintenance dose 
Protocol 1A (induction) 100 IU/L 800 IU/m2 600 IU/m2 
 250 IU/L 1,800 IU/m2 1,400 IU/m2 
 350 IU/L 2,200 IU/m2 1,600 IU/m2 
Medium risk intensification 100 IU/L 600 IU/m2 400 IU/m2 
 250 IU/L 1,500 IU/m2 1,000 IU/m2 
 350 IU/L 1,800 IU/m2 1,800 IU/m2 
 
Based on the half-life during the first 13 days, the steady state is estimated to be 
reached after 2 doses, after which the dose can be adjusted based on trough or 
week asparaginase activity levels targeting trough levels between 100 and 250 IU/L 
or 250 and 400 IU/L (Table 5). If an infection occurs, it is advised to increase the 
dose with 38%, if clinically possible.  
Table 5. Dosing guideline, dose adjustments 
Target trough level: 100-250 IU/L Target trough level: 250-400 IU/L 
Week level Trough level Dose 
adjustment 
Week level Trough level Dose 
adjustment 
50-100 IU/L 25-50 IU/L 400% 100-200 IU/L 50-100 IU/L 400% 
100-250 IU/L 50-75 IU/L 300% 200-300 IU/L 100-150 IU/L 300% 
150-200 IU/L 75-100 IU/L 200% 300-250 IU/L 150-200 IU/L 200% 
200-450 IU/L 100-250 IU/L 100% 350-450 IU/L 200-250 IU/L 175% 
450-550 IU/L 250-300 IU/L 60% 450-700 IU/L 250-400 IU/L 100% 
550-750 IU/L 300-400 IU/L 50% 700-900 IU/L 400-500 IU/L 70% 
750-1100 IU/L 400-600 IU/L 40% 900-1100 IU/L 500-600 IU/L 60% 
1100-1500 IU/L 600-800 IU/L 25% 1100-1250 IU/L 600-700 IU/L 50% 
1500-1800 IU/L 800-1000 IU/L 20% 1250-1800 IU/L 700-1000 IU/L 35% 
The dose adjustments apply for biweekly administration of PEGasparaginase during steady state. The doses may 
be adjusted based on week (7 days) or trough (14 days) after administration targeting at trough asparaginase 
activity levels of 100-250 IU/L or 250-400 IU/L. 
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In this study, the population pharmacokinetics of PEGasparaginase were 
investigated in order to identify patient and clinical characteristics associated with 
the CL of PEGasparaginase. Furthermore, the population PK model was used to 
develop a dosing guideline for the drug. It was shown that the CL is constant 
during the first 13 days after administration and increases thereafter. In addition, 
the CL was higher during induction, and during an infection.  
During development of the structural model, both first- and zero-order, nor 
Michaelis Menten elimination described the concentration-time profile of 
PEGasparaginase adequately. This has also been reported by Hempel et al. and 
Würthwein et al.17, 21 In the present study, similar to Würthwein et al., the time 
dependency of CL proved to be described most adequately with a split model, 
showing that CL increases substantially after a period of approximately 13 days. 
This induced CL could be explained by the hydrolysis of the PEG moiety from the 
PEGasparaginase molecule, resulting in native E. coli asparaginase with a linker 
attached, originally connecting PEG with the asparaginase. Thus, CL will increase to 
a value more or less comparable with that of  native E. coli asparaginase, which has 
a half-life of 1.3 days16, after several days.  
Several associations between covariates and the PEGasparaginase CL were 
identified. The metabolism of PEGasparaginase appears to depend on treatment 
phase and is influenced by the presence of an infection. Native E. coli asparaginase 
is being eliminated mainly by the macrophages of the mononuclear phagocyte 
system (MPS) in the bone marrow, spleen and liver.22 Although the mechanism of 
elimination of PEGasparaginase has not been studied, it is likely that this also holds 
for the PEGylated formulation as other PEGylated drugs are also eliminated by the 
cells of the MPS.23  
CL was the highest during protocol 1A containing vincristine, prednisone and 
daunorubicin. MR intensification, maintenance and SR protocol IV had lower CL 
and all contain vincristine as well, so an effect of vincristine is unlikely. Especially 
because the CL during MR maintenance is lower than MR intensification, either 
doxorubicin and/or methotrexate probably influence the PEGasparaginase CL. The 
fact that the CL is the highest in induction might be caused by the other 
anthracycline, daunorubicin, which is administered weekly, whereas doxorubicin, 
is administered once every 3 weeks in intensification.  
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Beside the administration of specific chemotherapeutics, other mechanisms may 
explain the differences in CL between the treatment phases. It has to be taken into 
account that the physical condition of the patient alters during ALL treatment: 
during protocol 1A (and also 1B), the tumor load is higher and therapy is more 
intense compared to protocol M, MR intensification and maintenance, and SR 
protocol IV, which all had a lower CL. The MPS plays a role in tumor lysis 24, 25, 
which may explain why the CL is higher during this treatment phase as well, 
although the asparaginase treatment starts at day 12 of the treatment protocol.  
Strikingly, the occurrence of an infection increases the CL with 38%, independent 
of the treatment phase and BSA, probably because of the activation of the MPS, 
which is responsible for the CL of asparaginase. This means that the 
PEGasparaginase activity levels will be 38% lower during an infection and that the 
PEGasparaginase dose should be increased with this percentage to obtain similar 
levels. Evidently, this should first be validated in clinical practice, taking into 
account the clinical situation of the patient.    
BSA was included in the structural model, showing that the CL of PEGasparaginase 
increases with BSA, which is in line with the findings of Hempel et al.17 Sassen et 
al., however, have studied the CL of Erwinia asparaginase and found the opposite: 
patients with a lower weight have a higher CL, requiring a higher starting dose of 
the drug.26 Shrey et al. have studied the native E. coli asparaginase levels in 
different age groups and also show lower asparaginase activity levels in younger 
patients, suggesting a higher CL in these patients.27 Thus, for a PEGylated form of 
asparaginase, this does not seem to apply, which is also supported by a study of 
PEGylated interferon alfa-2b in children, which also shows that the CL increases 
with age.28  
Based on the population pharmacokinetic model, dosing guidelines were 
developed taking into account the effect of treatment phase on PEGasparaginase 
CL. Next, dose adjustments based on both week- and trough levels were suggested 
targeting 100-250 IU/L or the higher range of 250-400 IU/L. These dosing 
guidelines, however, should first be validated clinically. In addition, the effect of 
increasing the dose in case of an infection on PEGasparaginase activity levels 
should be analyzed. 
In conclusion, 18% of the inter- and 8% of the intra-patient variability in CL of 
PEGasparaginase, normalized for BSA, can be explained by 1) treatment phase 
showing a higher CL during induction treatment (protocol 1A), and 2) the 
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occurrence of an infection, which increases the CL. With the population PK model 
developed in this study, PEGasparaginase treatment may be individualized further, 
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Population PK analysis 
The activity data were logarithmically transformed and the analysis was performed 
with the First Order Conditional Estimation method with interaction (FOCE+I). 
In the development of the structural model, one- and two compartment models 
were evaluated. Subsequently, models with first- and zero-order elimination, 
Michaelis-Menten elimination, and time-dependent elimination were explored. 
The pharmacokinetics were expressed in terms of clearance (CL) and volume of 
distribution (Vd).  
Time profiles of PEGasparaginase activity versus time were adequately described 
using a one-compartment model. Addition of  a second compartment did not 
improve the model. Models with first- and zero-order elimination did not describe 
the data adequately. Models with time-dependent CL, previously described by 
Würthwein et al.1 described the data better.  
Inter-individual variability and inter-occasion variability, with an occasion defined 
as administration of a new dose, and correlation between Cl and Vd were assessed 
in the models. Inter-individual and inter-occasion variability in Cl and Vd was 
characterized with exponential models. For example, the elimination for the ith 
patient was estimated using the following equation: 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 =  Θ𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × 𝑒𝑒𝑒𝑒(𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂+𝑘𝑘𝑘𝑘𝜂𝜂𝜂𝜂) 
Were Θpop is the typical population value for CL.  ηi and ki represent random 
effects accounting for individual and occasion variation from the typical value. η i 
and ki are assumed to be symmetrically distributed with a mean of 0 and estimated 
variance of ω2 and π2. 
Additional and proportional error models were evaluated to account for the 
residual error. Furthermore, since body surface area (BSA) is known to be an 
important covariate for PEGasparaginase pharmacokinetics, this was included in 
the structural model.  
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 =  Θ𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑥𝑥𝑥𝑥 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 × 𝑒𝑒𝑒𝑒(𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂+𝑘𝑘𝑘𝑘𝜂𝜂𝜂𝜂) 
To allow for asparaginase activity levels below the limit of quantification (LLQ), 
several methods were applied. Both the M3 2 and M2 method, however, resulted 
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in unstable runs of particularly the time-varying elimination models. Because only 
4% of the patients had developed a neutralizing hypersensitivity reaction, this has 
only little influence on the analysis. Therefore, we have decided to exclude the 
values <LLQ. 
The precision of the parameter estimates, objective function values (OFV’s) and 
goodness of fit plots were used for selection of the models evaluated. A decrease 
in the OFV of >3.84 points and >10.83 points was considered as a significant 
improvement of the model with significance of p<0.05 and p<0.001, respectively.  
After obtaining the structural model, several covariates were evaluated as 







𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 × 𝑐𝑐𝑐𝑐𝛩𝛩𝛩𝛩 
 
For example, the effect of the continuous covariate leukocyte count on Cl was 
explored by incorporating the leukocyte count divided by the median (2.4 *109/L) 
to the power of Θ in the equations of Cl and Vd. The discontinuous covariate 
‘infection’ was explored by multiplying the Cl and Vd by Θ in case of an infection. 
The covariates were first explored with univariate analysis after which the 
significant covariates (OFV -3.84) were evaluated with stepwise forward inclusion 
and backward elimination (OFV -10.83).  
A bootstrap analysis with 1000 bootstrap replicates was used to assess the 
robustness of the model. Visual predictive check (VPC) plots were used for internal 
validation of the model. An independent validation dataset, obtained by randomly 
selecting 25% of the total population, was used to validate the final model 
externally. The VPCs were prediction corrected to correct for the dose adjustments 
of PEGasparaginase. 
 





First, the asparaginase activity levels were log transformed. To account for residual 
error, an additive and proportional model were evaluated. As a combined model of 
proportional and additive error was superior, this was further used in development 
of the model. Linear models and models with time-constant elimination did not 
adequately describe the data. This analysis, however, showed that a one-
compartment model was sufficient and adding body surface area (BSA) as a 
covariate did significantly improved the model (OFV -22.7). Also inter-individual 
variability (IIV) on Cl and Vd, inter-occasion variability (IOV) on Cl, and correlation 
between Cl and Vd significantly improved the model. Next, the models with time-
varying clearance as described by Würthwein et al.1 were tested. These models 
comprised several exponential elimination equations with initial and induced 
clearance. However, these models did not adequately describe the data as well. 
Würthwein et al.1 have concluded that a split point model best describes the 
PEGasparaginase pharmacokinetics by exploring transit models. They concluded 
that the Cl was constant at first but increased after approximately 10 days. 
Therefore, we next have evaluated a transit model, estimating after how many 
days the clearance increases.  
This model most adequately described the data, estimating the split point at 12.9 
days after administration. Hence, the final structural model was as follows: 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 (𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 13 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑓𝑓𝑓𝑓) =  𝛩𝛩𝛩𝛩1 ∗ 𝑒𝑒𝑒𝑒𝜂𝜂𝜂𝜂+ 𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂 ∗ 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 (𝑑𝑑𝑑𝑑𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑒𝑒𝑒𝑒𝑓𝑓𝑓𝑓 13 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑓𝑓𝑓𝑓) =  𝛩𝛩𝛩𝛩1 ∗  𝑒𝑒𝑒𝑒𝜂𝜂𝜂𝜂+ 𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂𝜂 ∗ 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 ∗  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 = 1 + 𝛩𝛩𝛩𝛩2 ∗ (𝑇𝑇𝑇𝑇𝐵𝐵𝐵𝐵𝑇𝑇𝑇𝑇 − 𝑓𝑓𝑓𝑓𝑠𝑠𝑠𝑠𝐶𝐶𝐶𝐶𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑓𝑓𝑓𝑓𝑝𝑝𝑝𝑝𝑓𝑓𝑓𝑓) 
𝑉𝑉𝑉𝑉𝑑𝑑𝑑𝑑 =  𝛩𝛩𝛩𝛩3 ∗ 𝑒𝑒𝑒𝑒𝛩𝛩𝛩𝛩4∗ 𝜂𝜂𝜂𝜂 ∗ 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 
Where TAD is time after dose and the Clind increases with 𝛩𝛩𝛩𝛩2 per day. In the 
equation of Vd, 𝛩𝛩𝛩𝛩4 represents the correlation between Cl and Vd. Table 2 shows 
the parameter estimates of the final model with a Cl of 0.075 L/day/m2 , increasing 
with 0.079 L/day/m2 after 12.9 days, and a Vd of 0.92 L/m2. IIV on Vd could not be 
estimated as this completely correlated with the correlation between Cl and Vd.  
After obtaining the structural model, the covariates were evaluated one by one. 
Univariate analysis resulted in 16 significant covariates influencing the clearance 
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(Table 3). However, the anti-asparaginase antibodies, creatinine and leukocytes 
had large relative standard errors and the 95% confidence interval included 0. 
Infection, treatment phase and intensive care unit (ICU) admission resulted in the 
largest decrease of OFV and were therefore first evaluated during the multivariate 
analysis. Multivariate analysis with treatment phase and the presence of an 
infection significantly improved the model (OFV -21.6) compared to the structural 
model. Further addition of ICU admission did not improve the model (OFV -2.6) 
and was, therefore, excluded. Similar results were found for anti-asparaginase 
antibodies, creatinine and leukocyte levels. As explained in the main article, only 
methotrexate and doxorubicin significantly improved the model on top of 
treatment phase and infection (OFV -10.3, mean effect (RSE): 0.88 (5%) and OFV -
6.0, mean effect (RSE): 1.24 (6%), respectively). Adding both drugs in the analysis 
did not improve the model (OFV -0.04) and both drugs were not significant during 
backward elimination. Finally, treatment phase and infection were included in the 
final model.  
 
Simulations 
Using the final population model, Monte Carlo simulations were performed for 
2000 virtual patients with BSA ranging from 0.52 to 2.3 m2. All patients received bi-
weekly steady-state doses of PEG-asparaginase with doses ascending from 100 
IU/m2 to 3000 IU/m2 in 100 IU/m2 steps. Trough levels and levels one week after 
administration were evaluated. Target trough levels of 100 – 250 IU/ml 
corresponded to levels of 200 – 450 IU/ml at one week after administration. 
Similarly, target trough levels of 250-400 IU/ml corresponded to levels of 450-750 
IU/ml at one week after administration. When simulated levels were outside the 
target range it was evaluated to what extent the dose had to be increased or 
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Supplemental Table 1: DCOG ALL-11 treatment protocol 
Treatment phase Therapy 
Protocol 1A  
   Prednisone 60 mg/m2/day for 29 days followed by 3x3 days tapering 
   Vincristine 1.5 mg/m2/dose at day 8, 15, 22 and 29 
   Daunorubicin 30 mg/m2/dose at day 8, 15, 22 and 29 (not in case of Down 
syndrome) 
   PEGasparaginase 1,500 IU/m2 at day 12, 26 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 15 and 33. Only intrathecal methotrexate 
at day 1. 
Protocol 1B  
   PEGasparaginase 1,500 IU/m2 at day 40 
   Cyclophosphamide 1,000 mg/m2/dose at day 36 and 64 
   Cytarabine 75 mg/m2/day at days 38 – 41, 45 – 48, 52 – 55, 59 – 62 
   6-Mercaptopurine 60 mg/m2/day at days 36 – 63 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 45 and 59 
Protocol M for SR and MR patients  
   6-Mercaptopurine 25 mg/m2/day for 56 days 
   Methotrexate 5,000 mg/m2/dose at day 8, 22, 36 and 50 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 8, 22, 36 and 50 
Protocol IV for SR patients  
   Dexamethasone 10 mg/m2/day for 15 days followed by 3x3 days tapering 
   Vincristine 1.5 mg/m2/dose at day 1 and 8 
   PEGasparaginase   Individualized dose at day 1 
Maintenance for SR patients  
   6-Mercaptopurine* 50 mg/m2/day for 81 weeks 
   Methotrexate*  20 mg/m2/week for 81 weeks 
Intensification and maintenance for MR 
patients 
 
   Dexamethasone 6 mg/m2/day for 5 days every 3 weeks until week 82 
   Vincristine 2 mg/m2/dose every three weeks until week 82 
   Doxorubicin 30 mg/m2/dose at week 1, 4, 7 and 10 (not in case of Down 
syndrome or TEL/AML1) 
   PEGasparaginase Individualized doses biweekly from week 1 – 27** 
   Methotrexate* 30 mg/m2/week from week 13 – 84 (or week 2 – 84 in case 
of Down syndrome or TEL/AML1), not during intrathecal 
therapy 
In case of an IKZF1 deletion, 200 mg/m2/dose every three 
weeks from week 85 - 136 
   6-Mercaptopurine* 50 mg/m2/day from week 1 – 12 in courses of 2 weeks with 1 
week interruption (without interruption in case of Down 
syndrome or TEL/AML1) and from week 13 – 84 daily, 
without interruption 
In case of an IKZF1 deletion, 100 mg/m2/day for 10 days after 
each methotrexate dose from week 85 - 136 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
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High risk blocks for HR patients 
HR block 1  
   6-Mercaptopurine 25mg/m2/day from days 1 - 14 
   Methotrexate 5,000 mg/m2 at day 1 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 1 
   Cyclophosphamide 1,200 mg/m2/dose at day 15, 16 and 17 
   Etoposide 350 mg/m2/dose at day 15, 16 and 17 
   PEGasparaginase 1,500 IU/m2 at day 22 
   Vincristine 1.5 mg/m2/dose at day 22 and 29 
HR block 2  
   Methotrexate 5,000 mg/m2 at day 1 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 1 
   Cytarabine 1,500 mg/m2/dose at day 15, 16, 17, 18 and 19 
   Mitoxantrone 5.25 mg/m2/dose at day 15, 16, 17, 18 and 19 
   PEGasparaginase 1,500 IU/m2 at day 22 
   Vincristine 1.5 mg/m2/dose at day 22 and 29 
HR block 3  
   Methotrexate 5,000 mg/m2 at day 1 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 1 
   Idarubicin 6 mg/m2/dose at day 15, 16 and 17 
   Fludarabine 22.5 mg/m2/dose at day 15, 16, 17, 18 and 19 
   Cytarabine 1,500 mg/m2/dose at day 15, 16, 17, 18 and 19 
HR block 4   Equal to HR block 1, but without 6-Mercaptopurine 
HR block 5  Equal to HR block 2 
HR block 6  Equal to HR block 3, but without Idarubicin 
HR Protocol II   
   Dexamethasone 10 mg/m2/day at days 1 – 21 followed by 3x3 days tapering 
   Vincristine 1.5 mg/m2/dose at day 8, 15, 22 and 29 
   Doxorubicin 30 mg/m2/dose at day 8, 15, 22 and 29 
   PEGasparaginase 1,500 IU/m2 at day 8 
   Cyclophosphamide 1,000 mg/m2 at day 36 
   6-Thioguanine 60 mg/m2/day at days 36 – 49 
   Cytarabine 75 mg/m2/day at days 36 – 39 and 43 – 46 
   Intrathecal methotrexate, cytarabine and 
      prednisone 
8 – 12 mg methotrexate, 20-30 mg cytarabine, 8-12 mg 
prednisone at day 36 and 43  
HR maintenance   
   6-Mercaptopurine 50 mg/m2/day from week 1 – 37 
   Methotrexate 20 mg/m2/week from week 1 – 37 
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Supplemental Table 2. Patient characteristics 
  Index dataset n = 92 Validation dataset n = 28 
Sex  
   Male 







Age, years (median, IQR) 4.8 (3.3 – 8.2) 7.7 (3.3 – 12.5) 
Weight, kg (median, IQR)* 19.2 (14.9 – 29.3) 28.0 (16.5 – 47.9) 
BSA, m2 (median, IQR)* 0.76 (0.65 – 1.05) 1.04 (0.68 – 1.44) 
Type of ALL 
   Pro-B cell 
   Common B-cell 
   Pre-B cell  
   Common T-cell 













Genetics of ALL 
   TEL/AML1 
   t(1;19) 
   MLL-rearrangements 
   Hyperdiploid 
   Other B cell 
   Other T cell 
   IKZF1-deletion 




















   Standard risk 
   Medium risk (%)  
     Continuous 
     Discontinuous 
   High risk 















Asparaginase related toxicity 
   Allergy 
   Silent inactivation 
   Central neurotoxicity# 
   Thrombosis# 
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Supplemental Table 2 continued       
Number of infections$  






Number of ICU admissions 






Leukocytes, * 109/L (median, 
IQR) 
Measurements missing (%)% 
2.4 (1.5 – 4.0) 
100 (8%)  
2.4 (1.6 – 3.4) 
20 (5%) 
AST, U/L (median, IQR) 
Measurements missing (%)%  
44 (30 – 65)  
364 (45%)  
46 (33 – 66) 
155 (38%) 
ALT, U/L (median, IQR) 
Measurements missing (%)% 
65 (40 – 95) 
364 (45%)  
67 (45 – 97) 
155 (38%) 
Creatinine, μmol/L (median, 
IQR) 
Measurements missing (%)% 
27 (22 – 33) 
508 (62%) 
27 (21 – 38) 
237 (59%) 
Albumin, g/L (median, IQR) 
Measurements missing (%)% 
33 (29 – 40) 
721 (88%) 
32 (27 – 39) 
370 (91%) 
Native E. coli asp AB, OD 
(median, IQR) 
Measurements missing (%)% 
0.018 (0.010 – 0.030) 
333 (41%) 
0.008 (0.006 – 0.018) 
228 (56%) 
PEGasp AB, OD (median, 
IQR) 
Measurements missing (%)% 
0.019 (0.010 – 0.034) 
333 (41%) 
0.009 (0.006 – 0.017) 
228 (56%) 
IQR: interquartile range; BSA: body surface area; PRES: posterior reversible encephalopathy syndrome; ICU: 
intensive care unit; AB: antibodies; AST: aspartate transaminase ; ALT: alanine transaminase; OD: optical density; 
AB: antibodies asp: asparaginase; PEGasp: PEGasparaginase. Laboratory measurements were done during 
asparaginase activity level measurement. 
% Clinical data of the patients not treated in the Sophia Children’s Hospital was missing.  
* Weight and BSA measured at start PEGasparaginase therapy. 
# Only Common Terminology Criteria for Adverse events 4.03 grade 3 and 4.  
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Supplemental Figure 1 shows the PEGasparaginase activity levels versus time after administration for the 
index database (  , n=92 ) and the validation database (  , n=28 ). Note that the asparaginase activity 
levels nonlinearly decline after 12.7 days. Of note, dose adjustments could (partially) explain the variation 
in asparaginase activity levels shown in this figure. 
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Supplemental Figure 2A and 2D show the observed asparaginase activity levels plotted against the population predicted values for 
the main and external database, respectively. In these figures, the dots are evenly distributed around the line of unity.  
Figure 2B and 2E show the observed values plotted against the individual predicted values. Also in this figure, the dots are evenly 
distributed around the line of unity.  
Figure 2C and 2F show the conditional weighted residuals (CWRES) plotted against the time after dose. Here, most dots are 
between -2 and 2, and show no trend. 
3
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Supplemental Figure 3A and 3B show the visual predictive checks of the index and validation dataset, 
respectively. The observations and their corresponding median and 95% confidence intervals are indicated 
by the points, and the solid and dashed red lines. In both graphs, these lines fall within the 95% confidence 
intervals of the median and 95% confidence intervals (red and blue shaded areas) as obtained by 
simulation.  
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Allergic-like Reactions to 
Asparaginase: Atypical Allergies 
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Background Asparaginase is an important component of pediatric acute 
lymphoblastic leukemia therapy. Unfortunately, this treatment is hampered by 
hypersensitivity reactions. In general, allergies cause complete inactivation of the 
drug, regardless of the severity. However, we report atypical allergic reactions 
without inactivation of asparaginase, here called allergic-like reactions.    
Methods Patients with an allergic-like reaction, who were treated according to the 
Dutch Childhood Oncology Group ALL-11 or the CoALL 08-09 protocol, were 
described. The reactions were identified by continuous measurement of 
asparaginase activity levels. Characteristics, including timing of occurrence, 
symptoms, grade and the presence of anti-asparaginase antibodies, were 
compared to those of real allergies. 
Results Fourteen allergic-like reactions occurred in nine patients. Five reactions 
were to PEGasparaginase and nine to Erwinia asparaginase. Allergic-like reactions 
occurred relatively late after the start of infusion compared to real allergies. 
Antibodies were absent in all but one patient with an allergic-like reaction while 
they were detected in all patients with a real allergy. Symptoms and grade did not 
differ between the groups. Asparaginase was continued with the same formulation 
in six patients of whom four finished treatment with adequate activity levels. 
Conclusion In conclusion, allergic-like reactions occur relatively late and without 
antibodies. Despite these clinical differences, allergic-like reactions can only be 
distinguished from real allergies by continuously measuring asparaginase activity 
levels. If clinically tolerated, formulations should not be switched in case of 
allergic-like reactions. Moreover, failure to recognize these reactions may lead to a 
less favorable prognosis if second line asparaginase therapy is terminated 
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Asparaginase is one of the key components of childhood acute lymphoblastic 
leukemia (ALL) therapy as intensive dosing-schedules improve event free survival 
with 10-15%.1-7 Unfortunately, asparaginase treatment is hampered by 
hypersensitivity reactions like clinical allergies and silent inactivation, which 
neutralize asparaginase completely.8 In case of silent inactivation, asparaginase is 
inactivated in absence of clinical symptoms. If asparaginase is neutralized due to 
an allergy or silent inactivation, formulations should be switched to maintain 
effective asparaginase treatment.9-11 
Previously, we have studied trough PEGasparaginase activity levels and allergies to 
asparaginase in pediatric ALL. The patients were first treated with several doses of 
native E. coli asparaginase in the induction phase. PEGasparaginase was 
administered in the intensification phase approximately 12 weeks after the last 
native E. coli asparaginase dose.8 Twenty two percent of the patients developed an 
allergic reaction. Most importantly, all allergic reactions to PEGasparaginase 
resulted in complete neutralization of asparaginase. This was regardless of the 
severity or grade of the reaction and was accompanied by anti-asparaginase 
antibodies. Premedication with clemastine or hydrocortisone reduced symptoms 
of the allergy but could not prevent neutralization of asparaginase.8 Ninety percent 
of the reactions occurred during the second PEGasparaginase dose. Interestingly, 
trough asparaginase activity levels already proved to be zero after the first 
PEGasparaginase dose, meaning asparaginase was already neutralized before the 
allergic reaction occurred. 8  
Beside these neutralizing hypersensitivity reactions, there seem to be atypical 
allergic reactions to asparaginase, also called allergic-like reactions, not resulting in 
inactivation of asparaginase. In case of these allergic-like reactions, formulations 
do not have to be switched to maintain adequate asparaginase therapy. Moreover, 
therapy may even be withheld unnecessarily when second line asparaginase is 
terminated prematurely because of it. Therefore, it is very important to distinguish 
between real allergies and allergic-like reactions. It is challenging, though, to 
interpret activity levels after an allergic reaction when the infusion is truncated 
prematurely and only part of the dose is administered. Fortunately, the trough 
asparaginase activity level of the preceding dose can be used to evaluate possible 
neutralization, which can be accomplished by continuous therapeutic drug 
monitoring (TDM). 
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In this article, we describe allergic-like reactions and compare these reactions to 
real allergies in order to find differences that can be used in clinical practice to 




Patients and treatment protocols 
Patients with allergic symptoms without asparaginase inactivation were described. 
These patients were treated according to the CoALL 08-09 treatment protocol or 
the Dutch Childhood Oncology Group (DCOG) ALL-11 protocol, in multiple pediatric 
oncology centers. These protocols are currently still open for inclusion and data 
are not complete yet. Therefore, the frequency of allergies and allergic-like 
reactions is not available at this time. As a comparison, we used all patients with 
an allergy and asparaginase inactivation from the Sophia Children’s Hospital, 
Rotterdam, the Netherlands, who were treated according to the DCOG ALL-10 
protocol and were partially described earlier.8 Use of data from the enrolled 
patients was approved by the Institutional Review Board.  
The CoALL 08-09 protocol contained three or four PEGasparaginase doses in the 
intensification phase, and one or two in the reinduction phase (2,500 IU/m2) after 
an asparaginase-free interval of approximately 4 weeks. The doses were 
administered intravenously over two hours: ten percent of the dose during the 
first hour, the remaining during the second.  Asparaginase activity levels were 
measured to detect silent inactivation. 
The DCOG ALL-11 protocol included three doses of PEGasparaginase in induction 
and, after an interval of approximately 12 weeks, 14 doses in the intensification 
and maintenance phase. After three doses of 1,500 IU/m2, TDM was used to 
individualize the doses based on trough levels.  
Patients who were treated according to the DCOG ALL-10 protocol received eight 
doses of 5,000 IU/m2 native E. coli asparaginase in induction and 15 
PEGasparaginase doses (2,500 IU/m2 biweekly) in the intensification and 
maintenance phase, also after an asparaginase-free interval of approximately 12 
weeks. Trough PEGasparaginase activity levels were measured for research 
purposes.  
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In both the DCOG ALL-10 and ALL-11 protocol, asparaginase was administered 
intravenously over one hour. In case of allergy or silent inactivation, patients were 
switched to 20,000 IU/m2 Erwinia asparaginase, administered three times a week. 
TDM was used to adjust the dose schedule for Erwinia asparaginase in the DCOG 
ALL-11 protocol. Erwinia asparaginase was administered intravenously over one 
hour. Asparaginase treatment was terminated when patients developed a 
hypersensitivity reaction to the latter formulation as well. 
 
Classification and description of allergic reactions 
Allergic reactions were classified as either ‘real’ or allergic-like, based on whether 
they were accompanied by asparaginase inactivation. An allergic reaction was 
considered real if trough levels of the preceding dose were already zero before 
administration of the reaction-inducing dose. In case of allergic-like reactions, 
asparaginase activity levels were measurable (> lower limit of quantitation) just 
prior to or after the reaction-inducing doses. 
When symptoms of an allergic reaction occurred, the following characteristics 
were described: asparaginase activity levels, time of occurrence, symptoms, 
further treatment and the presence of anti-asparaginase antibodies. Allergic and 
allergic-like reactions were graded according to the Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.03.  
 
Asparaginase activity analysis and anti-asparaginase antibody assay 
Asparaginase activity levels were measured based on the L-aspartic β-hydroxamate 
(AHA) assay.12 AHA was hydrolyzed by asparaginase to L-aspartic acid and 
hydroxylamine. Hydroxylamine (20 μL) was diluted with 8-hydroxiquinoline for 
condensation and oxidation and was quantified by photometric detection at 690 
nm. Trough PEGasparaginase activity levels were measured two weeks after 
administration and were considered adequate when >100 IU/L. Trough Erwinia 
asparaginase activity levels were measured 48 or 72 hours after administration 
and were also considered adequate when >100 IU/L.  
Antibodies against the different asparaginase formulations were determined by 
enzyme-linked immunosorbent assays (ELISA) as described earlier.8   
 
 




The data was analyzed with the software package IBM SPSS Statistics (IBM Corp, 
Armonk, New York, USA) version 21.0 for Windows. The time of occurrence of the 
reactions after the start of infusion and the presence of anti-asparaginase 
antibodies were analyzed by non-parametric tests. Symptoms were analyzed using 




Fourteen allergic-like reactions occurred in nine patients (Table 1). Five reactions 
were to PEGasparaginase, the remaining nine to Erwinia asparaginase. As a 
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Table 1. Allergic-like reactions 
Asp type Treatment protocol, 
phase and dose number 





 Trough level 
  (IU/L)* 
 Antibodies$ Action taken 
1 PEGasp COALL-08-09 
Reinduction, 2nd  
Grade 1: 
rash, itchiness 
60 min 137~ Unknown PEGasp continued, 
finished without other 
reactions. 
2 PEGasp COALL-08-09 




24 hours 1,657** 
749~ 
Unknown PEGasp continued, 
finished without other 
reactions. 
3 PEGasp ALL-11 
Intensification, 1st  
Grade 2:  
rash, edema, 
dyspnea 
20 min 83** Negative Switch to Erw, 
successfully# finished. 
4 PEGasp ALL-11 
Induction, 4th  
Grade 2:  
vomiting, pale 
45 min 561**  
122 




   Erw 
ALL-11 
Intensification, 1st  
Intensification, 6th  
 
- 












Switch to Erw. 
Erw stopped. 
6 Erw  ALL-11 
Intensification, 14th  
Grade 2:  
vomiting 
53 min 32 (T48) Negative Erw stopped. 
7 Erw ALL-11 
Intensification, 12th  
Intensification, 14th  
 
Intensification, 20th  
1. Grade 2:  
nausea 
2. Grade 2:  
dyspnea 

















1. Erw continued with 
clemastine and reduced 
infusion rate. 
2. Dose stopped but 
restarted and finished. 
3. Dose postponed, Erw 
successfully# finished. 
8 Erw ALL-11 
Intensification, 17th  
Grade 2:  
rash, dyspnea 
38 min 146 (T48) Negative Erw was continued but 
not finished because of 
an allergy. 
9 Erw ALL-11 
Intensification, 55th  
Intensification, 58th  
 
Intensification, 59th  
1. Grade 1: 
 rash 
2. Grade 1: 
rash 

















1. Erw continued with 
HCT and reduced 
infusion rate.  
2.Dose stopped but 
restarted and finished. 
3. Erw stopped. 
Asp, asparaginase; PEGasp, PEGasparaginase; Erw, Erwinia asparaginase; min, minutes; T48/72, 48 or 72 hours after 
previous dose; HCT, hydrocortisone. 
* Trough level just before reaction occurred. ** Week level after reaction occurred. ~ Trough level after reaction 
occurred. # Successfully: with adequate (>100 IU/L) asparaginase activity levels. $ In case of a reaction to 




Chapter 498   |
93 
 
Table 2. Allergic reactions 
Asp type Treatment 
protocol, phase 
and dose number 





 Trough level 
  (IU/L)* 
 Antibodies$ Action taken 





5 min 0 Positive Switch to Erw, reaction 
at dose 11, stop Erw. 
11 PEGasp ALL10 
Intensification, 2nd 
Grade 2: 
rash, edema,  
hypotension 
10 min 0 
0~ 
Positive PEGasp continued at 
first but successfully# 
switched to Erw after a 
second reaction.  




20 min 0 
0~ 
Positive PEGasp continued at 
first but successfully# 
switched to Erw after a 
second reaction. 




3 min 0 Positive Switch to Erw, 
successfully# finished. 





2 min 0 Positive Switch to Erw, 
successfully# finished. 





1 min 0 Positive Switch to Erw, 
successfully# finished. 





1 min 0 Positive Switch to Erw, 
successfully# finished. 




1 min 0 Positive Switch to Erw, 
successfully# finished. 




1 min 0 Positive Switch to Erw, 
successfully# finished. 




1 min 0 Positive Switch to Erw, 
successfully# finished. 




20 min 0 Positive Switch to Erw, 
successfully# finished. 





1 min 0 Positive Switch to Erw, 
successfully# finished. 





1 min 0 Positive Switch to Erw, 
successfully# finished. 




5 min 0 Unknown Switch to Erw, 
successfully# finished. 




5 min 0 Unknown Switch to Erw, 
successfully# finished. 
Asp, asparaginase; PEGasp, PEGasparaginase; Erw, Erwinia asparaginase; min, minutes. 
* Trough level just before reaction occurred. ~ Trough level after the reaction. # Successfully: with adequate 
asparaginase activity levels (>100 IU/L). $ Antibodies against PEGasparaginase and native E. coli asparaginase 
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Asparaginase activity levels 
The asparaginase activity levels are described in Table 1. Nine levels were obtained 
just prior to the allergy-inducing dose, five were measured after the reaction. In 
patients number one and two, the infusion was not stopped after the allergic-like 
reaction. Both patients had adequate trough PEGasparaginase activity levels after 
this dose (137 and 749 IU/L respectively).  
Patient number three, who received approximately one-third of the individualized 
dose (700 IU/m2), had an asparaginase activity level of 83 IU/L one week after the 
reaction to PEGasparaginase.  
Most patients had adequate Erwinia asparaginase trough levels after a dose 
interval of 48 hours. Only patient number six had an asparaginase activity level of 
32 IU/L just before the reaction-inducing dose. Asparaginase therapy was 
permanently discontinued  after this reaction. Patient number seven had 
inadequate asparaginase activity levels after each 72-hour dose interval. However, 
after increasing the dose frequency to a 48-hour schedule, asparaginase activity 
levels were adequate. 
All patients with a real allergic reaction already had asparaginase activity levels of 
zero prior to the reaction (Table 2). Since the majority of the reactions occurred 
almost immediately after start of infusion, which was stopped directly, 
asparaginase activity levels after the reaction would not have been informative 
and were therefore not measured. However, in patients number 11 and 12, trough 
activity levels after the reaction were available and were both zero.  
 
Anti-asparaginase antibodies 
Anti-asparaginase antibodies were not measured in patients number one and two. 
The other three allergic-like reactions to PEGasparaginase were not accompanied 
by antibodies against native E. coli asparaginase or PEGasparaginase (Table 1). 
Antibodies were also absent in all patients with an allergic-like reaction to Erwinia 
asparaginase, except for patient number seven. 
In contrast, all 15 patients with a real allergy to PEGasparaginase had detectable 
antibodies against both  PEGasparaginase and native E. coli asparaginase, which 
was significantly more frequent than in patients with an allergic-like reaction 
(p=0.001).  
 




The clinical characteristics are described in Table 1 for the allergic-like reactions, in 
Table 2 for the real allergies and summarized in Table 3.  
 
Table 3. Summary of clinical characteristics 
 Allergic-like reactions  Allergic reactions P-value 
Symptoms 
 Rash/oedema/itchiness/urticaria 
 Pulmonary symptoms 
 Gastro-intestinal symptoms 
 
9/13 reactions (69%) 
3/13 reactions (23%) 
6/13 reactions (46%) 
 
 14/15 reactions (93%) 
 6/15 reactions (40%) 





Timing of allergic reaction (median, IQR) 29 (12 – 47)  2 (1 – 5) <0.001 
Anti-asparaginase antibodies present 1/7 patients (14%)  13/13 patients (100%) 0.001 
IQR: interquartile range.  
 
 
The median CTCAE grade was grade two in both allergic and allergic-like reactions. 
Four out of the 14 allergic-like reactions were grade one, the grade of one reaction 
is unknown and the remaining nine were grade two. All real allergic reactions were 
grade two. The type of reactions, i.e. a) symptoms of rash, edema, itchiness or 
urticaria, b) pulmonary symptoms and c) gastro-intestinal symptoms,  did not 
differ between patients with an allergic or allergic-like reaction (Table 3).  
Allergic-like reactions occurred significantly later after the start of infusion 
(median: 29 minutes, interquartile range (IQR): 12-47 minutes) than real allergic 
reactions (median 2 minutes, IQR: 1-5 minutes) (p<0.001). Patient number two 
developed an allergic-like reaction 24 hours after administration. It could be 
questioned if this reaction was associated with the asparaginase infusion. 
Excluding this case, the allergic-like reactions occurred after a median of 27 
minutes (IQR: 11-42 minutes) (p<0.001).  
 
Further treatment 
In three out of five patients with an allergic-like reaction to PEGasparaginase 
(patients number one, two and four), the drug was successfully continued without 
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new allergic-like reactions. The activity levels were adequate in patient number 
four but not measured in the other two patients. In the two other patients 
(patients number three and five), formulations were switched to Erwinia 
asparaginase directly after the reaction. 
In two out of five patients with an allergic-like reaction to Erwinia asparaginase 
(patients number five and six), the drug was permanently stopped directly after 
the reaction. In two patients (patients number eight and nine), the drug was 
continued initially but was finally terminated after one or more subsequent allergic 
or allergic-like reactions. Patient number seven successfully completed the Erwinia 
asparaginase doses with adequate levels, although three allergic-like reactions 




In this article, allergic-like reactions to asparaginase were reported and compared 
to real allergies. It is important to distinguish between these types of reactions 
because, if allergic-like reactions are incorrectly interpreted as real allergies, 
asparaginase formulations will be switched or terminated unnecessarily. 
Asparaginase activity levels are difficult to interpret when measured after an 
allergic reaction. A low asparaginase activity level could be caused by either 
neutralizing antibodies or premature termination of the dose. However, our 
patients with real allergic reactions already show complete asparaginase 
inactivation of the previous dose. Therefore distinction between allergic-like and 
real allergic reactions can be made based on the trough level of the preceding 
dose.  
The correlation between hypersensitivity reactions and anti-asparaginase 
antibodies has been frequently studied. To date, four groups can be distinguished. 
The first group contains patients with an allergic reaction, accompanied by the 
presence of anti-asparaginase antibodies.9, 13, 8 Patients in the second group 
neutralize asparaginase in absence of clinical symptoms, so called silent 
inactivation, and also have antibodies against asparaginase.8 The third group 
includes patients without a hypersensitivity reaction to or neutralization of 
asparaginase, but with anti-asparaginase antibodies which has been  reported in 6-
38% of patients treated with asparaginase.14, 13, 8 The fourth group contains 
patients who have allergic symptoms without development of anti-asparaginase 
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antibodies. This was described by Liu et al. in 4-7% of the patients and by Panosyan 
et al. in 10%.9, 13 Unfortunately, both studies did not describe asparaginase activity 
and these reactions might have been allergic-like reactions. In our cohort, all 
patients with a real allergic reaction had anti-asparaginase antibodies whereas 
antibodies were absent in all but one of the allergic-like patients (p=0.001). Thus, 
the occurrence of allergic symptoms in absence of anti-asparaginase antibodies 
may indicate an allergic-like reaction, without inactivating asparaginase.  
Patients with an allergic-like reaction cannot be distinguished from allergic 
reactions based on clinical symptoms or allergy grade. The only clinical difference 
between allergic-like reactions and real allergies,  appeared to be the time of 
occurrence. In our cohort, allergic-like reactions occurred significantly later after 
the start of administration. Most real allergic reactions occurred within minutes 
after start, although two patients developed a real  allergic reaction after more 
than 10 minutes. Thus a late timing of the reaction after the start infusion is a 
strong indication of an allergic-like reaction but distinction cannot be made 
conclusively.  
The mechanism of allergic-like reactions is unclear. Based on a review recently 
published by Asselin, it can be discussed that allergic-like reactions are related to 
the non-antibody mediated hypersensitivity reactions that were described. Thus, 
the allergic-like reactions might be explained by a rapid increase of ammonia levels 
caused by the administration of asparaginase. Symptoms of this ammonia peak 
include nausea, vomiting and rash.15 Although these symptoms overlap with part 
of the allergic-like symptoms, half of the patients with an allergic-like reaction had 
edema, dyspnea or urticaria, which cannot be explained by hyperammonemia. On 
the other hand, Tong et al. have shown that ammonia levels are higher after 
Erwinia asparaginase therapy than after PEGasparaginase therapy, probably 
caused by the higher glutaminase activity of Erwinia asparaginase.16 This can 
explain why allergic-like reactions occur relatively frequent during Erwinia 
asparaginase treatment. Unfortunately, ammonia levels were not measured in our 
cohort but their role in the development and identification of allergic-like reactions 
should be studied. 
In conclusion, we describe allergic-like reactions to PEGasparaginase and Erwinia 
asparaginase, not leading to inactivation of the drug. These reactions occur 
relatively late after the start of infusion and anti-asparaginase antibodies are 
absent in the far majority of these patients. Distinction, however, can only be 
made when asparaginase activity levels are monitored continuously, as it is done 
with therapeutic drug monitoring. Most importantly, patients are able to complete 
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their asparaginase treatment with the same formulation if clinically tolerated. 
Although not useful in case of a real allergy,  reducing the infusion rate and 
administering premedication may prevent symptoms  in case of an allergic-like 
reaction. 
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Background Polyethylene glycol (PEG) conjugated asparaginase (PEGasparaginase) 
is essential for treatment of pediatric acute lymphoblastic leukemia. We developed 
an assay identifying antibodies against the PEG-moiety, the linker and the drug 
itself in patients experiencing hypersensitivity reactions to PEGasparaginase.  
Methods Eighteen patients treated according to the DCOG ALL-11 protocol, with a 
neutralizing hypersensitivity reaction to PEGasparaginase to the first 
PEGasparaginase doses in induction (12 patients) or during intensification after 
interruption of several months (6 patients) were included. ELISA was used to 
measure antibodies, coating with the succinimidyl succinate linker conjugated to 
BSA, PEGfilgrastim and E. coli asparaginase, and using hydrolyzed PEGasparaginase 
and mPEG5.000 for competition.   
Results Anti-PEG antibodies were detected in all patients (IgG 100%; IgM 67%) of 
whom 39% had anti-PEG antibodies exclusively. Pre-existing anti-PEG antibodies 
were also detected in patients who not previously received a PEGylated 
therapeutic (58% IgG; 21% IgM). Antibodies against the SS-linker were 
predominantly detected during induction (50% IgG; 42% IgM). Anti-asparaginase 
antibodies were detected in only 11% during induction but 94% during 
intensification.  
Conclusion Anti-PEG and anti-SS-linker antibodies predominantly play a role in the 
immunogenic response to PEGasparaginase during induction. Thus, switching to 
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Asparaginase treatment is essential for childhood acute lymphoblastic leukemia 
(ALL) treatment. The drug depletes extracellular asparagine, an essential amino 
acid for leukemic cells, selectively killing these cells.1 Because asparaginase is 
derived from bacteria, patients can develop antibodies to the non-human epitopes, 
neutralizing the drug completely. Neutralizing reactions can present with or 
without symptoms of an allergy, the latter being called silent inactivation.2-5 These 
reactions mainly occur after an interruption of asparaginase treatment, during 
which anti-asparaginase antibody levels increase.5 Three forms of asparaginase are 
clinically available which are derived from either Escherichia coli or Erwinia 
chrysanthemi.  By conjugating native E. coli asparaginase with polyethylene glycol 
(PEG), the drug is less immunogenic.6-8 Therefore, PEGylated E.coli asparaginase 
(PEGasparaginase) is used for the treatment of pediatric ALL.9-14 In case of a 
hypersensitivity reaction, patients have to switch from PEGasparaginase to 
asparaginase derived from Erwinia chrysanthemi bacteria for adequate 
treatment.15  
PEGasparaginase consists of E.coli derived asparaginase, a 32kDa homotetramer to 
which 5-10 mPEG5,000 chains are conjugated using a succinimidyl succinate linker 
(SS-linker) on the ε-amino groups of lysine residues of the protein. Although 
PEGylation reduces the immunogenicity of asparaginase, neutralizing 
hypersensitivity reactions still occur.5 Surprisingly, these reactions seem to shift to 
the first PEGasparaginase doses in induction and not necessarily during the 
intensification course after an interruption of treatment, as seen in our patient 
cohort. This leads to the question whether antibodies to the PEG moiety or even 
the SS-linker may cause these reactions.  
Although PEGylation decreases the immunogenicity of biotherapeutics, it has been 
reported that repeated administration of PEGylated therapeutics can induce anti-
PEG antibodies associated with hypersensitivity reactions and rapid clearance.16, 17 
Anti-PEG antibodies have been reported in patients treated with PEG conjugated 
uricase and PEGinesatide, erythropoietin that is covalently attached to PEG and 
withdrawn from the market after severe hypersensitivity reactions.18 Also in ALL-
patients treated with PEGasparaginase, the formation of anti-PEG antibodies has 
been associated with rapid clearance of the drug.16  
We hypothesize that reactions to PEGasparaginase may be partly triggered by anti-
PEG antibodies. Secondly, we hypothesize that the SS-linker can expose a neo-
antigen to which antibodies can be formed. The linker contains an ester group 
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which has limited stability at neutral pH in vitro and is subject to hydrolysis by 
endogenous esterases in vivo.19 The exposed succinate group may function as an 
hapten, enhancing immunogenicity.20 19  
Because of the lack of proper developed anti-PEG antibody assays, especially 
lacking proper controls, the aim of this study was to develop a sensitive and specific 
assay to detect possible antibodies to both PEG and the SS-linker. For this we 
identified patients who had a neutralizing allergy to or silent inactivation of 
PEGasparaginase during the first administrations (induction phase) or after an 




Patients and treatment protocol 
Eighteen children with ALL treated according to the Dutch Childhood Oncology 
Group (DCOG) ALL-11 protocol between April 2012 and December 2016,  who had 
developed a neutralizing hypersensitivity reaction (silent inactivation or allergy) to 
PEGasparaginase, were selected for the development of the assay. The DCOG ALL-
11 protocol (Dutch Trial Register: NTR3379), including use of patient material, was 
approved by the Institutional Review Board and informed consent was obtained 
from patients >12 years old, parents or guardians in accordance with the 
declaration of Helsinki.  
According to the DCOG ALL-11 protocol, all patients started with the induction 
phase containing prednisolone, vincristine  daunorubicin, and PEGasparaginase 
(1,500 IU/m2 i.v. administered at day 12, 26 and 40). After induction, patients were 
stratified in a standard, medium or high risk group. In this study, all patients with a 
hypersensitivity reaction after induction were treated according to the medium risk 
group. After induction, two consolidation courses were given leading to an 
asparaginase-free interval of approximately 12 weeks. Thereafter, medium risk 
patients were treated with 14 PEGasparaginase doses, individualized based on 
asparaginase activity levels, in the intensification phase. If a hypersensitivity 
reaction occurred, patients were switched to Erwinia asparaginase.  
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To study the reactions specifically observed during the first PEGasparaginase doses, 
12 patients with a neutralizing hypersensitivity reaction during the induction phase 
and 6 patients with a reaction during the intensification phase were selected (Table 
1). The antibodies were quantified in serum obtained within two weeks after the 
reaction. Allergies were graded according to the Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.03. 
 
Asparaginase activity 
Whole blood was taken prior to each PEGasparaginase administration and 
centrifuged at 800xg for 10 minutes at room temperature (RT). Samples were 
stored at -20°C. PEGasparaginase activity levels were measured after thawing using 
the L-aspartic β-hydroxamate (AHA) assay as described earlier.21 Inactivation of 
PEGasparaginase is defined as PEGasparaginase activity level <100 IU/L at day 7±1 
after administration and/or a trough PEGasparaginase activity level (14±1 days 
after a dose) below the limit of detection (<10 IU/L).  
 
Size-exclusion chromatography of PEGasparaginase  
The hydrolysis of mPEG5.000 from PEGasparaginase (Oncaspar, Shire, Amsterdam, 
the Netherlands) was investigated by size-exclusion chromatography. 
PEGasparaginase and native E.coli asparaginase (Paronal, Medac, Wedel, 
Germany) were diluted to 100 IU/mL in 0.1M sodium bicarbonate buffer pH9.5 
(Sigma Aldrich Zwijndrecht, the Netherlands) or PBS pH 7.4 (Fisher BioReagents, 
Landsmeer, the Netherlands) at RT for 24h to investigate the dissociation at 
different pH. Size-exclusion chromatography was performed on a Waters 2695-
Separations Module connected to a Waters 2414-Refractive Index Detector and a 
Waters 2487 Dual λ-Absorbance Detector (Waters Corporation, Milford, MA) to 
which a PL-Aquagel-OH mixed 8µm column (Agilent Technologies, Santa Clara, 
United States) was attached. Samples were incubated in one of the above buffers, 
and, over a 30 hour time period at RT, injected  at 1mL/minute flowrate. UV-
absorbance was recorded at 280nm. 
 
Synthesis of the PEG BSA conjugate 
BSA (Sigma Aldrich, Zwijndrecht, the Netherlands) was conjugated to succinic 
anhydride (BSA-SS) (Sigma-Aldrich, Zwijndrecht, the Netherlands) or n-ethyl 
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maleimide (BSA-MAL) (Sigma-Aldrich, Zwijndrecht, the Netherlands) at a molar 
ratio of 1:10 in 0.1M sodium carbonate pH8.5, to model the exposed linker upon 
PEG hydrolysis. The pH was kept constant by adding 0.1M sodium hydroxide to the 
reaction. Upon conjugation, both solutions were dialyzed against 0.1M sodium 
carbonate pH8.5 and subsequently against PBS at 4°C. Protein concentration was 
determined by the Pierce™ BCA Protein Assay (Thermo Fisher Scientific, Breda, the 
Netherlands). Samples were stored at -20°C.  
 
Anti-drug antibody determination 
To investigate the specificity of antibodies against asparaginase, PEG and the SS-
linker, an enzyme-linked immunosorbent assay (ELISA) was developed coating 
medium binding Costar® 96-well ELISA plates (Corning, Amsterdam, the 
Netherlands) with 0.4 IU/L PEGasparaginase, 1.4 IU/L native E.coli asparaginase, or 
1 µg/mL of PEGfilgrastim (Neulasta, Amgen), filgrastim (Neupogen, Amgen), BSA or 
BSA-SS in PBS overnight. PEGfilgrastim, a 19kDa protein to which a 20kDa PEG is 
coupled by aldehyde chemistry using selective N-terminal amine conjugation, was 
used to investigate anti-PEG antibodies. Patient sera were screened for anti-
filgrastim and anti-BSA antibodies to rule out false positive results.  Plates were 
blocked with 2-5% BSA dissolved in PBS for a minimum of 2 hours at room 
temperature. Patient sera were incubated for 2 hours in block buffer. Plates were 
washed 5 times with 0.05% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate CHAPS (Merck Chemicals, Amsterdam, the Netherlands) in PBS. 
IgG and IgM were detected by rabbit polyclonal anti-IgG or anti-IgM (Abcam, 
Cambridge, UK).  
Patients were positive for antibodies if binding exceeded the cut-off point 
calculated by absorbance value of sera obtained from patients before their first 
PEGasparaginase administration who did not experience a hypersensitivity reaction 
(n=26) as well as sera obtained from healthy donors (n=11) (Mini Donor Dienst, 
UMCU, the Netherlands). The cut-off point for PEGfilgrastim and PEGasparaginase 
was determined in the presence of 0.1% mPEG5,000 to exclude binding of possible 
pre-existing anti-PEG antibodies. 
Specificity of antibodies was determined by competition with different 
concentrations of E.coli asparaginase, mPEG5.000, or hydrolyzed PEGasparaginase. 
For this, PEGasparaginase was diluted to 375 IU/mL in a 0.1M sodium carbonate 
buffer pH 9.8 and stored for 20 hours at 37°C. Samples were concentrated by 
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centrifugation in Vivaspin®20 tubes (GE-Healthcare, the Netherlands) and diluted in 
PBS. The pH was adjusted to pH7.4 by dropwise addition of 1M HCl. 
To exclude any nonspecific competition of mPEG5.000, its competitive properties 
were investigated in a varicella zoster virus (VZV) ELISA, as all patients are expected 
to be positive for VZV-antibodies. A polyclonal TransChromo bovine anti-PEG IgG 
antibody (Bristol-Myer Squibb, USA) was provided by Bristol-Myers Squibb to serve 
as a positive control.  
 
Statistics 
SPSS Statistics (IBM Corp, Armonk, New York, USA) version 21.0 and GraphPad 
Prism (GraphPad Software, Inc, La Jolla, USA) version 5.01 for Windows were used 
for statistical analyses. Cut-offs are defined as the mean plus one standard 
deviation. To compare the titers of different antibodies, relative titers were 
calculated by dividing the patient titer by the corresponding minimal required 
dilution. Relative titers were plotted with boxplots, with the 25th, 50th and 75th 
percentiles in the boxes and the ranges indicated by whiskers. Dose response 




Table 1 shows the 18 patients included as described in the Methods section. Of 
those, nine patients had silent inactivation of PEGasparaginase (6 patients during 
induction, 3 during intensification); the other patients had an allergy. Asparaginase 
activity levels measured after this allergic reaction were below the limit of 
quantification in all patients. Two patients had an allergic reaction against the first 
dose. Thus, only a small amount of PEGasparaginase was administered.  
 
Antibodies against asparaginase and PEG  
Presence of anti-PEGasparaginase antibodies, which could be directed to any 
epitope in the molecule, was investigated (Figure 1 and Table 1). Anti-
PEGasparaginase IgG was detected in 92% (11/12) and 100% of the patients in 
respectively the induction and intensification phase; anti-PEGasparaginase IgM in 
67% (8/12) and 83% (5/6). Antibody titers were higher for IgG than for IgM.  
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Figure 1 shows the titers relative to the minimal required dilution per epitope for IgG and IgM in patients with a 
hypersensitivity reaction during the induction and intensification. Each graph also show the percentage of 
patients positive for the antibodies during induction (n=12) and intensification (n=6). The relative titers were 
obtained by dividing the titers measured by the corresponding minimal required dilutions.  
Figure 1A shows the relative titers of anti-PEGasparaginase antibodies.  
Figure 1B shows the relative titers of anti-native E. coli asparaginase antibodies.  
Figure 1C shows the relative titers of anti-PEG antibodies.  
Minimal required dilutions (MRD): Anti-PEGasparaginase IgG 1,000x; IgM 2,000x; native E. coli asparaginase 
IgG 1,000x; IgM 2,000x; PEG-filgrastim IgG 75x, IgM 75x. 
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Specificity against asparaginase or PEG was investigated by coating plates with 
native E.coli asparaginase or PEGfilgrastim (Table 2). In patients with a 
hypersensitivity reaction during induction, anti-asparaginase IgG was detected in 
17% (2/12) and IgM in none of the patients. In contrast, these antibodies were 
detected in 83% (5/6) and 33% (2/6) of the patients with a reaction during 
intensification (Figure 1B and Table 1-2). All patients were positive for anti-PEG IgG 
antibodies, whereas 75% (9/12) and 50% (3/6) of patients were positive for anti-
PEG IgM in the induction and intensification phase, respectively (Figure 1C and 
Table 1-2). 
 
Table 2. Antibodies against asparaginase, PEG and the SS-linker in patients with a 
reaction to PEGasparaginase during induction or intensification 
Type of antibodies Induction n=12 Intensification n=6 
 IgG IgM IgG IgM 
Anti-PEGasparaginase antibodies 92% 67% 100% 83% 
Anti-Asparaginase antibodies 17% 0% 83% 33% 
Anti-PEG antibodies 100% 75% 100% 50% 
Anti-SS-linker antibodies 50% 42% 17% 17% 
 
All patients were negative for anti-filgrastim IgG and IgM. Anti-PEG titers were 
around 100x higher for anti-PEG IgG than for anti-PEG IgM. Patients with  
undetectable PEGasparaginase levels in combination with an allergic reaction had 
higher anti-PEG IgG titers than patients with silent inactivation. Although the anti-
PEG titers were lower in the nine patients with silent inactivation, 6 out of these 9 
patients were exclusively positive for anti-PEG antibodies (Table 1). Specificity 
towards PEG was confirmed by mPEG5,000 competition and validated by a 
polyclonal anti-PEG IgG antibody (Figure 2A).22 Specificity of mPEG5,000 to compete 
solely with anti-PEG antibodies was confirmed by its non-competitive properties to 
anti-VZV antibodies (Figure 2D).  
Pre-existing anti-PEG IgG antibodies were detected in 58% (14/24) and anti-PEG 
IgM in 21% (5/24) patients (Figure 2C). These patients did not experience any 
hypersensitivity reaction to or neutralization of PEGasparaginase during 
asparaginase treatment.  
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Figure 2 shows the specificity of the anti-PEG antibodies in normalized dose-response curves. Gradually 
added mPEG5,000 concentrations competed with the PEGfilgrastim, decreasing the extinction relative to the 
extinction without competition (%).  
Figure 2A shows the normalized dose-response curve for anti-PEG IgG with PEG-competition (n=5) and the 
polyclonal anti-PEG IgG (pAb) as a positive control.  
Figure 2B shows the percentage of signal remaining after PEG competition for IgM (n=6), which has an 
approximately 100x lower affinity for mPEG5k than IgG.  
Figure 2C shows normalized anti-PEG binding of patient samples obtained prior to the first 
PEGasparaginase dose, who did not have any symptoms of hypersensitivity or increased clearance of 
PEGasparaginase during treatment, in (+) or without (-) the presence of 0.1% mPEG5,000.  
Figure 2D shows binding of healthy donor serum to varicella zoster virus antigen in the presence of 
different mPEG5,000 concentrations. Also dilutions of sera are shown to indicate the doses-response relation 
in this assay.    
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Antibodies against the SS-linker  
We found that PEG is rapidly hydrolyzed from PEGasparaginase when incubated in 
sodium bicarbonate pH9.5 (Figure 3A). Specificity of anti-PEGasparaginase 
antibodies towards the SS-linker was determined by coating plates with BSA-SS. 
Anti-BSA-SS IgG was detected in 50% (6/12) and 17% (1/6) during the induction 
and intensification phase; anti-linker IgM in 42% (5/12) and 17% (1/6) (Figure 3B 
and Table 1-2). No antibodies were found against unmodified BSA or the unrelated 
BSA-MAL linker (Figure 3C). Competition by hydrolyzed PEGasparaginase inhibited 
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Figure 3 shows the hydrolysis of PEGasparaginase and the detection of anti-succinate linker 
antibodies. 
Figure 3A shows the hydrolysis of mPEG5,000 from PEGasparaginase at pH 9.5 and room 
temperature. After approximately 12 hours, the concentration free mPEG5k stabilizes, showing 
complete hydrolysis of mPEG5,000.  
Figure 3B shows the relative titers to the SS-linker conjugated to BSA. The relative titers were 
obtained by dividing the titers measured by the minimal required dilutions (75x for both IgG and 
IgM). Percentages indicate fraction of patients positive for anti-succinate antibodies. 
In Figure 3C, patients were screened for the n-ethyl maleimide group conjugated to BSA (random 
linker) and BSA. This figures shows that the antibodies were specific for the succinate group.  
Figure 3D shows IgG (●) and IgM (□)  normalized dose-response curve of BSA-SS coated plates in 
presence of different concentrations of hydrolyzed PEGasparaginase.  




In this study we assessed the specificity of anti-drug antibodies in pediatric ALL 
patients treated with PEGasparaginase who had a neutralizing hypersensitivity 
reaction (silent inactivation or allergy) to the drug during the induction or 
intensification phase.5, 23 The patients were selected, though randomly, and the 
conclusions stated below should be confirmed by larger patient samples.  
Patients with a hypersensitivity reaction to PEGasparaginase developed IgG and 
IgM antibodies towards asparaginase, the PEG chain and the linker. The incidence 
of anti-E.coli asparaginase antibodies in our sample was lower during induction 
(IgG 17% (2/12); IgM 0%) than intensification (IgG: 83% (5/6); IgM: 33% (2/6)), 
indicating that asparaginase antibodies are mainly developed in an 
PEGasparaginase-free period and are primarily IgG. Patients with a reaction during 
induction mainly had anti-PEG (100% IgG and 75% IgM of 12 patients) and anti-
succinate linker antibodies (50% IgG and 42% IgM of 12 patients). Thus, after a 
hypersensitivity reaction during the first PEGasparaginase administrations, 
patients might benefit from a switch to native E.coli asparaginase instead of 
Erwinia asparaginase for adequate treatment.  
In contrast to E.coli asparaginase antibodies, the patients from our cohort were 
positive for anti-PEG IgG and IgM antibodies during hypersensitivity reactions both 
treatment phases. Mainly patients with an allergy had high anti-PEG antibody 
titers, suggesting that these antibodies may induce clinical symptoms of an allergy. 
Also, 39% (7/18) with a hypersensitivity reaction had exclusively anti-PEG 
antibodies, confirming the neutralizing capacity of these antibodies. Overall, IgM 
titers were low compared to anti-PEG IgG suggesting isotype class switching. 
Previous articles suggest that anti-PEG antibodies are predominantly induced 
through a T-cell independent manner.24 Production of anti-drug antibodies that 
bypass T-cells are typically IgM or low-affinity IgG.25 Binding of these antibodies 
can form immune complexes that are recognized by Fc- or complement-receptors 
promoting uptake by antigen processing cells such as splenic marginal B-cells.26 
The presence of pre-existing anti-PEG antibodies suggest a mechanism of memory 
B-cells. Although effective B-cell memory requires involvement of Th-cells, there is 
growing evidence that T-cell independent type II antigens can form B-cell 
memory.27 T-cell independent type II antigens are associated with polysaccharides, 
bearing repetitive structures.28 The repetitive ethylene oxide (-CH2-CH2-O) units of 
PEG may be recognized by the same mechanism as these T-cell independent type II 
antigens.  
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In line with our observations, Rau et al. reported lower anti-PEG IgM titers than 
IgG in patients with an allergic reaction to PEGcrisantaspase, a PEGylated form of 
recombinant Erwinia asparaginase using glutaric acid spacer as a linker, 
administered after a hypersensitivity reaction to PEGasparaginase.29 Whereas anti-
PEG antibodies detected in animals are predominantly reported as anti-PEG IgM, 
human studies primarily show anti-PEG IgG.17,30  
In our study, 58% (14/24) of the patients without any reaction had pre-existing 
anti-PEG IgG, and 21% anti-PEG IgM. Although anti-PEG antibodies were already 
described in the healthy population31, this study shows that the antibodies can be 
developed relatively early in life and may have been formed during previous 
exposure to PEG containing food or cosmetic products.32, 33, 31, 34 The fact that also 
patients without neutralization had anti-PEG antibodies proves that these 
antibodies do not necessarily possess neutralizing characteristics. Why these 
antibodies result in a neutralizing hypersensitivity reaction in only part of the 
patients should be further investigated. 
Our study is the first to report that antibodies can be formed against the succinate 
succinimidyl linker and provides clinical evidence that use of a cleavable linker that 
remains on the therapeutic protein upon hydrolysis can induce the formation of 
anti-drug antibodies. Anti-SS-linker antibodies were predominantly found during 
induction. However, all patients positive for anti-SS-linker antibodies also had anti-
PEG antibodies. We could, therefore, not identify if these  anti-linker antibodies 
only bind to the linker or also induce an immunological response. The anti-PEG 
antibodies may also be directed towards both the linker and the PEG chain. 
Angiolillo et al. studied the presence of antibodies and occurrence of 
hypersensitivity reactions in patients treated with PEGasparaginase or 
Calaspargase pegol, a PEGylated E.coli asparaginase with a succinimidyl carbamate 
linker. Treatment with this type of asparaginase seems to result in a less rapid 
clearance and slightly less hypersensitivity reactions during induction (3% vs. 7%, 
although not significant).35 These findings may imply that PEGylation with the SS-
linker results in a more immunogenic therapeutic than by the other linker.  
Anti-PEGasparaginase antibodies are frequently measured by various study groups 
with ELISA using a standard carbonate buffer of pH 9.0–9.5. However, PEG 
hydrolyses from PEGasparaginase at pH9.5 (Figure 3A). Thus, by using this buffer 
only anti-E.coli asparaginase and anti-SS-linker antibodies can be measured. 
Therefore, we recommend to coat plates using a buffer of pH7.4 for 
PEGasparaginase antibody detection. 
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In conclusion, first, we identified that anti-PEG antibodies play a significant role in 
the neutralization of PEGasparaginase, mainly during the first doses in induction, 
since part of the patients are only positive for this type of antibodies. Second, anti-
asparaginase antibodies are almost exclusively developed during hypersensitivity 
reactions after an asparaginase-free interval in our patient cohort. Thus, patients 
with a reaction during the first doses of PEGasparaginase theoretically could switch 
to the less expensive native E.coli asparaginase for adequate treatment, reserving 
Erwinia asparaginase as an extra alternative. Third, pre-existing anti-PEG 
antibodies are found in part of the patients with no clinical effect. Therefore, these 
antibodies not necessarily trigger a hypersensitivity reaction and screening of anti-
PEG antibodies is not a good marker to estimate patient outcome. And fourth, the 
discovery of the SS-linker as a neo-antigen shows that PEGylation through an 
unstable linker remaining on the therapeutic protein upon hydrolysis can serve as 
a hapten. Future drug development efforts should therefore focus on stable PEG-
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Background Asparaginase and methotrexate (MTX), both essential for pediatric 
acute lymphoblastic leukemia therapy, are often used concomitantly. Depending 
on the sequence, in vitro, asparaginase inhibits MTX-polyglutamate (MTXPG) 
formation, and side effects overlap.  
Methods MTX toxicity and efficacy, reflected by intracellular erythrocyte MTXPG’s, 
were compared between children treated with and without asparaginase during 
high dose MTX (HD-MTX) courses of the DCOG ALL-11 protocol (NL50250.078.14).   
Results Seventy-three patients, of whom 23 received asparaginase during the HD-
MTX courses, were included. Grade 3-4 leukopenia and neutropenia occurred 
more often (59% and 86% versus 30% and 62%). The number of infections, grade 
3-4 hepatotoxicity, nephrotoxicity and neurotoxicity did not differ. Patients with 
asparaginase had lower MTXPG levels, although to a lesser extent than in vitro 
studies.  
Conclusion Although patients with asparaginase during HD-MTX courses showed 
more myelosuppression, this had no (serious) clinical consequences. Regarding the 
MTX efficacy, the schedule-related antagonism seen in in vitro seems less 
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Asparaginase and methotrexate (MTX) are both essential for the treatment of 
pediatric acute lymphoblastic leukemia (ALL). These drugs are often used 
concomitantly, among other chemotherapeutics, to achieve better survival  
rates.1-8 The sequence of administration, however, seems important as several in 
vitro studies have shown an antagonistic effect of native E.coli asparaginase on 
MTX when asparaginase is administered prior to the MTX.9-12 It has been shown 
that MTX efficacy, reflected by intracellular MTX polyglutamates (MTXPGs) 13-15, is 
decreased due to the asparagine depletion caused by asparaginase. The 
asparagine depletion inhibits folylpolyglutamyl synthetase (FPGS), the enzyme that 
forms the MTXPGs. 9, 16-18, 12 In contrast, if asparaginase is administered after MTX, 
there seems to be a synergistic effect in vitro.12 Moreover, in vivo, MTX is 
administered prior to native E. coli asparaginase with the Capizzi regimen, 
increasing the dose guided by toxicity, which permits toleration of higher MTX 
doses and leads to successful remission rates.18  
Currently, most treatment protocols use PEGasparaginase, with therapeutic 
activity of at least two weeks, resulting in continuous asparagine depletion19. So 
treating patients with PEGasparaginase during MTX doses may influence the 
formation of MTXPGs, independently of the sequence of administration. 
Treatment protocols using these dosing schedules, however, are successful, 
suggesting that in vivo the effect of asparaginase on MTX efficacy seems less 
important.20, 5, 21   
Beside MTX efficacy, concomitant asparaginase and MTX therapy may alter toxicity 
profiles because the drugs have overlapping side effects, including neurotoxicity, 
hepatotoxicity and myelosuppression. On the other hand, MTX toxicity can be 
decreased in vitro by drugs that prevent cells from entering the S-phase, which is 
the case when asparaginase depletes the extracellular asparagine pools.22 
In the current Dutch Childhood Oncology Group (DCOG) ALL-11 protocol, medium 
risk patients are being randomized either to a continuous or a discontinuous 
PEGasparaginase dosing schedule, which contains an asparaginase-free period of 
several months, to study the effect of the dosing schedule on the occurrence of 
hypersensitivity reactions. Patients who are treated according to the continuous 
dosing schedule are concomitantly treated with asparaginase and high dose MTX 
courses, enabling us to study the possible effects of asparaginase on MTX efficacy 
and toxicity. The aim of this study is to compare the MTX efficacy, reflected by 
intracellular erythrocyte MTXPG levels, and toxicity between patients who are 
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Patients and treatment 
Pediatric patients with ALL, diagnosed between November 2014 and June 2017, 
and treated according to the medium or standard risk group of the DCOG ALL-11 
protocol were included in this study. The patients were treated in the Sophia 
Children’s Hospital, Rotterdam, The Netherlands; the Academic Medical Center, 
Amsterdam, The Netherlands; or the Princess Máxima Center for Pediatric 
Oncology, Utrecht, The Netherlands. The study (CCMO register: NL50250.078.14) 
was approved by the local ethics committee and informed consent was signed by 
children >12 years old and/or the parents or guardians in accordance with the 
declaration of Helsinki.  
The complete DCOG ALL-11 treatment protocol is described in Table 1. Both 
standard and medium risk patients treated according to the discontinuous 
asparaginase dosing group, received three doses of PEGasparaginase (1,500 IU/m2, 
IV, biweekly) during induction (course 1A and 1B), followed by an asparaginase-
free interval of approximately 12 weeks (remaining course 1B and M). During the 
following intensification phase, standard risk patients received one more 
PEGasparaginase dose; medium risk patients another 14 doses. The medium risk 
patients who were treated according to the continuous dosing schedule, received 
the PEGasparaginase once every two weeks, also during the consecutive courses 
1B and M. The PEGasparaginase doses  were individualized after the third dose, 
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Table 1 DCOG ALL-11 protocol for medium and standard risk patients. 
Treatment phase Therapy 
Protocol 1A  
   Prednisone 60 mg/m2/day for 29 days followed by 9 days tapering 
   Vincristine 1.5 mg/m2/dose at day 8, 15, 22 and 29 
   Daunorubicin 30 mg/m2/dose at day 8, 15, 22 and 29 (not in case of Down 
syndrome) 
   PEGasparaginase 1,500 IU/m2 at day 12, 26 
   Intrathecal MTX, cytarabine  
      and prednisone 
8 – 12 mg MTX, 20-30 mg cytarabine, 8-12 mg prednisone at day 15 
and 33. Only intrathecal MTX at day 1. 
Protocol 1B  
   PEGasparaginase † 1,500 IU/m2 at day 40 
   Cyclophosphamide 1,000 mg/m2/dose at day 36 and 64 
   Cytarabine 75 mg/m2/day at days 38 – 41, 45 – 48, 52 – 55, 59 – 62 
   6-Mercaptopurine 60 mg/m2/day at days 36 – 63 
   Intrathecal MTX, cytarabine 
      and prednisone 
8 – 12 mg MTX, 20-30 mg cytarabine, 8-12 mg prednisone at day 45 
and 59 
Protocol M   
   6-Mercaptopurine 25 mg/m2/day for 56 days 
   MTX 5,000 mg/m2over 24h at day 8, 22, 36 and 50 
   Intrathecal MTX, cytarabine 
       and prednisone 
8 – 12 mg MTX, 20-30 mg cytarabine, 8-12 mg prednisone at day 8, 
22, 36 and 50 
   PEGasparaginase Only continuous group: individualized doses, biweekly 
†Medium risk patients in the continuous dosing schedule will continue PEGasparaginase treatment 
during course 1B and M , administered biweekly. MTX: methotrexate. 
 
The asparaginase-free period for both standard and medium risk patients of the 
discontinuous dosing schedule started with course 1B containing 6-
mercaptopurine, cytarabine and cyclophosphamide, followed by course M with 
four high dose MTX courses (5,000 mg/m2/dose IV over 24 hours) and 6-
mercaptopurine (25 mg/m2/day orally) (Table 1). MTX was administered biweekly, 
except if patients suffered from a (severe) infection, mucositis or hepatotoxicity 
(AST/ALT >10x upper limit of normal), or when the white blood count was <1.5 * 
109 or platelets were <50* 109. In that case, the course was postponed for at least 
one week. Folinic acid was administered after the MTX dose until the 48 h plasma 
MTX level was <0.4 μM or the 72 h plasma MTX level <0.25 μM. The patients with 
the continuous asparaginase dosing schedule also received PEGasparaginase 
during course 1B and M. The asparaginase doses were administered biweekly, 
even if the requirements of MTX administration were not fulfilled and MTX had to 
be postponed.  
This is also true for any delay in protocol 1B, for example if cyclophosphamide has 
to be postponed. Evidently, patients had to fulfill the requirements for 
asparaginase administration, which included the absence of hepatotoxicity 
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(AST/ALT >10x and bilirubin >3x upper limit of normal), jaundice, clinical signs of 
pancreatitis and cerebral thrombosis.   
 
Toxicity 
Methotrexate toxicity was prospectively studied using case report forms which 
were completed by the physician two weeks after each high dose MTX course. 
These toxicity forms included central neurotoxicity (ataxia, somnolence, a 
depressed level of consciousness, agitation, seizures and posterior reversible 
encephalopathy syndrome), infections, mucositis and diarrhea. In addition, 
complete blood count, liver enzymes (alanine transaminase (ALT) and aspartate 
transaminase (AST)), creatinine and albumin concentrations were measured prior 
to the next high dose MTX courses. Toxicity was graded according to the Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.03. In addition, total 
treatment delay due to toxicity, extra hospital admissions and prolongation of 
hospital admissions for MTX administration were registered.  
 
MTX polyglutamates  
MTX polyglutamates were measured two to three weeks after each MTX course. 
Blood was drawn to measure intracellular MTXPG concentrations in the 
erythrocytes as described by Den Boer et al.24 EDTA whole blood tubes were 
centrifuged at 2,700 x g for 10 minutes at room temperature. The red cell pellet 
was harvested and stored at -80°C until analysis. For the analysis, first stable-
isotope-labelled internal standards were added, followed by incubation of the 
sample with 16% perchloric acid for protein precipitation. After centrifugation at 
21,350xg for 7 minutes, MTXPG 1-5 concentrations were measured using liquid 
chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-
MS/MS). MTXPG 1 is freely transportable out of the cells, so very variable.25 
Therefore, only MTXPG 2-5 were used for the analysis. Beside the intracellular 
MTXPG levels, 48 h plasma MTX levels were analyzed. 
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SPSS Statistics version 21.0 (IBM Corp, Armonk, New York, USA) and R Sigmaplot 
Version 3.4.1 (Systat Software Inc, London, UK) were used for the data analysis. 
Baseline characteristics were stated as mean and standard deviation (SD) for 
normal distributed data, and median and interquartile range (IQR) for skewed 
data. Student t-tests, Mann-Whitney U tests, χ2-(trend)tests, Fisher exact tests and 
corresponding post-hoc analyses were used to compare the baseline 
characteristics and maximal toxicity during protocol M. The MTXPG levels were 
longitudinally analyzed using marginal models to study the levels between patients 
with and without concomitant asparaginase treatment. The data was log 
transformed to obtain normally distributed data. We have corrected for the 
number of days between the MTX dose and sampling, the MTX dose number, age, 
sex, and whether there was an erythrocyte transfusion administered less than two 
weeks before the sample. In addition, we have studied whether asparaginase 
doses were administered directly after the MTX doses or one week after the MTX 
dose. The 48 h MTX plasma levels were also analyzed with marginal models. The 
data was log transformed to obtain normally distributed data. In the model, we 
have corrected for sex, age, the MTX dose number, albumin levels and whether 
patients had an increased creatinine level. Also in this analysis it was included 
whether asparaginase doses were administered directly after the MTX doses or 




Baseline characteristics are described in Table 2. In total, 73 patients were included 
in the study. Twenty-three patients were concomitantly treated with asparaginase 
during the high dose MTX courses in protocol M. Of the group without 
asparaginase treatment during the MTX courses, 17/50 (34%) were treated 
according to the standard risk group; the other 33 patients according to the 
discontinuous dosing schedule of the medium risk group. Of the group with 
concomitant asparaginase treatment, one patient had to switch to the high risk 
group half way during protocol M due to high minimal residual disease.  
There were no statistically significant differences in other baseline characteristics 
between the patients with and without asparaginase treatment during protocol M. 
Of note, some of the patients were standardly treated with intravenous 
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immunoglobulins (IVIG) as part of another randomized study. The number of 
patients standardly treated with IVIG, however, did not differ between the groups.  
 
Table 2 Patient characteristics 
 No asparaginase 
during high dose MTX 
courses 
n = 50 
Asparaginase 
during high doses 
MTX courses 
n = 23 
P-value 
Sex (%) 
 Male  








Age at diagnoses, years, median (IQR) 5.4 (3.0 – 9.2) 4.1 (3.4 – 5.5) 0.319 
Type of ALL (%) 
 Pre-B cell ALL 
 Common B-cell ALL 
 Pro-B cell ALL 












Risk group (%) 
   Standard risk 
   Medium risk, 
     Discontinuous group 










23 (100%) † 
- 










Average trough‡ asparaginase level 
during protocol M, IU/L, mean (SD) 
- 249 (48) - 
† One patient had to switch to high risk therapy due to high minimal residual disease.  ‡Trough 
asparaginase level: 14 ± 2 days after an asparaginase dose. MTX: methotrexate; IQR: interquartile range; 
ALL: acute lymphoblastic leukemia; IVIG: intravenous immunoglobulins; SD: standard deviation; MRD: 
minimal residual disease 
 
Toxicity  
The maximum toxicity per group and the number of infections and transfusions 
during protocol M are described in Table 3. Patients with asparaginase treatment 
during the high dose MTX courses received significantly more erythrocyte and 
thrombocyte transfusions  (median and IQR of 1 (0.75 – 2) and 0 (0 – 0.25), 
respectively) than patients without concomitant asparaginase treatment (median 
and IQR of 0 (0 – 0) and 0 (0 – 0), respectively). Patients with asparaginase 
treatment received a maximum of 5 erythrocyte and 4 thrombocyte transfusions; 
in the group without asparaginase, the maximum was 1 for both erythrocyte- and 
thrombocyte transfusions. In addition, the occurrence of grade 3-4 leukopenia and 
neutropenia  was higher in the group of patients with concomitant asparaginase 
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treatment (leukopenia 59% versus 31%, and neutropenia 86% versus 63%, 
respectively). However, the number of infections during the high dose MTX 
courses did not differ between patients with or without concomitant asparaginase 
treatment.  
Table 3 Toxicity during protocol M 
 No asparaginase during 
high dose MTX courses 
n = 50 
Asparaginase during high 
doses MTX courses 
n = 22 † 
P-value 
Number of infections, 
median (IQR) 
0 (0 – 1)  0 (0 – 1)  0.347 
Number of transfusions 
during protocol M, median 
(IQR) 
   Erythrocytes 




0 (0 – 0) 




1 (0.75 – 2) 



















Leukopenia  33 (66%) ¶ 15 (30%) ¶ 9 (41%) ¶ 13 (59%) ¶ 0.022 
Neutropenia  12 (24%) 31 (62%) ¶ 3 (14%) 19 (86%) ¶ 0.032 
Increased ALT/AST  16 (32%) ¶ 1 (2%) 20 (91%) ¶ 2 (9%) <0.001 
Increased creatinine prior 
to MTX 
4 (8%) 0 1 (5%) 0 0.504 
Increased creatinine 48 h 
after MTX 
2 (4%) 0 3 (14%) 0 0.163 
Decreased albumine  0a 0 14 (100%) §,¶ 0 <0.001 
Neurotoxicity ‡ 5 (10%) 2 (4%) 6 (27%) 0 0.233 
Mucositis 18 (36%) 16 (32%) 10 (46%) 5 (23%) 0.580 
Diarrhea 10 (20%) 1 (2%) 5 (23%) 1 (5%) 0.572 
† In one patient, protocol M was not completed because he had to switch high risk therapy due to high 
minimal residual disease.  
‡ Neurotoxicity included somnolence (grade 1-2), depressed consciousness (grade 1-2),  agitation (grade 3-4) 
and seizures (grade 3-4). 
§ Albumine was standardly measured only in part of the patients (n=14 and n=36 for the groups without and 
with asparaginase, respectively). 
¶ Statistically significant (p<0.05) after post-hoc analysis.  
Grading according to the common terminology criteria for adverse events version 4.03.  
MTX: methotrexate; IQR: interquartile range; ALT: alanine transaminase; AST: aspartate transaminase. 
 
Regarding hepatotoxicity, significantly more patients who were treated with 
asparaginase during the high dose MTX courses had grade 1-2 increased ALT and 
AST. On the other hand, grade 3-4 increased ALT and AST only occurred in one and 
two patients of the patients without and with concomitant asparaginase 
treatment, respectively.  
All patients with asparaginase had grade 1-2 hypoalbuminemia, in contrast to 
patients without asparaginase, who all had normal albumin levels. This, however, 
Chapter 6138   |
131 
 
had no clinical consequences.  
The number of patients with increased creatinine, neurotoxicity, mucositis and 
diarrhea did not significantly differ between the groups. Nephrotoxicity 48 hours 
after one of the high dose MTX courses occurred in 5 patients (3 patients with and 
2 patients without asparaginase), all grade 1-2 . 
 
The duration of protocol M, and prolonged and extra hospital admissions during 
this treatment phase are described in Table 4. Without any delay, protocol M 
would have a duration of 63 days. The mean duration of protocol M for patients 
without asparaginase administrations was 68 days (SD 7 days); the mean duration 
for patients with asparaginase administrations was 80 days (SD 14 days) (p=0.001).  
The hospital admission duration for MTX administration is usually 2 days, although, 
among other clinical reasons, admissions may be prolonged if plasma 48 h MTX 
plasma levels are >0.4 μM. There was no statistically significant difference in the 
hospital admission duration between the groups. Also, there was no statistically 
significant difference in the number of extra hospital admissions (median number 
and IQR of 1 (0 – 1) for both groups). 
Table 4 Duration of protocol M 
 No asparaginase during 
high dose MTX courses 
n = 49† 
Asparaginase during 
high doses MTX 
courses 
n = 22† 
P-value 
Duration of protocol M  
   in days, mean ± SD 
68±7 80±14 0.001 
Duration of hospital 
   admissions for MTX 
   administration in days, 
   median (IQR) 
Dose 1  
Dose 2  
Dose 3  
Dose 4 
2 (2 – 4)  
2 (2 – 3) 
2 (2 – 3) 
2 (2 – 4) 
2 (2 – 2) 
2 (2 – 3) 
2 (2 – 2) 





Extra hospital admissions during  
   protocol M (median, IQR) 
0 (0 – 1) 0 (0 – 1) 0.266 
T48 MTX plasma level, μM, 
   median (IQR) 
0.39 (0.30 – 0.52) 0.39 (0.26 – 0.64) 0.510‡ 
† In two patients, protocol M was not completed. In one patient due to severe neurotoxicity, protocol 
M was postponed for several weeks; the other patient had to switch to high risk treatment during 
protocol M.  
‡ The difference in T48 MTX plasma levels between the groups was analyzed using marginal models 
and corrected for sex, age and albumin levels.  
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MTX polyglutamates  
In total, 240 erythrocyte MTXPG samples were obtained. Longitudinally analyzed, 
MTXPG 2-5 were lower in patients treated with asparaginase during the high dose 
MTX courses. All MTXPG levels increased in the consecutive high dose MTX courses 
(Figure 1). The number of days between the MTX dose and sampling, sex and age 
did not significantly alter the MTXPG levels. Also the timing of the asparaginase 
dose with respect to the MTX dose did not have a significant influence on the 
MTXPGs. Figure 1 shows the median MTXPG levels two weeks (12 – 16 days) after 
the high dose MTX courses, corrected for administration of erythrocyte 
transfusions. Comparing patients with and without concomitant asparaginase 
treatment, the median (IQR) MTXPG levels were 4.0 μM (2.1 – 7.6 μM) versus 10.8 
μM (6.6 – 19.8 μM) for MTXPG 2 (p<0.001), 18.7 μM (9.9 – 27.2 μM) versus 27.5 
μM (18.5 – 37.4 μM) for MTXPG 3 (p=0.004), 29.2 μM (13.0 – 42.1 μM) versus 37.9 
μM (26.6 – 58.3 μM) for MTXPG 4 (p=0.002), and 19.4 μM (9.9 – 28.8 μM) versus 
32.8 μM (20.3 – 48.1 μM) for MTXPG 5 (p=0.004). Overall, the median (IQR) 
MTXPG 2 – 5 levels were 72.7 μM (37.7 – 110.4 μM) for patients with and 118.6 
μM (74.8 – 16.1 μM) for patients without asparaginase treatment during protocol 
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Figure 1 shows the concentrations of erythrocyte MTXPG 2, 3, 4, 5 and 2-5, measured two weeks (12 – 16 
days) after the MTX dose, excluding measurements less than two weeks after an erythrocyte transfusion. 
The p-values have been obtained from the longitudinal analysis. The MTXPG 2-5 levels are shown per 
MTX dose. 
The boxplot includes the 25th, 50th and 75th percentile in the boxes, the outliers (○), extreme outliers (*), 
and the ranges (indicated by the whiskers).  
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MTX plasma levels 
The 48 h MTX plasma levels are shown in Table 4 and shown in Figure 2. The 
median 48 h MTX plasma level for patients without concomitant asparaginase 
treatment was 0.39 μM (IQR 0.30 – 0.52 μM); for patients with concomitant 
asparaginase treatment this was 0.39 μM (IQR 0.26 – 0.64 μM).  








Figure 2 shows the 48 h MTX plasma levels after each high dose MTX for patients with and without 
concomitant asparaginase treatment. The p-value has been obtained from the longitudinal analysis. 
The boxplot includes the 25th, 50th and 75th percentile in the boxes, the outliers (○), and the ranges 
(indicated by the whiskers). The extreme outliers were excluded as described. The T48 MTX plasma levels 
did not differ between the patients who were treated with and without asparaginase (p=0.510).  
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In the longitudinal analysis, we have corrected for sex, age and albumin. Creatinine 
levels were not increased just prior to the MTX doses. During the analysis, outliers 
violated the normality assumption, even after log-transformation of the data. 
Therefore, we have performed the analysis also excluding the extreme outliers 
(n=5). In both models, concomitant asparaginase treatment did not statistically 
significantly alter the 48 h plasma levels (p=0.624 with outliers and p=0.510 
without outliers). Also the albumin levels did not significantly affect the 48 h MTX 
plasma levels.  
 
DISCUSSION 
In this study, the toxicity and efficacy of high dose MTX were analyzed for patients 
with and without concomitant asparaginase therapy. Patients with asparaginase 
treatment had more often severe neutropenia and leukopenia, and they received 
more erythrocyte and thrombocyte transfusions. However, the most important 
consequence of myelosuppression, namely the occurrence of (severe) infections, 
did not differ between the groups. As a result of this myelosuppression, the high 
dose MTX courses had to be postponed more often in patients with asparaginase, 
resulting in a delay of protocol M. It could be questioned if this delay is clinically 
relevant. It could even have a positive effect as MTX therapy may be more 
effective when administered every three weeks instead of two:  a possible rescue 
effect of folinic acid on leukemic cells may be diminished three weeks after the 
previous dose.26, 27 In addition to a difference in myelosuppression, all patients in 
the group with asparaginase had increased ALT and AST, although the far majority 
had grade 1-2 hepatotoxicity which had no clinical consequences.  
Beside differences in myelosuppression and hepatotoxicity, we have found lower 
albumin levels in patients who were treated with asparaginase. MTX is a week acid 
and binds to serum albumin. Reiss et al. have shown that hypoalbuminemia is 
associated with decreased MTX clearance and an increased length of 
hospitalization.28 In our patients, however, the 48 h MTX plasma levels and length 
of hospitalization did not differ in the patients with and without hypoalbuminemia. 
Unfortunately, in the study of Reiss et al., the severity of hypoalbuminemia was 
not reported. In our study, patients only had mild (grade 1-2) hypoalbuminemia, 
possibly explaining the lack of association between albumin levels, and MTX 
clearance and hospitalization.   
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The occurrence of nephrotoxicity, neurotoxicity and mucositis did not differ 
between the groups. The incidence of these side effects was in line with the 
incidences found by den Hoed et al., who have shown CTCAE grade 3-4 
neurotoxicity in 3% and CTCAE grade 3-4 mucositis in 20% of the patients treated 
with high dose MTX.27 The occurrence of nephrotoxicity has been reported in 2 – 
10% of the patients after high dose MTX courses.29 These toxicities have been 
correlated with MTX plasma levels.29, 27 In our study, asparaginase has no effect on 
these plasma levels, which may explain that the toxicity did not differ between the 
groups.  
Beside toxicity during the high dose MTX courses, one should consider the toxicity 
during the intensification phase as well: patients in the continuous asparaginase 
dosing schedule will receive fewer asparaginase doses during the intensification 
and maintenance phase. These patients, probably, will tolerate a higher amount of 
6-mercaptopurine and MTX, which is administered during these phases when they 
have completed their asparaginase doses, as reported by Merryman et al.30 In 
addition, one could expect fewer infections and less hepatotoxicity during the 
intensification and maintenance phase in these patients.  
Regarding MTX efficacy, we found that erythrocyte MTXPG levels were 
significantly lower in patients who were treated with asparaginase during the high 
dose MTX courses. The question is whether this is of clinical relevance. To the best 
of our knowledge, this is the first study comparing MTXPG levels in patients 
treated with and without asparaginase during high dose MTX. In earlier studies, 
Jolivet et al. and Sur et al. have concluded that asparaginase inhibits MTX 
polyglutamination in vitro by inhibition of FPGS due to asparagine depletion.11, 12 
However, this resulted in a decrease of mainly long chain MTXPG levels: MTXPG 4 
levels were more than 80% lower, MTXPG 5 was not even measurable, but MTXPG 
2 did not alter with asparaginase treatment. In our study, all MTXPG chains were 
lower, regardless of the chain length and, in contrast to the in vitro studies, all long 
chain MTXPGs were formed. Moreover, the overall decrease in levels is not as 
large as was found in vitro by Jolivet et al. This implies that the effect of 
asparaginase on MTX efficacy in vivo is smaller. However, it also has to be taken 
into account that erythroblasts, in which the erythrocyte  MTX polyglutamination 
takes place, contain asparagine synthetase31 and therefore, in contrast to leukemic 
blasts, do not depend on extracellular asparagine levels.  This may influence the 
effect of asparaginase on MTX polyglutamination. In addition, the type and 
cytogenetic characteristics of the leukemic cells influence the degree of MTX 
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polyglutamination. For example, the formation of MTXPGs is increased in 
hyperdiploid ALL and decreased in T-cell ALL.32, 33 On the other hand, also the 
asparaginase sensitivity varies, and leukemic cells which are less sensitive for 
asparaginase may encounter a smaller effect of asparagine depletion on MTX 
polyglutamination.34 When the DCOG ALL-11 has been completed, survival 
analyses might provide differences between the asparaginase treatment arms, 
which then may be explained by the difference in  MTXPG levels found in this 
study, although the number of relapses may be too low to draw these conclusions.  
Though we found inhibition of MTX polyglutamylation, there was no effect of the 
timing of asparaginase administration on the MTXPG levels. In our study, 
asparaginase was either administrated directly or a week after the MTX. Several in 
vitro studies have shown that asparaginase inhibits MTX polyglutamylation and 
efficacy specifically when asparaginase has been administered prior to the MTX. 
Vice versa, asparaginase administration after MTX would have a synergistic effect. 
9, 17, 11, 12 In line with these findings, several treatment protocols prove to be 
successful when asparaginase is administered after MTX.35, 2, 5, 36 These protocols, 
however, used native E. coli asparaginase, which has shorter therapeutic activity 
than PEGasparaginase (three days versus two weeks). By administering 
PEGasparaginase biweekly, asparagine is continually depleted, which could explain 
our finding that the timing of asparaginase administration relative to the MTX 
doses had no effect on the formation of MTXPGs. However, in our study patients 
were not treated with asparaginase directly prior to MTX. Therefore, we cannot 
draw conclusions about a possible effect of very high (top) asparaginase activity 
levels prior to MTX administration.  
We conclude that the schedule-related antagonism seen in the early in vitro 
studies seems less important in vivo, especially when patients are treated with 
PEGasparaginase during the high dose MTX. In addition, the results of this study 
suggest that MTX toxicity caused by concomitant asparaginase therapy only 
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Background Therapeutic drug monitoring (TDM) of asparaginase is necessary to 
respond to variability in asparaginase activity levels, detect silent inactivation, and 
distinguish between real allergies and allergic-like reactions with and without 
asparaginase neutralization, respectively. In this study, the costs of an 
individualized and fixed asparaginase dosing schedule were compared. 
Methods Patients, treated according to the DCOG ALL-11 protocol (individualized 
PEGasparaginase treatment, starting dose 1,500 IU/m2) or ALL-10 protocol (native 
E.coli asparaginase followed by 2,500 IU/m2 PEGasparaginase), were included. To 
focus on TDM of PEGasparaginase, the costs were also calculated excluding 
patients treated with Erwinia asparaginase, and compared to a hypothetical 
protocol with a fixed dose of 1,500 IU/m2 PEGasparaginase. Direct asparaginase-
related medical costs, including costs for asparaginase use (calculated with the 
absolute dose), TDM, laboratory tests, daycare treatment, and outpatient clinic 
visits, were calculated.  
Results Eighty-three ALL-10 patients and 51 ALL-11 patients were included. The 
asparaginase-related costs were 30.8% lower in ALL-11 than in ALL-10 ($29,048 vs. 
$41,960). The ALL-11 costs of non-allergic patients were 20.4% lower when using 
TDM, than the hypothetical protocol with a fixed dose of 1,500 IU/m2($13,178 vs. 
$16,551). TDM accounted for 12.4% of the costs. Including asparaginase waste, 
TDM in ALL-11 will be cost-saving if three doses can be prepared out of one vial, 
compared to a fixed dose of 1,500 IU/m2.  
Conclusion TDM of asparaginase is cost-saving if calculated with the absolute 
asparaginase dose and will be if the waste is minimalized by preparing multiple 
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Asparaginase is one of the key components of the treatment of acute 
lymphoblastic leukemia (ALL) in children and significantly improves the event-free 
survival (EFS) if patients are treated intensively.1-6 Unfortunately, hypersensitivity 
reactions may occur, usually resulting in complete neutralization of the drug.7, 8 In 
that case, asparaginase formulations should be switched to maintain optimal 
treatment. Patients can also develop allergic symptoms without asparaginase 
neutralization, so called allergic-like reactions.8 A third type of reaction to 
asparaginase is silent inactivation, which is neutralization of asparaginase without 
clinical symptoms. Distinction between these three reactions can only truly be 
made by continual measurement of asparaginase activity levels.  
 
In addition, high inter- and intra-patient variability of asparaginase activity levels 
has been observed 9, which requires individualized dosing of the drug. In our 
previous Dutch Childhood Oncology Group (DCOG) ALL-10 protocol, patients were 
treated with a fixed dose of 2,500 IU/m2 PEGasparaginase.10 These patients had 
relatively high asparaginase activity levels (mean 899 IU/L), possibly causing 
unnecessary toxicity since an asparaginase activity level of >100 IU/L is considered 
sufficient for complete asparagine depletion.11-18 In addition, 8% of the patients 
turned out to have silent inactivation.7 For these reasons, therapeutic drug 
monitoring (TDM) was implemented in the consecutive DCOG ALL-11 protocol to 
individualize the asparaginase treatment.  
 
Because asparaginase activity levels are high after the fixed dose of 2,500 IU/m2, 
individualized asparaginase treatment will decrease asparaginase use, 
consequently reducing the costs. On the other hand, the individualization of 
asparaginase therapy requires the measurement of asparaginase activity levels 
and the formulation of dosing advices. This will, in turn, increase the costs. 
PEGasparaginase treatment accounts for a substantial amount of the total ALL 
therapy costs.19 Therefore, a change in asparaginase costs will have a significant 
impact on the total costs. 
The aim of this study was to analyze whether TDM of asparaginase is cost saving 
when compared to the  fixed dosing schedule. For this, we have compared the 
individualized dosing schedule of the DCOG ALL-11 protocol to the fixed dosing 
schedule of DCOG ALL-10 (2,500 IU/m2 PEGasparaginase), and to a hypothetical 
dosing schedule with a fixed dose of 1,500 IU/m2 PEGasparaginase, the starting 
dose used in the DCOG ALL-11 protocol.   





This retrospective study was performed in in the Sophia Children’s Hospital, 
Rotterdam, the Netherlands and the VU University Medical Center, Amsterdam, 
the Netherlands. Patients with ALL, diagnosed between May 2009 and March 
2015, who were treated according to the medium risk group of the DCOG ALL-10 
or ALL-11 protocol, were included. These patients were treated with asparaginase 
most intensively. The study was approved by the Institutional Review Board in 
accordance with the Declaration of Helsinki. 
 
Treatment protocols 
ALL-10 contained eight doses of native E.coli asparaginase (5,000 IU/m2, every 
three days) in induction and 15 doses of PEGasparaginase (2,500 IU/m2, biweekly) 
in intensification. When an allergy occurred, formulations were switched to 
Erwinia asparaginase (20,000 IU/m2, three times a week).  
In ALL-11, native E.coli asparaginase was omitted to prevent hypersensitivity 
reactions and replaced by three doses of PEGasparaginase (1,500 IU/m2, biweekly). 
The intensification phase contained 14 doses, individualized based on trough 
asparaginase activity levels. Week levels were measured after the first dose in 
induction and intensification to detect silent inactivation.  
In case of asparaginase inactivation, patients were switched to Erwinia 
asparaginase (20,000 IU/m2, three times a week). The dose and/or dosing schedule 
was adjusted to ensure adequate levels.  
 
Asparaginase activity analysis 
Asparaginase activity levels were measured using the AHA-test as described 
earlier.20, 8 Asparaginase inactivation was defined as PEGasparaginase activity <100 
IU/L after one week and/or <10 IU/L after two weeks (trough level). The targeted 
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Direct medical costs of the asparaginase treatment were calculated from a hospital 
perspective and were retrieved from medical files. The different cost categories 
with corresponding costs were described in Table 1 and 2.  
 
Table 1. Cost categories 
Cost categories Costs 
PEGasparaginase  $1,387/vial of 3,750 IU 
Erwinia asparaginase $850/vial of 10,000 IU 
Native E. coli asparaginase $77/vial of 5,000 IU 
Daycare treatment for asparaginase administration $250/day 
Outpatient clinic visits preceding an asparaginase 
   dose or week asparaginase activity level 
$152/visit 
Laboratory tests* $7/set of tests 
TDM# $105 
TDM: Therapeutic drug monitoring *Tests routinely measured prior to an asparaginase dose, 
including AST, ALT, bilirubin, amylase and glucose. # The TDM costs include the costs for the AHA-
test and the formulation of the dosing advice. 
 
These categories included the costs for asparaginase use ($1,387 per vial of 3,750 
IU PEGasparaginase, $850 per vial of 20,000 IU Erwinia asparaginase and $77 per 
vial of 5,000 IU native E.coli asparaginase), daycare treatment for asparaginase 
administration ($250 per day), outpatient clinic visits preceding an asparaginase 
dose or week level ($152 per visit), specific laboratory tests which were performed 
prior to an asparaginase dose ($7 for AST, ALT, bilirubin, amylase and glucose 
measurement), and the costs for TDM ($105 per AHA-test and dosing advice). The 
latter cost category included the costs for the test itself but also the costs for the 
preparation of the blood sample, the dose advice and the effort of prescribing the 
adjusted dose (Table 2). Transport costs were not included because this will 
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Table 2. Therapeutic drug monitoring costs 
 Costs per hour Duration (min) Total costs 
Preparation of the blood sample $30 10 $5 
Test* 
   Equipment costs 
   Chemicals 
   Technician costs 




















   Advise**    
   Determine advises dose $120 5 $10 
   Prescription of medication $120 5 $10 
Total - - $105 
*Based on 1200 asparaginase activity samples a year. ** The formulation of the dosing advices is 
done by pediatric oncologists.  
The asparaginase-related costs were calculated by counting the amount of cost 
categories per patient, multiplied with the unit prices. Dutch tariffs were used for 
unit prices.21 All costs were converted to US dollars according to the average 
currency exchange rate of 2015 (€1=$1,067).  
 
Analysis 
The data was analyzed with the software package SPSS Statistics version 21.0 (IBM 
Corp, Armonk, New York, USA). To calculate the differences between the 
treatment protocols, we used t-tests, χ2-tests or Mann-Whitney U-tests. Two-sided 
p-values of <0.05 were considered statistically significant.  
 
The following comparisons were made: first, the total asparaginase costs of ALL-11 
(individualized dosing, starting with 1,500 IU/m2 PEGasparaginase) were compared 
with ALL-10 (fixed dose of  
2,500 IU/m2 PEGasparaginase). Second, the two protocols were compared 
excluding the patients with a hypersensitivity reaction because the occurrence of 
hypersensitivity reactions and subsequent use of Erwinia asparaginase was 
strongly influenced by the earlier use of native E.coli asparaginase in induction, 
which has a major impact on the costs.19 Third, the hypothetical costs of ALL-11 
with a fixed dose of 1,500 IU/m2 and no TDM were calculated using the existing 
data of ALL-11 and compared with the individualized ALL-11 protocol. Thus, the 
lower starting dose of ALL-11 compared to ALL-10 was taken into account. 
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Asparaginase vials must be used directly after opening so waste should be taken 
into consideration. One vial contains 3,750 IU PEGasparaginase. The number of 
doses that can be prepared out of a single vial depends on the (mean) absolute 
dose and the number of patients that are treated with asparaginase on the same 
day. The total costs per patient were also calculated, taking this into account. 
 
Sensitivity analysis 
To evaluate the uncertainty of the data, a one-way sensitivity analysis was 
performed: the cost categories were varied one by one (mean costs ± 1 SD) to 




Patient characteristics  
The patient characteristics are described in Table 3. In total, 134 patients were 
included: 83 patients were treated according to the ALL-10 protocol with a fixed 
dose of 2,500 IU/m2, and 51 patients were treated according to the individualized 
dosing schedule of the ALL-11 protocol. The incidence of hypersensitivity reactions 
was lower in the ALL-11 protocol than in ALL-10 (10% vs. 22%, p=0.077). The 
patients who were treated according to the ALL-11 protocol were slightly older 
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Table 3. Patient and treatment characteristics 
 ALL-10 (n=83) ALL-11 (n=51) P-value 
Sex (% male, 95% CI) 39% (28 – 49%) 41% (27 – 55%) 0.763 
Age (years) (median, range) 5.0 (1.5 – 18.1) 6.4 (1.3 – 17.1) 0.074 
BSA (m2) (median, range) 
   Start intensification 
   Week 19 of intensification 
 
0.8 (0.4 – 2.0)  
0.8 (0.5 – 2.1) 
 
0.9 (0.5 – 2.3)  




Number of PEGasparaginase doses  
   (median, range) (mean) 
15 (0 – 15) (14.5) 17 (1 – 17) (16.4) <0.001 
Number of Erwinia asparaginase doses 
   (median, range) 
0 (0 – 84) 0 (0 – 99) 0.170 
Number of native E. coli asparaginase doses 
   (median, range) 
8 (3 – 8) 0 (0 – 4) <0.001 
Number of AHA-tests (median, range) 0 16 (2 – 53) <0.001 
Number of out-patient clinic visits 
   (median, range) 
23 (2 – 100) 18 (1 – 41) <0.001 
Number of daycare admissions (median, 
range) 
23 (3 – 94) 17 (1 – 105) <0.001 
Number of laboratory tests (median, range) 6 (1 – 23) 16 (6 – 40) <0.001 
Hypersensitivity reactions (%, 95% CI) 22% (13 – 31) 10% (01 – 18)* 0.077 
Average absolute PEGasparaginase (IU) dose 
   (median, range) 
2,025 (1,225 – 
5,188) 
726 (366 – 2,400) <0.001 
Average PEGasp dose (IU/m2) per patient 
   (median, range) 
2500 778 (482 – 1500) <0.001 
* Four patients had silent inactivation of PEGasparaginase, one patient had an allergy to 
PEGasparaginase. 
AHA-test: method used to measure asparaginase activity levels. 
 
Asparaginase costs 
The total asparaginase-related costs of the ALL-10 protocol and ALL-11 protocol 
are described in Table 4; the costs of these protocols without patients with a 
hypersensitivity reaction, and the costs of the hypothetical protocol with a fixed 
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Table 4. Total asparaginase-related costs ($)  
Cost category ALL-10 
Mean ± SD; % of total 
median (IQR)  
ALL-11 
Mean ± SD; % of total 






   (IU used)  
10,604 ± 6,867; 22.4% 
10,064 (5,112)  
4,363 ± 2,168; 15.0% 
3,733 (3,293)   
-6,241 <0.001  
Erwinia asparaginase 
   (IU used) 
18,624 ± 40,552; 
44.4% 0 (0)  
13,816 ± 43,506; 
47.6% 0 (0)  
-4,808 0.159** 
Native E. coli asparaginase 
   (IU used) 
750 ± 284; 1.6% 
614 (0)  
8 ± 54; 0.03% 
0 (0)  
-742 <0.001** 
Daycare 8,129 ± 5,487; 17.2% 
5,771 (0)  
5,874 ± 5,493; 20.0% 
4,265 (0)  
-2255 <0.001* 
Outpatient clinic visits 3,803 ± 1,586; 8.0% 
3,502 (0)  
2,953 ± 1,013; 10.2% 
2,741 (152)  
-850 <0.001** 
Laboratory tests 51 ± 37; 0.1% 
43 (50)  
118 ± 36; 0.4% 
114 (14)  
67 <0.001* 
TDM - 1,917 ± 945; 6.6% 
1,680 (210)  
1,917 <0.001** 
Total 41,960 ± 43,205 
22,268 (14,529) 





No CI because of logarithmic transformation (*) or Mann-Whitney test (**). SD: standard deviation; IQR: 
interquartile range; TDM: therapeutic drug monitoring. 
 
First, the comparison between the ALL-10 protocol (fixed dose of 2,500 IU/ m2 
PEGasparaginase) and ALL-11 protocol (individualized dosing, starting with 1,500 
IU/ m2 PEGasparaginase) was made (Table 4): the asparaginase-related costs of 
ALL-11 were 30.8% lower than ALL-10 ($29,048 versus $41,960, p<0.001). These 
costs were calculated using the absolute asparaginase dose, disregarding 
asparaginase waste. If the whole vial has to be used for each asparaginase dose, 
the asparaginase-related costs for ALL-11 would still be less than for ALL-10, 
although the difference is smaller: $47,624 versus $54,892 for ALL-11 and ALL-10 
respectively (p<0.001). One patient of the ALL-11 protocol was initially treated 
with native E. coli asparaginase after silent inactivation of PEGasparaginase but 
switched to Erwinia asparaginase after a few doses. In the ALL-11 protocol, 
laboratory tests were standardly done before each PEGasparaginase dose, in 
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Table 5. Total asparaginase-related costs ($) in patients without a hypersensitivity 
reaction 
Cost category ALL-10 (n=66) 
Mean ± SD; % of total 
median (IQR) 
ALL-11 (n=46) 








13,015 ± 5,744; 56.8% 
11,063 (5,042)  
4,672 ± 2,043; 35.5% 





Native E. coli asparaginase 
(IU used) 
747 ± 292; 3.3% 
614 (0)  




Daycare 5,662 ± 627; 24.7% 
5,771 (0)  
4,107 ± 640; 31.2% 





Outpatient clinic visits 3,438 ± 399; 15.0% 
3,502 (0)  
2,658 ± 434; 20.2% 





Laboratory tests 52 ± 37; 0.2% 
43 (54)  
111 ± 19; 0.8% 





TDM - 1,630 ± 266; 12.4% 





Total 22,916 ± 6,373 
20,965 (5,503) 
13,178 ± 2,660 
12,548 (3,345) 
-9,738 (42.5%) <0.001 
 
SD: standard deviation; IQR: interquartile range; TDM: therapeutic drug monitoring. 
 
Secondly, the comparison was made between ALL-10 and ALL-11 without patients 
who had developed a hypersensitivity reaction (Table 5) because the difference in 
costs for Erwinia asparaginase use contributes to a substantial amount of the 
incremental costs. The risk of switching to this type of asparaginase was higher in 
ALL-10 due to native E.coli asparaginase use in induction. Excluding hypersensitive 
patients, the total asparaginase-related costs were 42.5% (p<0.001) lower in ALL-
11 ($13,178) when compared to ALL-10 ($22,916). The mean costs for the TDM 
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Table 6. Total asparaginase-related costs ($), in patients without a hypersensitivity 
reaction 
Cost category ALL-11  
TDM (n=46) 
Mean ± SD; % of total 
median (IQR) 
ALL-11  
Fixed  dose (n=46) 









4,672 ± 2,043; 35.5% 
3,905 (3,204) 
9,675 ± 4,218; 58.5% 
8,618 (5,678) 
-5,003 <0.001 
Daycare 4,107 ± 640; 31.2% 
4,265 (0) 
4,107 ± 640; 24.8% 
4,265 (0) 
0 - 
Outpatient clinic visits 2,658 ± 434; 20.2% 
2,741 (38) 
2,658 ± 434; 16.1% 
2,741 (38) 
0 - 
Laboratory tests 111 ± 19; 0.8% 
114 (16) 
111 ± 19; 0.7% 
114 (16) 
0 - 
TDM 1,630 ± 266; 12.4% 
1,680 (131) 
- 1,630 <0.001 
Total 13,178 ± 2,660 
12,548 (3,345) 
16,551 ± 4,626 
15,698 (5,911) 
-3,373 (20.4%) <0.001 
SD: standard deviation; IQR: interquartile range; TDM: therapeutic drug monitoring. 
 
Thirdly, the comparison was made between the ALL-11 protocol and the 
hypothetical ALL-11 protocol with a fixed dose of 1,500 IU/m2 PEGasparaginase 
and no TDM (Table 6) because the starting dose of PEGasparaginase was 1,000 
IU/m2 lower in ALL-11 than in ALL-10, which already led to a cost reduction. 
Furthermore, the fact that three doses of PEGasparaginase were used instead of 
eight native E.coli asparaginase doses in induction resulted in a cost reduction of 
daycare admissions and outpatient clinic visits. On the other hand, the drug 
PEGasparaginase is more expensive than native E.coli asparaginase (Table 1). The 
costs of PEGasparaginase use of the ALL-11 protocol ($4,672) were 48.3% lower 
(p<0.001) than the PEGasparaginase costs of the hypothetical protocol with the 
fixed dose of 1,500 IU/m2 ($9,675). Taking into account the costs for the AHA-tests 
as well, in total, still $3,373 (20.4%) will be saved per patient when using TDM 
(p<0.001). 
 
In clinical practice, left-over asparaginase after preparation of the dose may have 
to be discarded if it cannot be used for another patient. However, if patients are 
treated at the same day, multiple doses can be prepared out of a single vial. 
Supplemental figure 1 shows the total asparaginase-related costs when vials can 
be shared between patients, taking into account the PEGasparaginase waste. 
Depending on the number of patients treated at the same day and the amount of 
PEGasparaginase administered per dose, multiple doses can be prepared out of 
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the same vial, resulting in less waste per dose. Supplemental figure 1 shows that, 
in our cohort, TDM is cost saving when compared to a fixed dose of 1,500 IU/m2, if 
three patients are treated with asparaginase on the same day. If only one 
PEGasparaginase dose can be prepared out of a single vial, TDM would be more 
expensive than the hypothetical protocol due to the measurement of asparaginase 
activity levels and the formulation of dosing advices. More information about this 




The one-way sensitivity analysis is shown in a tornado diagram (Figure 1). Erwinia 
asparaginase use has the greatest impact on the total costs. Except for the Erwinia 
asparaginase costs, the maximum costs of ALL-11 did not exceed the mean ALL-10 
costs when varying the cost categories one by one with 1 SD. The same is true for 
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Figure 1a shows the range of mean total asparaginase costs for ALL-10: for each cost category, the mean 
± 1 SD of each category was varied to calculate the total asparaginase costs. The minimal costs of Erwinia 
asparaginase were < $0 but were fixed at $0. The dotted line represents the mean total costs of ALL-11 
($29,048). 
Figure 1b shows the same for the ALL-11 protocol. Again, the minimal costs of Erwinia asparaginase were  
<$0 and were fixed at $0. The dotted line represents the mean ALL-10 costs ($41,960). 




In this study, several comparisons were made to study the effect of TDM on the 
asparaginase-related costs. Although the comparison between real treatment 
protocols is important, the fairest comparison made was between the ALL-11 
protocol and the hypothetical ALL-11 protocol with a fixed dose of  
1,500 IU/m2 and no TDM. This comparison has shown that TDM is costs saving 
despite the extra costs for the asparaginase activity analysis and dosing advices. 
However, with the current size of PEGasparaginase vials (3,750 IU), the costs will 
be higher than a fixed dosing schedule if left-over asparaginase from vials cannot 
be used for other patients: much asparaginase has to be discarded if only one or 
two doses can be prepared at the same time, which is the case in many pediatric 
oncology centers. Hence, centralization of pediatric oncology care would reduce 
the asparaginase waste and subsequent costs. The size of PEGasparaginase vials is 
based on the adult asparaginase dose of 2,000 IU/m2, for whom the average 
absolute dose is approximately 3,600 IU as the mean adult BSA is 1,79 m2.22  
Therefore, , smaller vials should become available to reduce the waste for 
pediatric asparaginase doses and lower doses in adults.  
 
Among the current treatment protocols used to treat children with ALL, 
asparaginase treatment differs considerably regarding the number of asparaginase 
doses and asparaginase dosage. Thus, the expenses that could be saved when 
using TDM will vary between countries. However, as PEGasparaginase is an 
expensive drug , a dose reduction of approximately 50% will significantly decrease 
the total treatment costs in most cases. Moreover, the starting dose of ALL-11 
(1500 IU/m2) is relatively low compared to other treatment protocols so 
theoretically the dose could be reduced even more, which will relatively save even 
more costs.  
 
Several pharmacoeconomic analyses of pediatric ALL treatment and asparaginase 
treatment have been performed.23-25, 19, 26 However,  none of these include TDM. 
Furthermore, analyses about TDM mainly focused on clinical outcomes such as 
hospitalization or complication rates while our study focused on cost savings due 
to dose reduction of asparaginase.27-30  
In this study, we have only performed a cost-analysis, without including the effects 
of individualized  asparaginase doses. In the short term, lower asparaginase 
activity levels may reduce toxicity such as hepatotoxicity and dyslipidemia. This, 
however, will have little impact on the total costs but will, of course, be important 
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for the patient. In addition, also the risk of pancreatitis, thromboembolic events 
and central neurotoxicity might be reduced, although the incidence of these side 
effects is relatively low and patient numbers may be too small to observe an 
effect.  
But more importantly, TDM of asparaginase will improve the long-term outcome 
of children with ALL: first, silent inactivation of asparaginase will be detected, 
which will result in a better EFS if formulations are switched. 31, 32 This will probably 
increase the total costs as relatively more patients will be treated with Erwinia 
asparaginase. However, because of a lower relapse rate, the costs may be lower 
though, as expensive relapse therapy will be given less frequently. In our ALL-11 
cohort, only four cases of silent inactivation occurred, which makes it difficult to 
draw conclusions regarding these costs.  Second, allergic-like reactions can only be 
distinguished from real allergies by TDM.8 The influence on the costs, however, 
should be studied more closely because not switching to Erwinia asparaginase 
after an allergic-like reaction to PEGasparaginase will reduce the costs, while 
continuation of asparaginase after an allergic-like reaction to Erwinia asparaginase 
will increase the direct medical asparaginase-related costs. Regardless of these 
direct costs, TDM allows patients with an allergic-like reaction to Erwinia 
asparaginase to finish their asparaginase treatment, which will improve their 
outcome and consequently prevent relapse associated costs.   
 
In our study, the TDM costs accounted for 12% of the total asparaginase-related 
costs. These costs may be an overestimation because of two reasons: first, the 
number of asparaginase activity levels measured is relatively high because enough 
insight in the population pharmacokinetics of PEGasparaginase is lacking. If we 
would be able to better predict asparaginase activity levels in individual patients, 
less AHA-tests would be needed, which would reduce the costs. Second, our TDM 
administration costs are relatively high as we now need 47 minutes per sample for 
administration.  This includes processing the samples before activity measurement 
and entering all information in the database which is used for the formulation of 
dosing advices. Especially the latter is time consuming and is partly caused by 
entering information which is irrelevant for the dosing advices, but necessary for 
research purposes. Without the administration costs, the actual AHA-test costs 
$55. 
 
In conclusion, TDM of asparaginase will save expenses when calculated with the 
amount of IU asparaginase administered. TDM will also be cost saving if the 
asparaginase waste is minimized by preparing multiple doses out of a single vial or 
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if smaller vials become available. Although the effects of TDM were not included in 
the analysis, TDM has several advantages including the possible prevention of 
toxicity, the detection of silent inactivation, the distinction between real allergies 
and allergic-like reactions, and consequently the improvement of the EFS. 
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Supplemental figure 1 illustrates when TDM will become cost saving, varying the 
number of doses that can be prepared out of a single vial. The mean absolute dose 
of ALL-11 with TDM was 726 IU; the mean absolute dose of ALL-11 with a fixed 
dose of 1,500 IU/m2 would be 1,350 IU, calculated with the mean overall BSA of 
ALL-11, which was 0.9 m2. The figure shows that, in our cohort, TDM is cost saving 
when compared to a fixed dose of 1,500 IU/m2, if three patients are treated with 
asparaginase at the same day: if the doses of these three patients are 
individualized, they can be prepared out of one vial of  
3,750 IU (2,178 IU PEGasparaginase needed in total; mean total costs of the 
asparaginase treatment: $16,088) but a second vial should be opened if these 
patients would be treated with a fixed dose of 1,500 IU/m2  (4,080 IU 
PEGasparaginase needed in total; mean total costs of the asparaginase treatment: 
$22,041), saving $5,953 per patient, including TDM costs. 
Although the costs shown in Supplemental figure 1 are not applicable for other 
pediatric oncology centers and treatment protocols, the figure can be used to 
check whether TDM would be cost saving for other centers with certain amounts 
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Background Erwinia asparaginase is used as second-line formulation after a 
neutralizing hypersensitivity reaction to the first-line formulation of asparaginase. 
Here, we have performed a cost-effectiveness analysis of Erwinia asparaginase 
treatment. 
Methods Children with acute lymphoblastic leukemia treated according to the 
Dutch Childhood Oncology ALL-10 or ALL-11 protocol were included and initially 
treated with PEGasparaginase in the intensification phase. The total treatment 
costs of this treatment phase, quality of life (QoL), and life years saved (LYS) were 
studied for two scenarios: 1) patients were switched to Erwinia asparaginase 
treatment after a hypersensitivity reaction; 2) asparaginase would have been 
permanently stopped.  
Results Sixty-eight patients were included. There was no difference in QoL 
between patients with and without a hypersensitivity reaction. The mean costs of 
the intensification phase per patient were $40,925 if PEGasparaginase could be 
continued, $175,632 if patients had to switch to Erwinia asparaginase, and $21,190 
if asparaginase would have been stopped permanently. An extrapolation of the 
literature suggests that the 5-year event-free survival would be 10.3% lower 
without intensive asparaginase treatment, so if asparaginase is stopped after a 
reaction. Thus, the costs per LYS were $1,892 for scenario 1 and $872 for scenario 
2. 
Conclusions Switching to Erwinia asparaginase increases the costs per LYS by 
$1,020, which is modest in view of the total costs. Moreover, when asparaginase 
treatment can be completed by switching to Erwinia asparaginase, relapses - and 
consequential costs - will be avoided. Therefore, from a cost perspective, we 
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Asparaginase is a cornerstone of the treatment of acute lymphoblastic leukemia 
(ALL) in children as adequate, intensive treatment improves the event-free survival 
(EFS) significantly.1-7 However, asparaginase treatment may be hampered by the 
development of hypersensitivity reactions, generally resulting in complete 
neutralization of the drug. This requires a switch in formulations to maintain 
adequate asparaginase activity levels.8-10 In most developed countries, 
PEGasparaginase is now used as a first-line formulation and Erwinia asparaginase 
as second-line. The latter formulation is administered more frequently than 
PEGasparaginase (three times a week instead of every other week) due to different 
half-life’s of the two drugs, resulting in a substantial increase in therapy costs.11, 12 
Due to increasing restrictions on healthcare resources, evaluations of costs in 
relation to benefits become more important, especially for expensive drugs, such 
as Erwinia asparaginase. Therefore, we have performed a cost-effectiveness 
analysis in which we have compared the costs, quality of life, and life years saved 
between two scenarios: according to scenario 1, patients were switched to Erwinia 
asparaginase after a hypersensitivity reaction to PEGasparaginase. Scenario 2, 
which was unethical and therefore hypothetical, described the situation in which 
the asparaginase treatment was permanently stopped after a hypersensitivity 





The study was performed in the Sophia Children’s Hospital, Rotterdam, the 
Netherlands and the VU University Medical Center, Amsterdam, the Netherlands. 
Patients were enrolled prospectively between May 2012 and October 2016 and 
were treated according to the medium risk group of the Dutch Childhood Oncology 
Group (DCOG) ALL-10 (until April 2012) or the consecutive ALL-11 protocol. The 
study was approved by the Institutional Review Board. Informed consent was 
obtained from children >12 years old, parents or children’s guardians in 








In this study, the treatment costs of the intensification phase, which contained the 
majority of the asparaginase doses and hypersensitivity reactions to 
PEGasparaginase, were calculated. According to ALL-10, patients were treated with 
native E. coli asparaginase (eight intravenous doses of 5,000 IU/m2) in the 
induction phase, and 15 doses of PEGasparaginase (2,500 IU/m2, biweekly, 
intravenous) in the intensification phase. According to ALL-11, patients were 
treated with PEGasparaginase in both the induction (three intravenous doses, 
1,500 IU/m2) and the intensification phase (14 intravenous doses, biweekly). In this 
protocol, therapeutic drug monitoring (TDM) was used to individualize the doses in 
the intensification phase based on asparaginase activity levels. In case of a 
hypersensitivity reaction, defined as an allergy to or silent inactivation of 
PEGasparaginase, patients were switched to Erwinia asparaginase (20,000 IU/m2, 
three times a week). According to ALL-11, the Erwinia asparaginase dose and/or 
dosing schedule was individualized to ensure adequate asparaginase activity levels.  
Table 1 describes an overview of the first 30 weeks of the ALL intensification 
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Table 1. Intensification of the DCOG ALL-10 and ALL-11 treatment protocols 
Intensification (30 weeks) DCOG ALL-10  DCOG ALL-11 
Dexamethasone 6 mg/m2/day orally 
Day 0-4, every 3 weeks, 
starting in week 1 
6 mg/m2/day orally 
Day 0-4, every 3 weeks, 
starting at week 1 
Vincristine 2 mg/m2/dose intravenously 
Every 3 weeks, starting in 
week 1 
2 mg/m2/dose intravenously 
Every 3 weeks, starting in 
week 1 
Doxorubicin 30 mg/m2/dose 
intravenously 





Weeks 1, 4, 7, 10 
Not in case of a TEL/AML1 
translocation or Down 
syndrome patients without a 
IKZF1 deletion 
Methotrexate 30 mg/m2/ dose 
intravenously 
1x/week, weeks 20 – 30 
30 mg/m2/ dose 
intravenously 
1x/week, weeks 13 – 30 
PEGasparaginase 2,500 IU/m2 intravenously 
Biweekly, weeks 1 - 29 
Dose adjusted based on 
asparaginase activity levels 
Biweekly, weeks 1 - 27 
6-Mercaptopurine 50 mg/m2/day orally 
Courses of 2 weeks starting 
in weeks 1, 4, 7, 10, 13, 16 
Daily from weeks 19 – 30 
50 mg/m2/day orally 
Courses of 2 weeks starting 
in weeks 1, 4, 7, 10 




Methotrexate 8 – 12 mg 
Cytarabine 20 – 30 mg 
Prednisolone 8 -12 mg 
Week 1 and 19  
Methotrexate 8 – 12 mg 
Cytarabine 20 – 30 mg 
Prednisolone 8 -12 mg 
Week 1 and 19  
Costs Data 
The direct medical costs of the intensification phase were retrospectively obtained 
and calculated from a Dutch hospital perspective.13 All costs were converted to US 
dollars according to the average currency exchange rate of 2015 (€1=$1.067). The 
costs included were costs for (1) PEGasparaginase ($1,387 for one vial of 3,750 IU) 
and Erwinia asparaginase ($850 for one vial of 10,000 IU), rounded to whole vials 
to take into account the waste; (2) chemotherapy other than asparaginase; (3) 
supportive care medication; (4) out-patient clinic visits ($175 per visit in an 
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academic hospital, $85 in a satellite hospital); (5) daycare admissions; (6) inpatient 
days ($689 per day in an academic hospital, $476 in a satellite hospital); (7) 
intensive care unit days ($2,163 per day); (8) blood products, (9) laboratory tests; 
(10) surgical procedure costs (mainly for bone marrow punctures performed under 
complete anesthesia);  and (11) TDM costs ($105, including asparaginase activity 
level measurements and the formulation of dosing advices12). The costs described 
included costs for staff, materials used, nutrition and overhead. Data were 
adapted from the medical files of the Erasmus MC Rotterdam and the VU 
University Medical Center. Dutch tariffs (index year 2015) retrieved from the Dutch 
Healthcare Authority or the hospitals were used for the unit prices.14 Costs were 
discounted by 4% per year to account for the time value of money in accordance 
with Dutch guidelines.14  
To calculate the costs of scenario 2 for the patients with a hypersensitivity 
reaction, the number of outpatient clinic visits was assumed to be equal to the 
median number of visits of patients without a reaction. In addition, in these 
patients, the daycare admissions for Erwinia asparaginase administration only 
were excluded. And finally, for ALL-11 patients with a hypersensitivity reaction, 




To assess the health related quality of life (HRQoL), the Health Utilities Index (HUI) 
survey version 3.0 15 was completed by the patient and/or parents in week 1, 3, 4 
(in case of a hypersensitivity reaction) and 19 of the intensification phase. The 
questionnaire included 10 general attributes (vision, hearing, speech, emotion, 
pain, ambulation, dexterity, cognition, caretaking, and health) each with 5 or 6 
levels, describing a patient’s health state. The single-attribute utility (SAU) and 
multi-attribute utility (MAU) scores were calculated, representing the HRQoL for 
each attribute and overall, respectively. In order to calculate the quality-adjusted-
life years (QALYs), the MAU scores were multiplied by the total duration of the 
treatment phase (30 weeks).  
Beside the validated HUI questions, several extra questions about the impact of an 
allergic reaction and change in dosing schedule were added to the questionnaire. 
These questions were not validated and, therefore, could not be quantified as part 
of the HUI analysis. 
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The number of life years saved was calculated using the EFS described in literature 
to indicate the difference in EFS between intensified and less intensified 
asparaginase treatment: a systematic search was performed to find trials studying 
the effect of intensified asparaginase treatment. Next, a weighted mean difference 
of the EFS of patients with and without intensified asparaginase treatment was 
calculated by multiplying the difference in EFS reported with the number of 
patients included in the study, and dividing this by the total number of patients.  
In our study, patients who were switched to Erwinia asparaginase after a 
hypersensitivity reaction to PEGasparaginase were considered to have the same 
prognosis as patients without an allergy as they were still intensively treated with 
asparaginase.16 Because the inclusion of the ALL-10 protocol has been completed, 
the EFS of this protocol was used for these patients.7  
All hypersensitivity reactions occurred during the first or second PEGasparaginase 
dose in intensification. Therefore, not switching would have resulted in a worse 
prognosis, similar to ALL treatment without asparaginase treatment during 
intensification. Hence, for the patients with a hypersensitivity reaction in whom, 
according to scenario 2, the asparaginase therapy would have been permanently 
stopped, we have subtracted the weighted mean difference in EFS reported in the 
literature, from the EFS of ALL-10.7  
Both the QALYs and the number of life years saved were discounted by 1.5% per 
year to account for the value of time, according to Dutch guidelines.14 This way, it 
is taken into account that life years saved in the future are considered as less 
valuable than life years saved today. 
 
Statistical Analysis  
Data was analyzed with SPSS Statistics version 21.0 (IBM Corp, Armonk, New York, 
USA) and MS Excel 2013 (Microsoft Corporation, Redmond, WA, USA). Multiple 
imputation was used to impute missing data. T-tests, χ2-tests or Mann-Whitney U-
tests were used to calculate the differences between the patients with and 
without a hypersensitivity reaction, and the two scenarios. The quality of life was 
longitudinally analyzed using generalized estimating equations. A two-sided p-
value of <0.05 was considered statistically different. Data are presented as 
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Decision Tree Analysis  
A decision tree model was developed in order to compare the costs and effects of 
scenario 1, which included a switch to Erwinia asparaginase after a hypersensitivity 
reaction to PEGasparaginase, to scenario 2, in which the asparaginase therapy was 
permanently stopped after a hypersensitivity reaction to PEGasparaginase (Figure 
1). The mean costs per patient of the intensification phase and the life years saved 
for patients with and without a hypersensitivity reaction were calculated for both 
scenarios and multiplied by the probability of developing a hypersensitivity 
reaction. Next, the costs per life year saved were calculated by dividing the total 
costs by the number of life years saved.  
 
 
Sensitivity Analysis  
To account for uncertainty in the calculated costs per life year saved, a one-way 
sensitivity analysis was performed. For this, the costs per life year saved were 
calculated by varying the probability of developing a hypersensitivity reaction with 
the 95% confidence interval, and the mean total costs of the intensification phase 
with one standard deviation for all cost categories. The EFS for patients who would 
stop asparaginase therapy was varied using the minimal and maximal differences 





Table 2 describes the patient characteristics. In total, 68 patients were included in 
the study. Of these patients, 19 (27.9%) have developed a hypersensitivity reaction 
to PEGasparaginase. Most patients who developed a hypersensitivity reaction 
were treated according to the ALL-10 protocol. ALL-11 has a lower risk of 
hypersensitivity reactions because in the induction phase of this protocol, 
PEGasparaginase was used instead of native E.coli asparaginase. All allergies 
occurred during the first or second PEGasparaginase dose of the intensification 
phase. The age, gender and body surface area (BSA) did not statistically differ 
between the patients with and without a hypersensitivity reaction.  
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Table 2. Patient characteristics 












  % (95% CI) 
28% (17 – 39%) - - - 
Treatment protocol  
   % ALL-10 (95% CI) 
57% (46 – 69%) 47% (33 – 61%) 84% (67 – 100%) 0.006 
Sex  
   % male (95% CI) 
52% (40 – 64%) 49% (35 – 63%) 58% (35 – 81%) 0.594 
Age at start intensification 
   years, median (IQR) 
7.6 (4.8 – 11.6) 6.9 (4.3 – 11.4) 8.8 (5.4 – 12.9) 0.232 
BSA start intensification  
   m2, median (IQR) 
0.92 (0.73 – 1.35) 0.87 (0.69 – 1.30) 1.03 (0.81 – 1.44) 0.194 
PEGasp: PEGasparaginase; 95% CI: 95% confidential interval; IQR: interquartile range; BSA: body surface 
area; SD: standard deviation 
 
Cost Analysis 
Table 3 describes the mean costs of the intensification phase for the patients with 
and without a hypersensitivity reaction, for the different scenarios. The mean total 
costs per patient were $40,925 without a hypersensitivity reaction to 
PEGasparaginase, $175,632 when patients were switched to Erwinia asparaginase, 
and $21,190 if the asparaginase therapy was permanently stopped after a 
reaction.  The mean total drug costs for Erwinia asparaginase were $126,831, 
which corresponds with 149 vials of Erwinia asparaginase. The costs of the drug 
asparaginase itself accounted for 44.1%, 74.5% and 19.2% of the total treatment 
costs of the intensification phase for the three groups respectively. The percentage 
of costs for asparaginase use for the total study cohort was 63.0% of the total 
intensification costs. Because TDM was only implemented in the DCOG ALL-11 
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Cross-sectional analyses showed that the QALYs of the patients with and without a 
hypersensitivity did not differ significantly for the questionnaires completed in 
intensification week 1, 3 and 19. The longitudinal analysis showed that the MAU 
score overall decreased with 0.12 points per time-point of the questionnaire 
(p<0.001) but the occurrence of a hypersensitivity analysis was not a significant 
covariate. Thus, the development of a hypersensitivity reaction did not result in a 
significant change in the HRQoL. Therefore, this analysis was not further included 
in the decision tree analysis.  
 
Analysis of the extra questions about the burden of the allergic reaction and of 
switching to Erwinia asparaginase are described in table 4 and 5. The question 
about the burden of (potentially) switching to Erwinia asparaginase was answered 
by both the patients who were switched to Erwinia asparaginase and patients 
without a hypersensitivity reaction (Table 4).  
 
Table 4. The burden of switching to Erwinia asparaginase 
 Week 1* 
Mean ± SD 
median (IQR) 
Week 3* 
Mean ± SD 
median (IQR) 
Week 4* 
Mean ± SD 
median (IQR) 
Week 19* 
Mean ± SD 
median (IQR) 
Allergy 1.43 ± 0.65 
1.00 (1.00 – 2.00) 
1.35 ± 0.61 
1.00 (1.00 – 2.00) 
1.36 ± 0.63 
1.00 (1.00 – 2.00) 
2.00 ± 1.18 
2.00 (1.00 – 3.00) 
No allergy 2.11 ± 1.24 
2.00 (1.00 – 3.50) 
2.05 ± 1.24 
1.00 (1.00 – 3.00) 
- 2.09 ± 1.16 
2.00 (1.00 – 3.00) 
*There was no statistically significant difference between the median scores of patients with and 
without an allergic reaction. SD: standard deviation; IQR: interquartile range. 
Scoring system: 
1. Switching to Erwinia asparaginase would not be a problem 
2. Switching to Erwinia asparaginase would partially a problem 
3. Switching to Erwinia asparaginase would be a growing problem 
4. Switching to Erwinia asparaginase would be a major problem 
 
There was no statistically significant difference between the scores of both groups 
at all time-points, including week 19, when all patients with a hypersensitivity 
reaction had been switched. At these time-points, patients considered switching to 
Erwinia asparaginase as ‘no to partially a problem’. In patients who did experience 
an allergic reaction, the reaction was described as severe, resulting in severe 
illness and major discomfort during the reaction.  
 
 




Table 5. Experience of an allergy 
 
Week 1 
Mean ± SD 
median (IQR) 
Week 3 
Mean ± SD 
median (IQR) 
Week 4 
Mean ± SD 
median (IQR) 
Week 19 
Mean ± SD 
median (IQR) 
Severity of the allergic 
reaction* 
1.50 ± 0.67 
1.00 (1.00 – 2.00) 
2.75 ± 1.76 
2.00 (1.00 – 5.00) 
4.55 ± 1.21 
5.00 (5.00 – 5.00) 
4.31 ± 1.49 
5.00 (4.50 – 5.00) 
Extent of physical 
illness during the 
allergic reaction* 
1.08 ± 0.29 
1.00 (1.00 – 1.00) 
2.33 ± 1.83 
1.00 (1.00 – 4.75) 
4.36 ± 1.21 
5.00 (4.00 – 5.00) 
4.38 ± 1.50 
5.00 (5.00 – 5.00) 
Extent of discomfort 
during the allergic 
reaction* 
1.17 ± 0.58 
1.00 (1.00 – 1.00) 
2.25 ± 1.66 
1.00 (1.00 – 3.75) 
4.18 ± 1.40 
5.00 (4.00 – 5.00) 
4.15 ± 1.52 
5.00 (3.50 – 5.00) 
*Patients who had inactivation of PEGasparaginase without clinical symptoms of an allergy (silent inactivation) 
were excluded from this analysis (n=14). SD: standard deviation; IQR: interquartile range. 
Scoring system: 
Severity of the allergic-reaction: 
 
1. Not applicable  
2. No allergic reaction 
3. Minor allergic 
reaction 
4. Moderate allergic 
reaction 
5. Severe allergic 
reaction 
Extent of physical illness during 
the allergic reaction: 
1. Not applicable 
2. Not ill 
3. Minimally  ill 
4. Moderately ill 
5. Severely ill 
Extent of discomfort during the allergic 
reaction: 
1. Not applicable 
2. No discomfort 
3. Minimal discomfort, hampering 
of activities 
4. Moderate discomfort, hampering 
some activities 
5. Major discomfort, hampering 
most activities 
 
The 5-year EFS of the medium risk group of the DCOG ALL-10 protocol was 88.0% 
(standard error 2.0%).7 The EFS of the ALL-11 protocol is not available yet since the 
protocol is still ongoing. The studies that have reported the effect of asparaginase 
therapy are described in the supplemental results section. The weighted mean of 
the differences in 5-year EFS reported is 10.3% (range 3.3 – 17.0%).1-6 Of note, this 
percentage is an indication of the actual difference in EFS. Therefore, the 5-year 
EFS was assumed to be 88.0% for patients without a hypersensitivity reaction to 
PEGasparaginase and patients who were switched to Erwinia asparaginase, and 
assumed to be 77.7% (88.0% minus 10.3%) when asparaginase would have been 
permanently stopped. The life expectancy of patients without an event, probably 
will not differ between the groups. Therefore, if patients had no event within 5 
years, their life expectancy was assumed to be equal to the normal population for 
both groups. However, possible late effects of the ALL treatment could not be 
taken into account. The mean overall Dutch life expectancy in 2015 was 81.9 
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years17; the mean age of this study population at start of intensification was 8.4 
years. Therefore, on average, 73.5 years (81.9 minus 8.4 years) would be saved if 
the EFS would have been 100%. The EFS was 77.7% if asparaginase would have 
been permanently stopped after a hypersensitivity reaction so, in this case, the 
mean number of life years saved would have been 57.1 years (77.7% of 73.5 years; 
discounted by 1.5% per year to account for the value of time, 38.5 years). If 
patients were treated intensively with asparaginase, the EFS was 88.0%, so the 
mean number of life years saved was 64.7 years (88.0% of 73.5 years; discounted, 
41.5 years).  
 
Decision Tree Analysis 
Figure 1 shows the decision tree of the two scenarios including the costs and life 
years saved. Taking into account the probability of developing a hypersensitivity 
reaction to PEGasparaginase, the total costs of scenario 1 were $78,508 versus 
$35,419 of scenario 2. The discounted number of life years saved were 41.5 for 
scenario 1 and 40.6 for scenario 2. Thus, the costs per life year saved were $1,892 
if patients were switched to Erwinia asparaginase after a hypersensitivity reaction 
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In Supplemental figure 2, the costs per life year saved are shown, varying the 
probability of developing a hypersensitivity reaction (95% confidence interval), the 
total treatment costs (± one standard deviation for all cost categories), and EFS for 
patients who would have stopped with their asparaginase treatment (variation in 
EFS differences, reported in the literature). This one-way sensitivity analysis shows 
that mainly the treatment costs and probability of a hypersensitivity reaction 




In this cost-effectiveness analysis of Erwinia asparaginase, we have studied the 
costs of ALL intensification therapy, the HRQoL during asparaginase treatment, and 
the amount of life years saved for two scenarios. According to these scenarios, 
patients were either switched to Erwinia asparaginase after a hypersensitivity 
reaction to PEGasparaginase or asparaginase therapy would have been 
permanently stopped when the reaction occurred. The HRQoL was studied using 
validated HUI-questionnaires and did not significantly differ between patients with 
and without a hypersensitivity reaction, although this could possibly be addressed 
by the relatively small number of patients. Also the extra questions, added to 
specifically study the burden of switching to Erwinia asparaginase, did not show a 
significant impact. Therefore, the decision tree analysis only included the costs and 
life years saved.   
Switching to Erwinia asparaginase would cost $1,020 more per life year saved than 
permanently stopping asparaginase treatment after a hypersensitivity reaction to 
PEGasparaginase. Eichler et al. have reviewed cost-effectiveness thresholds 
reporting different maximal costs per life year saved, for example $93,500 as “rule 
of thumb” in the US.18 Although our study has been performed in the Netherlands 
and the threshold apply to adult patients, with an increase of $1,020 per life year 
saved for switching to Erwinia asparaginase, the costs per life year saved remain 
far below these costs and would be acceptable. Still, it has to be taken into 
account that health care costs vary considerably between countries hampering the 
generalizability of this study. 
However, the actual costs per life year saved may vary for different reasons: first, 
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the actual costs per life year saved for patients who would stop asparaginase may 
be higher: less asparaginase exposure will not only result in a higher mortality, but 
also in a higher relapse rate. Ideally, these costs would have been considered in 
the sensitivity analysis but cost data from relapse patients were not available. Kaul 
et al. report a threefold increase in costs when patients experience a relapse 
compared to no relapse, although actual costs of pediatric relapse therapy have 
not been described.19 Hence, switching to Erwinia asparaginase would save more 
future costs.  
Secondly, our treatment protocol contains relatively many asparaginase doses and, 
consequently, many Erwinia asparaginase doses in case of a hypersensitivity 
reaction, which increases the total intensification costs tremendously. For 
treatment protocols with less asparaginase doses, switching to Erwinia 
asparaginase will have less impact on the costs, and the difference in total costs 
between permanently stopping asparaginase and switching to Erwinia 
asparaginase will be smaller. 
Thirdly, the incidence of hypersensitivity reactions influences the costs per life year 
saved for both scenarios: a lower incidence will result in lower costs per life year 
saved in scenario 1, due to less Erwinia asparaginase use, but also in higher costs 
per life year saved in scenario 2 as more patients will complete their asparaginase 
treatment. Most patients in our cohort were treated with native E.coli 
asparaginase in induction (ALL-10), which increases the risk of developing a 
hypersensitivity reaction. Nowadays, most treatment protocols, including the 
DCOG ALL-11 protocol, use only the less immunogenic PEGasparaginase, 
decreasing the number of reactions significantly. Thus, the difference in costs per 
life year saved between the two scenarios will be even smaller. 
Finally, to evaluate the number of life years saved, we have used the EFS of the 
ALL-10 protocol for the patients who completed their asparaginase treatment. For 
the patients in scenario 2, in which asparaginase would have been permanently 
stopped after a hypersensitivity reaction, the EFS was calculated by subtracting the 
difference in EFS between intensive and no intensive asparaginase reported in the 
literature, from the EFS of ALL-10. One might question the accuracy of this 
difference as it is based on former treatment protocols. Ideally, the impact of less 
asparaginase exposure in our patients should be studied within the treatment 
protocol used. However, this would be unethical to study so the difference in EFS 
used is the best available evidence. Besides, the sensitivity analysis showed that 
varying the EFS only has a minor effect on the costs per life year saved as the costs 
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barely changed when the difference in EFS between intensive and less intensive 
asparaginase treatment was varied between 3.3 and 17.0%.  
In conclusion, according to this analysis, the costs per life years saved will be 
higher when patients switch to Erwinia asparaginase after a hypersensitivity 
reaction to PEGasparaginase. However, these costs are only 1% of the costs per life 
years saved that are considered acceptable.18 Therefore, we recommend switching 
to Erwinia asparaginase after a hypersensitivity reaction to PEGasparaginase, apart 
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Several studies have investigated the added value of intensive asparaginase 
treatment: Silverman et al. have found that the 5-year EFS was 17.0% higher in 
patients who tolerated >25 weeks of asparaginase than in patients who did not 
(n=377, EFS 90% vs. 73%).1 Pession et al. have investigated the effect of 20 weeks 
of asparaginase therapy in ALL patients and have reported a difference of 5.6% 
(n=355, 5-year EFS 88.1% vs. 82.5% for patients with and without intensive 
asparaginase therapy).2 Amylon et al. studied intensive asparaginase treatment (20 
extra weeks vs. no extra asparaginase) in T-cell ALL patients and found an increase 
in 5-year EFS of 13.4% (n=317, EFS 67.9% vs. 54.5%).3 The study of Rizzari et al. 
reported no significant difference in the 5-year EFS in ALL-patients who were 
treated more (20 weeks of asparaginase) and less intensive with asparaginase 
(n=610, EFS 75.7% vs. 72.4%).4 Duval et al. and Moghrabi et al. both compared 
patients who were treated with E.coli asparaginase vs. Erwinia asparaginase with 
the same dose.5, 6 Erwinia asparaginase, however, has a shorter half-life and 
patients treated with this formulation probably did not had complete asparagine 
depletion, which may have resulted in the difference in 5-year EFS found: Duval et 
al. report a difference of 13.6% in favor of patients who were weekly treated with 
10,000 IU/m2 native E.coli asparaginase compared to Erwinia asparaginase 
(n=700); Moghrabi et al. a difference of 11% in patients who were weekly treated 
with 25.000 IU/m2 of one of these formulations (n=286).5, 6 All differences in EFS 
reported were multiplied by the number of patients per study and divided by the 
total number of patients to obtain a weighted difference is EFS. This resulted in a 
difference in EFS of 10.3% (3.3% – 17%), which was used as indication of the actual 
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Supplemental figure 1 shows the costs per life year saved calculated for both scenarios, varying the event-
free survival (EFS), the costs, and the probability of an allergy. The dotted vertical line represents the 
costs per life year saved for the other scenario ($872 for scenario 2 and $1,892 for scenario 1).  
The differences in EFS for intensive versus less intensive asparaginase varied between 3.3 - 17% in 
literature. Using this variation reported, the costs per life year saved for scenario 2 varied between $858 
and $884. 
The total costs were varied by calculating the mean costs ± one standard deviation for all cost categories  
to show the maximum impact of uncertainty in costs. For scenario 1, the costs per life year saved varied 
between $1,002 and $2,781; and for scenario 2 between $395 and $1,349. 
The probability of a hypersensitivity reaction was varied by the 95% confidence interval (17.1% - 38.7%). 
For scenario 1, the total costs per life year saved varied between $1,541 and $2,242; and for scenario 2 
between $858 and $884 (the costs per life year saved increased when the probability of an allergy 
decreased). 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
In this thesis, several aspects of asparaginase treatment of children with acute 
lymphoblastic leukemia (ALL) were studied. First, the efficacy of the asparaginase 
therapeutic drug monitoring (TDM) program, and its effect on asparaginase-
associated toxicity were evaluated. To gain more insight in variability in 
PEGasparaginase activity levels, a population pharmacokinetic model was 
developed providing patient- and treatment characteristics explaining this 
variability. Second, hypersensitivity reactions to asparaginase were further 
explored: by measuring asparaginase activity levels, allergic-like reactions were 
recognized. And in order to study hypersensitivity reactions specifically to 
PEGasparaginase, an assay was developed to measure antibodies not only to 
asparaginase but also to PEG and the linker. Third, the effect of asparaginase on 
high dose methotrexate (MTX) efficacy, reflected by MTX polyglutamination, and 
toxicity was studied. Fourth, the costs of the TDM program were compared to a 
fixed dosing schedule, and the cost-effectiveness of Erwinia asparaginase 
treatment was analyzed.  
 
Therapeutic drug monitoring 
Efficacy  
The Dutch Childhood Oncology Group (DCOG) has incorporated a unique national 
TDM program to individualize the asparaginase treatment of pediatric patients 
with ALL treated according to the DCOG ALL-11 protocol. As described in chapter 
2, based on asparaginase activity levels, the PEGasparaginase dose has been 
reduced substantially targeting a trough asparaginase activity level of 100 – 250 
IU/L. After approximately 10 doses, of which the first three doses had a fixed dose 
of 1,500 IU/m2, the median dosage was 450 IU/m2, which is five times lower than 
the fixed dose used in DCOG ALL-10 (2,500 IU/m2). 
  
Although the target level used has been associated with complete asparagine 
depletion1, the efficacy of individualized asparaginase treatment had to be verified 
by measuring asparagine concentrations. To avoid possible ex vivo asparaginase 
activity, a strict protocol was used by putting samples directly on ice and adding 
sulfosalicylic acid for deproteinization as was previously suggested by others.2, 3 As 
asparagine was measurable in all samples and glutamine was not depleted, it was 




shown that the samples had been handled properly and in vivo asparagine 
concentrations were adequately reflected, With a very low limit of quantification 
of 0.05 μM, asparagine was measurable in all samples, though at very low levels, 
including those with high (>500 IU/L) asparaginase activity levels. For the majority 
of the PEGasparaginase samples with asparaginase activity levels >100 IU/L, 
asparagine concentrations were <0.5 μM (96% of the PEGasparaginase samples 
and 67% of the Erwinia asparaginase samples), which is very low compared to 
baseline asparagine concentrations, confirming efficacious asparaginase treatment 
in the DCOG ALL-11 patients.  
 
Human asparagine concentrations consist of L-asparagine and D-asparagine, the 
latter not being incorporated in proteins and, therefore, clinically irrelevant. D-
asparagine, as other D-amino acids, are known to be present in humans but their 
origin is currently unknown.4 Previous studies focused on total asparagine 
concentrations and the minimal asparaginase activity for complete asparagine 
depletion reported varied between 50 – 400 IU/L.5-8 This could partly be explained 
by inadequate handling of the samples but also by interference of D-asparagine, 
which varies between 0.017–0.18 µM.4 It would be interesting to focus more on L-
asparagine concentrations for evaluation of the efficacy of asparaginase 
treatment. In chapter 2, both total and L-asparagine concentrations were 
measured in a limited number of samples. It was expected that L-asparagine 
concentrations would more strongly correlate with asparaginase activity levels as 
the clinically irrelevant D-asparagine was not included. However, L-asparagine did 
not differ between samples with various asparaginase activity levels, even though 
samples with low (<50 IU/L) asparaginase activity levels were included in the 
analysis. This may be explained by the fact that the low asparaginase levels are 
already sufficient to deplete asparagine in the serum. The L-asparagine levers were 
very low (>95% reduction), though, which is probably effective. Still, the role of L-
asparagine in the verification of asparaginase treatment efficacy should be further 
studied, starting with L-asparagine measurement in more samples.  
Beside the role of L-asparagine in the reflection of the efficacy of asparaginase 
treatment, it is essential to study the correlation between asparaginase activity 
levels – which are relatively easy to measure – and treatment outcome. The 
number of relapses in DCOG ALL-11, however, is too low to draw conclusions 
about this correlation because confounders such as cytogenetic aberrations and 
toxicity resulting in treatment delay, should be taken into consideration in this 
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analysis. The next international ALL-Together treatment protocol, in which the 




With TDM not only the dose and/or dosing schedule can be individualized: also 
silent inactivation is detected. Vrooman et al. previously have shown that the 
event-free survival (EFS) is significantly higher when the asparaginase treatment is 
individualized, which was a direct result of the detection of silent inactivation and 
a consequential switch to Erwinia asparaginase.9 Therefore, (early) detection of 
this type of reaction is crucial.  
In the DCOG ALL-11 protocol, silent inactivation occurred in 4% of the patients 
treated with PEGasparaginase and 5% of the patients treated with Erwinia 
asparaginase. Especially during induction, the occurrence of silent inactivation did 
not follow a clear pattern and it was seen at all three doses administered 
according to DCOG ALL-11. During intensification, on the other hand, all silent 
inactivation reactions occurred at the first dose. Therefore, it is recommended to 
measure extra week levels for early detection of silent inactivation after all doses 
during induction, and after the first dose after an interruption of asparaginase 
treatment.   
Beside the detection of silent inactivation, TDM is essential for the identification of 
allergic-like reactions. This type of reaction will be discussed below. 
 
Erwinia asparaginase 
According to DCOG ALL-11, Erwinia asparaginase treatment started with 20,000 
IU/m2, three times a week. The dose and/or dosing schedule was adjusted based 
on the 48h and 72h asparaginase activity levels measured during the first two 
weeks. As only one fourth of these 72h levels was >100 IU/L, the starting dose or 
dosing interval seems inadequate for the majority of the patients. We and others 
reported that 67 – 87% of the patients treated with the same dosing schedule has 
72h asparaginase activity levels <100 IU/L in the first two weeks of treatment.10, 11 
In contrast to DCOG ALL-11, the dose was not adjusted in these studies. In DCOG 




ALL-10, the Erwinia asparaginase activity levels significantly increased after the 
first two weeks resulting in adequate asparaginase exposure in the majority of the 
patients (77% of the samples being >100 IU/L).11 Another study from our group 
using population pharmacokinetic analysis of Erwinia asparaginase, also described 
a lower clearance – and consequentially higher Erwinia asparaginase activity levels 
– after the first month of therapy.12 In the DCOG ALL-11 patients, only half of the 
patients eventually had to switch to an every-other day schedule of Erwinia 
asparaginase despite the low 72h levels during the first two weeks, which indicates 
a lower clearance after a few months. However, there was much variation in the 
dose (15,000 – 40,000 IU/m2) and the higher doses also result in higher 72h levels.   
It, however, could be questioned whether trough asparaginase activity levels 
should constantly be >100 IU/L for Erwinia asparaginase to be effective. Due to low 
relapse rates, this is difficult to investigate. Still, adjusting the dose and dosing 
schedule based on the first two weeks seems to be too early and the dose should 
be evaluated after four weeks. Evidently, Erwinia asparaginase activity levels 
should be measured during the first weeks to detect possible silent inactivation. 
Furthermore, to ensure adequate Erwinia asparaginase exposure during these first 
weeks, a starting dose of 25,000 IU/m2 should be considered.12  
 
Toxicity 
With TDM, high trough asparaginase activity levels were avoided, possibly 
resulting in less toxicity. However, the effect of the substantial dose reduction on 
asparaginase-related toxicity seems limited. Major toxicity, including pancreatitis, 
thrombosis and central neurotoxicity, were not correlated with the asparaginase 
activity levels. We did, however, found a significant correlation between 
hepatotoxicity, reflected by the bilirubin and alanine transaminase levels, and 
asparaginase activity levels, but this was not clinically relevant. Previously, we have 
reported a correlation between triglycerides and asparaginase activity levels.13 In 
chapter 2, however, it was described that this was not confirmed by the DCOG ALL-
11 data, although this could be explained by the lower asparaginase activity levels 
with less outliers compared with DCOG ALL-10. Vrooman et al., compared 
individualized treatment with native E. coli asparaginase with a fixed dosing 
schedule, also found no difference in toxicity between both groups was found but 
the difference in asparaginase activity levels between the individualized and the 
fixed dosing group were rather small. 9 Still, there seems to be no clinically relevant 
effect of lower asparaginase activity levels on asparaginase-associated toxicity. 




Asparaginase is believed to be cleared by the mononuclear phagocyte system 
(MPS) as the drug has a molecular weight (170 kDa) which exceeds the limit for 
renal filtration (approximately 60 kDa).14, 15 The MPS, or the reticuloendothelial 
system, is a class of hematopoietic myeloid cells, originating from progenitor cells 
in the bone marrow, which differentiate to monocytes and dendritic cells and then 
enter tissues as the liver and spleen to become tissue macrophages.16 Van der 
Meer et al. have shown in mice that native E. coli asparaginase is cleared by the 
phagocytic cells in the liver, spleen and bone marrow.15  As PEGasparaginase has 
an even higher molecular weight due to the PEGylation and other PEGylated drugs 
are eliminated by the MPS17, PEGasparaginase is likely to be eliminated by the MPS 
as well. In chapter 3, a pharmacokinetic model of PEGasparaginase was developed. 
This model showed that the clearance of PEGasparaginase is linear during the first 
13 days but increases exponentially thereafter. Würthwein et al. showed similar 
findings.18 As described in chapter 5, PEG rapidly hydrolyzes from PEGasparaginase 
in high pH but, also in a more neutral environment, for example inside the human 
body, the PEG probably detaches, increasing the clearance. The consequential 
non-linear clearance of PEGasparaginase complicates the TDM and, therefore, 
dosing guidelines were provided. Currently, trough asparaginase activity levels are 
targeted between 100 to 250 IU/L. As high asparaginase activity has a limited 
effect on asparaginase-associated toxicity, we recommend to only aim for a 
minimal asparaginase level, though a maximum level could be considered from a 
cost perspective. This minimal level should be determined based on L-asparagine 
depletion, as it is described above and/or survival if possible.  
In chapter 3, it was also reported that the clearance is higher in patients with a 
higher body surface area, during induction and, more important, also during an 
infection, which has not been reported earlier. This has serious clinical 
consequences as the dose should be increased with 40% to obtain therapeutic 
activity in case of an infection. Evidently, this increase should not comprise the 
clinical situation or the safety of patients. The higher clearance in case of an 
infection is probably due to activation of the MPS19 or eventually also by induction 
of the hydrolysis of PEG from the PEGasparaginase. In chapter 5, it was shown that 
the latter is the case with increasing pH but the effect of other environmental 
alterations on the hydrolysis of PEG remain unknown.  
 





As TDM resulted in a substantial reduction of the PEGasparaginase dose, the costs 
of an individualized dosing schedule were compared with a fixed dosing schedule 
in chapter 7. It was shown that, with an individualized dosing schedule, the costs 
are only reduced if a vial of PEGasparaginase can be used for multiple 
administrations and waste can be limited. For the DCOG ALL-11 protocol, the costs 
of individualized asparaginase treatment were lower when at least three patients 
could be treated at the same day. By centralization of the pediatric oncology care, 
this is achievable but in smaller pediatric oncology centers, relatively much waste 
has to be discarded. The TDM costs itself were very low and this should therefore 
not be a barrier to use TDM in order to detect silent inactivation of asparaginase. 
 
Hypersensitivity reactions to asparaginase 
Allergic-like reactions 
By measurement of asparaginase activity levels, it was noted that not all allergic 
reactions to PEGasparaginase or Erwinia asparaginase were accompanied by 
neutralization of asparaginase. These are called allergic-like reactions. This is in 
contrast to our previous study, showing neutralization of asparaginase even in case 
of mild allergic reactions.11 This study, however, was performed in 89 patients, 
which is a relatively small group compared to the number of DCOG ALL-11 patients 
analyzed in chapter 2.  
Allergic-like reactions are often not accompanied by antibodies and usually occur 
relatively late after start infusion. However, this is not always true and 
asparaginase activity levels should be determined to confirm the type of reaction. 
We also reported that asparaginase activity levels are already zero just prior to 
real, neutralizing reactions, which was also confirmed in chapter 2.11 Thus, the 
asparaginase activity level measured prior to an allergic-reaction can be used to 
distinct between allergic-like reactions and neutralizing allergies. However, if 
asparaginase activity levels are not standardly measured or if an allergic reaction 
occurs during the first dose, conclusions have to be drawn based on asparaginase 
activity levels measured directly after the reaction. In that case, the amount of 
asparaginase administered should be taken into account when interpreting these 
levels. As was shown in chapter 2, the far majority of patients with an allergic-like 
reaction during DCOG ALL-11, were able to complete their asparaginase treatment 
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with the same formulation. If Erwinia asparaginase has to be stopped prematurely, 
there are no alternative formulations available. Therefore, in case of allergic-like 
reactions to Erwinia asparaginase, the identification of these reactions and 
continuation of therapy probably contributes to a more favorable outcome.  
 
Hypersensitivity reactions to PEGasparaginase 
In DCOG ALL-10, patients were first treated with native E. coli asparaginase during 
induction and with PEGasparaginase during intensification. We have shown that 
one third of the patients in ALL-10 developed a reaction to PEGasparaginase, 
almost exclusively during the second dose in intensification and all in the presence 
of native E. coli asparaginase antibodies.11 Hypersensitivity reactions to native E. 
coli asparaginase during induction occurred in 5% of the patients.20 
In DCOG ALL-11, when PEGasparaginase was administered both in induction and 
intensification, the pattern of occurrence of hypersensitivity reactions and 
especially the antibodies formed, changed fundamentally. During intensification, 
only 7% of the patients had a hypersensitivity reaction, of which 60% was during 
the first and 40% during the second dose. On the other hand, still 3% developed a 
reaction during induction, which is more or less comparable with DCOG ALL-10. As 
described in chapter 5, the patients with a reaction to PEGasparaginase during 
induction rarely had native E. coli asparaginase antibodies but mainly had 
antibodies against the PEG and the succinimidyl succinate linker (SS-linker). 
However, native E. coli asparaginase antibodies were detected in all but one of the 
six patients with a hypersensitivity reaction during intensification. By coincidence, 
the three allergies included in the study were during the second dose. And as 
described in chapter 2, specifically the patients with a reaction during the second 
dose of intensification had native E. coli asparaginase antibodies, whereas the 
patients with a reaction during the first dose did not. Thus, only hypersensitivity 
reactions against the second PEGasparaginase dose during intensification are 
accompanied with native E. coli asparaginase antibodies. Therefore, the question 
arose whether reactions during the first PEGasparaginase dose after an 
interruption of treatment were also evoked by PEG and/or SS-linker antibodies. 
Unfortunately, antibodies against the PEG were not measured in these patients 
because the assay of PEGasparaginase antibodies turned out to be unsuccessful in 
measuring PEG antibodies. Still, it could carefully be concluded that, in contrast to 
in DCOG ALL-10, only the reactions to the second dose in intensification (1% of the 
medium risk patients) seem to be against the asparaginase moiety itself. The other 




reactions (during induction and the first dose in intensification) seem to be against 
the PEG and/or the linker moieties. This means that most patients with a reaction 
to PEGasparaginase may benefit from a switch to – the less expensive – native E. 
coli asparaginase instead of Erwinia asparaginase, which has a more inconvenient 
dosing schedule. Evidently, if these patients also develop antibodies to native E. 
coli asparaginase, they should switch to Erwinia asparaginase.  
 
Chapter 5 comprised both patients with an allergy to and silent inactivation of 
PEGasparaginase. Although the number of patients included is limited, the 
antibody titers of especially PEG antibodies are higher in patients with an allergic 
reaction to PEGasparaginase. This implies that these antibodies not only neutralize 
the drug but also evoke symptoms of an allergy. 
 
In general, PEGylated drugs are less immunogenic than non-PEGylated 
formulations, as is also the case for PEGasparaginase. However, a rapid clearance 
of these drugs has been observed, despite the PEGylation, probably due to PEG 
antibodies.21, 17 Several studies claim the formation of PEG antibodies in patients 
treated with PEGylated drugs, including studies about PEG-modified bovine 
adenosine deaminase22, PEG-interferon therapy in hepatitis C patients23, and 
PEGylated phenylalanine ammonia lyase in phenylketonuria patients24, but the 
antibodies described turned out not to be specifically against PEG itself.17 An actual 
correlation between the presence of PEG antibodies and reduced therapeutic 
efficacy has been observed only for PEGasparaginase and PEG-uricase.25, 26  
Neutralizing antibodies against PEG have been reported previously in patients 
treated with PEGasparaginase by Armstrong et al.27 In patients with gout treated 
with PEGylated uricase, the presence of PEG antibodies was associated with lower 
uricase activity levels and loss of efficacy of the drug.25, 26 Also in our study, 
described in chapter 5, several patients with neutralization of PEGasparaginase 
proved to have PEG antibodies in absence of antibodies against the asparaginase 
and the SS-linker. 
PEG antibodies have been described in healthy individuals as well.28-30 In line with 
these findings, in chapter 5, it was described that pre-existing PEG antibodies were 
present prior to the first PEGasparaginase dose in one third of the patients without 
any reaction. PEG has been widely used in cosmetics (shampoo, soap, lotions etc.) 
and processed foods, which is believed to be the explanation for the pre-existing 
PEG antibodies. In addition, macrogol, which is often used as a laxative, consists of 
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PEG and possibly may play a role in the development of PEG antibodies and 
hypersensitivity reactions against macrogol are reported.31 Yang et al. suggest that 
due to frequent lacerations and skin tears, local inflammatory reactions in close 
proximity to products containing PEG, may induce the formation of PEG 
antibodies. Evidence supporting this theory, however, is lacking.  
 
Asparaginase and methotrexate 
Methotrexate polyglutamates inhibit dihydrofolate reductase (DHFR), an essential 
enzyme for the intracellular folate homeostasis and inhibit the thymidylate and 
purine biosynthesis.32 MTX is polyglutaminated inside the cell which leads to 
better retention and more cytotoxicity.33-37 In the 1970’s and 1980’s, several in 
vitro studies showed that, if asparaginase has been administrated prior to a MTX 
dose, the MTX polyglutamination is inhibited in cell culture experiments and 
mouse models. In contrast, administration of asparaginase after the MTX, in turn, 
appeared to have a synergistic effect. 33, 34, 36, 37 Specifically the asparagine 
depletion caused by asparaginase seemed to cause the decrease of 
polyglutamination, probably by inhibition of folylpolyglutamyl synthetase (FPGS).36, 
37 Whether the antagonistic effect of asparaginase on MTX plays a role in vivo is 
unknown. In chapter 6, we have described the influence of asparaginase on MTX 
toxicity and therapeutic efficacy, the latter reflected by intracellular MTX 
polyglutamination. It appeared that concomitant asparaginase and high dose MTX 
treatment leads to more myelosuppression resulting in treatment delay of on 
average one week. The occurrence of grade III/IV toxicity was similar with and 
without asparaginase. Thus, considering toxicity, it is safe to administer 
asparaginase during high dose MTX treatment. However, the effect of 
asparaginase on MTX efficacy is less clear. As described in chapter 6, we found that 
asparaginase does inhibit MTX polyglutamination measured in erythrocytes of 
children with leukemia in vivo, although to a lesser extent than in vitro. Moreover, 
all polyglutamates were formed, including the long chain polyglutamates. The 
question whether the inhibition of polyglutamination is clinically relevant is 










Switching to Erwinia asparaginase after a hypersensitivity reaction to native E. coli 
or PEGasparaginase may, especially in less developed countries, be a problem due 
to the relatively high costs of Erwinia asparaginase. In chapter 8, a cost-
effectiveness analysis of Erwinia asparaginase was performed. Although Erwinia 
asparaginase is an expensive drug, the costs per life year saved only increase with 
$1,020 when patients are switched to Erwinia asparaginase after a reaction to 
PEGasparaginase. Evidently, these costs apply to patients treated according to 
DCOG ALL-11 – which has a very extensive asparaginase schedule –  and the exact 
costs per life year saved may differ between countries with other treatment 
protocols and/or healthcare prices.  
Apart from possible differences with other countries, it has to be taken into 
account that incomplete and less intensive asparaginase treatment could result in 
more relapses, which results in higher costs.38-41 Therefore, it pays off to switch to 
Erwinia asparaginase after a reaction and accept the high direct costs of the 
Erwinia asparaginase treatment. 
 
Conclusion and future perspectives 
In conclusion, TDM of asparaginase leads to a substantial reduction of the 
PEGasparaginase dose. However, this has no large impact on the reduction of 
asparaginase-associated toxicity. However, individualization of asparaginase can 
lead to a cost reduction and, most importantly, it optimizes the treatment by 
detection of silent inactivation and identification of allergic-like reactions. 
Therefore, TDM is recommended to improve treatment outcomes of those 
patients who develop silent inactivation or allergic-like reactions.  
Beside this, it can be concluded that the use of only PEGasparaginase instead of 
native E. coli asparaginase has led to a change in the occurrence of hypersensitivity 
reactions: first, the percentage of patients developing a reaction has significantly 
been decreased (35% to 10% in total). Second, the majority of the remaining 
inactivating reactions seem to be evoked by the PEG or the linker, connecting the 
PEG to asparaginase. This is important for ALL patients as patients with a reaction 
to these antigens may be switched to native E. coli asparaginase. Future research 
should focus on the immunogenic characteristics of different linkers, and it could 
Chapter 9210   |
197 
 
be questioned whether PEGylation of drugs is the best way to reduce 
immunogenicity of drugs.  
Although this thesis gave more insight in several aspects of the asparaginase 
treatment in children with ALL, new questions have arose based on these insights. 
The minimal asparaginase activity level for adequate asparagine depletion should 
be further investigated. Very important is to determine the correlation between 
asparaginase activity levels and outcome.  
The population pharmacokinetic model, including the effect of infections and 
treatment phase, should be prospectively evaluated. The efficacy of using the 
loading and maintenance dose, adjusting the dose based on week or trough levels, 
and increasing the dose when an infection occurs, should be studied.  
Third, the precise role of PEG- and SS-linker antibodies should be investigated. For 
this, the current assay should be validated before it can be used as a diagnostic 
tool. Finally, the clinical implications of hypersensitivity reactions accompanied by 
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In dit proefschrift hebben we onderzocht of het individualiseren van asparaginase 
tot een effectieve behandeling leidt en wat het effect is op de toxiciteit van 
asparaginase. Hiervoor hebben we verschillende onderzoeken gedaan. 
In hoofdstuk 2 hebben we laten zien dat het individualiseren van de asparaginase 
behandeling tot een significante reductie van de asparaginase dosis leidt. Dit had 
echter weinig effect op de toxiciteit. Wel wordt stille inactivatie van asparaginase 
gedetecteerd door asparaginase spiegels te meten. Patiënten die het middel 
inactiveerden zonder allergische symptomen konden op deze manier toch 
adequaat behandeld worden door te switchen naar Erwinia asparaginase.  
Meer dan 95% van de asparaginase dalspiegels was hoger dan 100 IU/L. De 
asparagine concentraties, en met name de L-asparagine concentraties, waren bijna 
onmeetbaar. Daarom kunnen we concluderen dat de geïndividualiseerde 
asparaginase behandeling effectief is. De correlatie tussen asparaginase en 
asparagine concentraties, en outcome moet verder onderzocht worden.  
In hoofdstuk 3 hebben we een model ontwikkeld dat de populatie farmacokinetiek 
van PEGasparaginase beschrijft. Het bleek dat de klaring van PEGasparaginase 
hoger is in het eerste deel van de behandeling – de inductie fase – en bij patiënten 
met een groter lichaamsoppervlak. Ook wordt het middel sneller uitgescheiden 
tijdens infecties. Daarom wordt aanbevolen om een hogere dosis PEGasparaginase 
toe te dienen tijdens de inductie en als een patiënt een infectie heeft. 
Verder zagen we dat de klaring van PEGasparaginase lineair is tijdens de eerste 13 
dagen maar daarna snel toeneemt, waarschijnlijk als gevolg van hydrolyse van de 
PEG. 
In hoofdstuk 4 worden allergic-like reacties tegen asparaginase beschreven. Deze 
reacties lijken klinisch sterk op echte, neutraliserende allergieën maar bij dit type 
reactie wordt de asparaginase niet geneutraliseerd. Allergic-like reacties treden 
relatief laat op na het starten van de infusie en patiënten hebben meestal geen 
antistoffen. Toch is het nodig om asparaginase spiegels te meten om daadwerkelijk 
onderscheid te maken tussen dit type reactie en neutraliserende reacties. Dit is 
belangrijk omdat patiënten met een allergic-like reactie behandeld kunnen blijven 
worden met dezelfde soort asparaginase.  
Hoofdstuk 5 beschrijft een assay om specifiek antistoffen tegen PEG en de 
succinimidyl succinaat linker aan te tonen. Uit dit hoofdstuk, en uit hoofdstuk 2, is 
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gebleken dat een groot deel van de reacties tegen PEGasparaginase niet zo zeer 
tegen de asparaginase maar tegen de PEG is. Alleen reacties tegen de tweede gift 
na een pauze in de behandeling lijkt tegen de asparaginase zelf te zijn. Patiënten 
met een reactie tegen de eerste giften of tegen de eerste gift na een pauze hadden 
over het algemeen geen antistoffen tegen de asparaginase maar juist tegen de PEG 
en/of de linker. Deze patiënten zouden daarom kunnen switchen naar native E. 
coli asparaginase. Aan de andere kant bleek ook dat een deel van de patiënten 
zonder reactie ook PEG antistoffen heeft dus wat de precieze rol van de PEG en 
linker antistoffen is, moet verder onderzocht worden. 
In hoofdstuk 6 is de invloed van asparaginase op de werkzaamheid en het 
optreden van bijwerkingen van methotrexaat onderzocht. Patiënten die tijdens de 
hoge dosis methotrexaat kuren gelijktijdig met asparaginase behandeld werden, 
hadden meer beenmergsuppressie en milde leverfunctiestoornissen maar er was 
geen verschil in het optreden van ernstige toxiciteit. Ook werd methotrexaat 
minder gepolyglutamineerd met gelijktijdige asparaginase behandeling, al was dit 
effect minder dan in vitro en werden zowel de korte als de lange ketens gevormd. 
In hoofdstuk 7 zijn de kosten van een geïndividualiseerde asparaginase 
behandeling vergeleken met de kosten van een vast doseerschema. Op basis van 
een berekening met de absolute dosis, leidt geïndividualiseerde asparaginase 
behandeling tot een dusdanig lagere dosis, dat dit opweegt tegen de extra kosten 
van het meten van asparaginase spiegels en formuleren van dosisadviezen. De 
PEGasparaginase ampullen zijn echter relatief groot en rekening houdend met de 
restjes, zouden, om kosten te besparen, meerdere patiënten op één dag 
behandeld moeten worden zodat ampullen gedeeld kunnen worden. 
De kosteneffectiviteit analyse in hoofdstuk 8 laat zien dat switchen naar Erwinia 
asparaginase de kosten per gewonnen levensjaar met $1,020 verhoogt, wat 
relatief weinig is in het perspectief van de kosten van de gehele behandeling. Ook 
wordt in dit hoofdstuk beschreven dat de kwaliteit van leven niet verandert als 
patiënten moeten switchen naar dit middel.  
In hoofdstuk 9 worden alle resultaten in perspectief geplaatst en wordt een 
voorstel gedaan waar het vervolgonderzoek zich op kan richten. Dit proefschrift 
heeft bijgedragen aan nieuwe inzichten betreft de farmacokinetiek, 
farmacodynamiek, en immunologische en economische aspecten van 
asparaginase. In de toekomst zal ten eerste de correlatie tussen asparaginase 
concentraties en outcome beter onderzocht moeten worden. Verder moet het 




model van de populatie farmacokinetiek gevalideerd worden. Tenslotte moet de 


























The aim of this thesis was to study the feasibility, efficacy and toxicity of 
individualized asparaginase treatment to optimize the asparaginase treatment of 
children with acute lymphoblastic leukemia. For this, several studies were 
performed.  
In chapter 2, it was shown that the Dutch therapeutic drug monitoring (TDM) 
program of asparaginase was feasible and resulted in a significant reduction of the 
PEGasparaginase dose. However, no effect on the asparaginase-related toxicity 
was observed. However, with TDM, silent inactivation of asparaginase was 
detected. This way, we were able to ensure adequate asparaginase treatment by 
switching those patients to Erwinia asparaginase.  
As the far majority (>95%) of the trough PEGasparaginase activity levels were >100 
IU/L. In addition, the asparagine concentrations, and especially L-asparagine 
concentrations, were very low. Thus, it was concluded that the TDM program 
results in effective asparaginase treatment. The correlation between asparaginase 
and asparagine concentrations, and outcome should, however, be further 
investigated.  
Chapter 3 was a population pharmacokinetic analysis of PEGasparaginase revealing 
that treatment phase, body surface area and the presence of an infection explain 
part of the variability in the clearance. Therefore, it was recommended to use a 
higher PEGasparaginase dose during the induction phase and if a patient develops 
an infection.  
Furthermore, it was confirmed that the PEGasparaginase clearance is constant 
during the first 13 days but increases thereafter, probably due to hydrolysis of the 
PEG.   
In Chapter 4, allergic-like reactions were described This reaction clinically mimics a 
real, neutralizing allergy but is not accompanied by inactivation of the drug. 
Although allergic-like reactions occur relatively late after start of infusion and are 
usually not accompanied by the presence of antibodies, measurement of 
asparaginase activity levels is necessary to distinct between these reactions and 
inactivating allergic reactions. This is important because patients with an allergic-
like reaction can continue asparaginase treatment with the same formulation.  
In chapter 5, an assay to detect antibodies against PEG and the succinimidyl 
succinate linker was described. In both this chapter and chapter 2, it was 




concluded that a substantial part of the hypersensitivity reactions to 
PEGasparaginase was to the PEG moiety. Only the reactions to the second dose 
after an asparaginase-free interval seemed to be against the asparaginase moiety. 
The other reactions, during induction or against the first dose after an 
asparaginase-free interval, seem to be evoked by PEG and/or the linker. Therefore, 
these patients could switch to native E. coli asparaginase. As also patients without 
any reaction proved to have pre-existing PEG antibodies, the exact role of these 
antibodies has to be further investigated.  
In chapter 6, the influence of asparaginase on methotrexate toxicity and efficacy 
was described. It was shown that with concomitant asparaginase therapy, patients 
had more myelosuppression and relevant hepatotoxicity during high dose 
methotrexate courses, but these patients did not have more clinically severe 
toxicity. In the presence of asparaginase, less methotrexate polyglutamates were 
formed. However, the effect of asparaginase on methotrexate polyglutamination 
was less than in vitro and both short chain and long chain polyglutamates were 
formed.  
The costs of the TDM program were calculated and compared to the costs of a 
fixed dosing schedule in chapter 7. Considering the absolute dose, the total costs 
of asparaginase therapy are lower using TDM than a fixed dosing schedule as less 
asparaginase has to be used. However, taking into account the waste, to save 
costs, multiple patients should be treated with asparaginase at the same day to 
share vials between patients.  
In chapter 8, a cost-effectiveness analysis on Erwinia asparaginase was performed, 
showing that switching would increase the costs per life year saved with only 
$1,020, which is modest considering the total treatment costs. Also, it was shown 
that the quality of life of patients who had to switch to Erwinia asparaginase did 
not differ from patients who were able to complete the PEGasparaginase 
treatment. 
Finally, in chapter 9, the results were discussed and future perspectives were 
described. This thesis contributes to the insights into the pharmacokinetic, 
pharmacodynamic, economic and immunogenic characteristics of asparaginase. 
However, several new research questions arose. First, the correlation of 
asparaginase activity levels and outcome should be further studied. Second, the 
population pharmacokinetic model of PEGasparaginase should be prospectively 
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Het dankwoord is het meest gelezen deel van een proefschrift. Niet geheel 
onterecht, dit proefschrift zou namelijk niet tot stand gekomen zijn zonder de hulp 
van anderen. 
Allereerst wil ik graag alle patiënten en hun ouders bedanken voor het meedoen 
aan de verschillende onderzoeken die we hebben uitgevoerd. Ik vind het 
bewonderingswaardig hoe iemand in zo’n zware en moeilijke periode zó voor een 
ander klaar kan staan, in de hoop dat de behandeling voor toekomstige patiënten 
weer een beetje beter wordt.   
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moet zijn om naast het bouwen van het Prinses Máxima Centrum en het 
behandelen van kinderen met kanker, ook nog promovendi te begeleiden. Ik heb 
er dan ook diep respect voor hoe ons onderzoek telkens weer beter werd tijdens 
onze besprekingen en hoe je het overzicht hield. Als ik van tevoren dacht dat ik 
alles goed op een rijtje had, wist je altijd weer díe vraag te stellen waar ik geen 
antwoord op had. Dankjewel, ik heb ontzettend veel van je geleerd. 
Geachte dr. van der Sluis, beste Inge, de afgelopen 4 jaar was woensdagochtend 
om 9 uur vaste prik. Maar ook daar buiten had je áltijd tijd, zelfs als je het 
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Geachte prof. Uyl-de Groot, beste Carin, door jou ben ik enthousiast geworden 
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De overige leden van de commissie, prof. Hoogerbrugge, prof. Zwaan, dr. Rijneveld 
en prof. Tissing, wil ik hartelijk bedanken voor het beoordelen van mijn 
proefschrift en het plaatsnemen in mijn commissie. 
Beste co-auteurs, dank voor de input, moeite en tijd die jullie in onze artikelen 
hebben gestoken. Beste dr. van Litsenburg, beste Raphaële, bedankt voor je hulp 
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bij het doorspitten van al die papieren statussen en het doen van de 
kostenanalyses. Ik voelde me erg welkom. Dear dr. Escherich, dear Gaby, thank 
you for your help with unraveling the allergic-like reactions. Beste dr. de Groot-
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Beste Jan-Jaap, vele uren in het lab hebben ervoor gezorgd dat we het PEG-
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dat je mijn grote vriend bent en me altijd stimuleert om het beste uit mezelf te 
halen. Van jullie heb ik geleerd dat je alles kunt, als je je maar focust. Semper, 
knvf! 
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Lieve, lieve Roderick, zonder jou was dit me nooit gelukt. We houden elkaar in 
balans en je brengt me tot rust. Jij bent mijn thuis, mijn alles. Ik hou de wereld van 
je, voor altijd en altijd. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
